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1.1 The feature of aging 
 
In modern society, the increase of life expectancy of global 
population, as a consequence of  improving life standards, health care 
progresses and vaccinations, will contribute to the increase of the number 
of older persons (aged 60 years or over) by 2050. Indeed it is estimated 
that approximately the most part of 2 billion people on Earth will be made 
up by elderly (Gui J, 2012). For these reasons, tailored strategies will be 
adopted by national health systems to improve the quality of life for older 
adults by alleviating or mitigating the most frequent adverse effects of 
aging and age-related diseases (Dewan SK et al., 2012). 
Aging is a complex process that involves anatomic structures, 
physiological and social processes and cellular, molecular, tissues 
changes (Goldberg AL et al., 2002; Singh T and Newman AB, 2011). 
Although variable for each individual, it is a gradual and progressive 
phenomenon, under genetic and environmental control. Both a diminished 
ability to maintain homeostasis of the organism and the reduced capacity 
to respond to environmental stimuli are correlated with the increased 
predisposition of elderly people to illness and death (Troen BR, 2003; 
Rattan SI, 2008). Clinical observations indicate that some infections are 
more prevalent and have poorer outcomes in the elderly than in younger 
adults and are the fourth most common cause of death in older people 
(Heron MP and Smith BL, 2007).  Indeed, the elderly population is more 
susceptible to influenza, pneumococci, (Nicholson KG et al., 1997) 
respiratory syncytial virus (RSV) and group B streptococcus (GBS) but 
also from opportunistic infections and re-emergent chronic infections 
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such as herpes zoster (Ginaldi L et al., 2001; Bulati M et al., 2011; Dewan 
et al., 2012; Oviedo-Orta E et al., 2013). The major reason for the 
increased susceptibility to infections in the elderly is the impairment of 
the immune system, called immunosenescence (Franceschi C et al., 1995; 
Pawelec G et al., 2005), which consists in progressive and cumulative 
modifications that  affect both innate and instructive immune reactions 
(Franceschi C et al., 1995; Pawelec G et al., 2005). Thus, clonotypic and 
innate immunity have a key role in the control of the survival of the 
elderly, since the susceptibility to these diseases depends, in part, on a 
good and functional immune system (Licastro F et al., 2005; Candore G 
et al., 2006a). In particular, Franceschi (Franceschi C et al., 1995) 
according to the “remodeling theory of aging”, proposed that 
immunosenescence is not a decline of immune functions but is its 
reorganization. Indeed, adaptive immunity deteriorates while innate 
immunity is largely conserved or even up-regulated with the age 
(Cossarizza et al., 1991). Moreover, it was demonstrated that even though 
elderly people are able to do anamnestic responses, they are not capable 
to establish a good primary type response against new antigens (Fagnoni 
FF et al., 2000), hence, for them, it is difficult overcome infections 
(Globerson A and Effros RB, 2000). In addition, the vaccine efficacy is 
decreased in old population because of the diminished of antibody 
responses to primary immunization with protein antigens such as hepatitis 
B vaccine, tetanus toxoid, rabies vaccines and for others factors, such as 
alimentation, pulmonary disease, diabetes mellitus, cancer, autoimmune 
and heart disease (Roman BE et al., 2013; Krawinkel MB et al., 2012; 
Moore SE et al, 2012; Oviedo-Orta E et al., 2013). 
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In addition to the remodeling of immune system, aging is also 
characterized by chronic low-grade inflammation state, named “inflamm-
aging” (Franceschi C et al., 2000a). Indeed, aged people show the increase 
in the production of inflammatory mediators, such as cytokines and acute 
phase proteins, which act as predictors of mortality independent on pre-
existing morbidity.  Many factors, including augmented amount of fat 
tissue, decreased production of sex steroid, smoking and chronic disorders 
as atherosclerosis, seem to contribute to this status (Krabbe K et al., 2004), 
although the most important cause of inflamm-aging may be the chronic 
antigenic load encountered during life and which affects the immune 
system. It is believed that pro-inflammatory status with the genetic 
background are linked to the majority of age-associated diseases as 
atherosclerosis, Alzheimer’s disease, cancer, type 2 diabetes and 
sarcopenia because prolonged activation causes chronic inflammation 
that damages organs (Franceschi C et al., 2000a,b; De Martinis et al., 
2005; Licastro F et al., 2005; Vasto S et al., 2007).  
One of the most aspect of inflamm-aging is the presence of elevate 
circulating levels of pro-inflammatory factors (IL-1β, IL-6, TNFα, and 
prostaglandin E2) and anti-inflammatory mediators, (IL-1 receptor 
antagonist, soluble TNF receptor, IL-10, transforming growth factor beta 
(TGF-β), acute phase proteins, C-reactive protein, and serum amyloid A) 
and contributes to the decreased ability of the elderly to mount an 
appropriate immune response following an infectious challenge (Gomez 
CR et al., 2010; Bruunsgaard H et al., 2010; Ginaldi L et al., 2001; 
Trzonkowski P et al., 2004).  
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It was demonstrated that TNF-α induces the production of Amyloid 
beta peptide in Alzheimer disease patients but it is also involved in 
atherosclerosis development because of the increase of the proliferation 
in smooth muscle cells (Wick G et al., 2000; Saurwin-Teissl M et al., 
2000). 
Another change that occurs with aging is the decrease of the serum 
levels of EGFR and EGF that regulates cell growth, proliferation and 
differentiation (Shurin GV et al., 2007).   
Therefore, inflamm-aging,  in a global perspective, could be seen as 
the common biological factor responsible for the decline and the onset of 
disease in old people, but at the present, this phenomenon has become 
more complicated than what was surmised in the past.  Indeed, inflamm-
ageing acts at different levels of complexity, from molecule to cell, from 
organ to organ system and also to organism. Thus it is difficult to predict 
exactly the changes related to age in different organs and cell types in 
body. Moreover, to this regard, it has been proposed that the inflamm-
aging is the result of overlapping between the level of pro-inflammatory 
molecules in the bloodstream and their production in different cells and 
tissues (Salvioli S et al., 2013; Cevenini E et al., 2013).  As a consequence, 
the balance between inflammatory and anti-inflammatory stimuli 
modifies cells microenvironment that affects organs and tissues, leading 
to the ‘mosaic of ageing’ (Cevenini E et al., 2008) that causes a 
remodeling in epigenetic and gene expression with aging (Cevenini E et 
al., 2013). Concerning this, it is known that IL-6, a cytokine involved in 
the growth of cancer cells, such as breast cancer (Sansone P et al., 2007; 
Studebaker AW et al.,2008), also has detrimental effects when produced 
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in excess in skeletal muscle (e.g. sarcopenia) whereas is normally released 
during exercise (Beyer I et al., 2012) and has beneficial in muscle 
metabolism (Pedersen BK et., 2008). 
In addition, senescent cells, over the time, could participate to this 
process with opposing effects: adopting a state of permanent cell cycle 
arrest, as response to damaging agents (e.g. oxygen free radicals), with 
beneficial effects (tumor suppression and tissue repair) or promoting 
cancer progression and ageing with deleterious effects on health of the 
organism (Rodier F et al., 2011; Cevenini E et al., 203). Recent findings 
suggest that the number of cells that express senescent markers increases 
with age and that their clearance is performed by immune system but it is 
not known about whether this process changes with age or in age-related 
disease, or if these cells escape to this mechanism (Campisi J et al., 2007). 
In conclusion, it is fundamental to clarify the complex process of 
inflamm-aging to improve targeted therapeutic interventions.  
A number of experimental evidences suggested that another cause  of 
immunosenescence is the persistent viral infection as it has been 
demonstrated for Citomegalovirus (CMV) (Vescovini R et al., 2007; 
Vescovini R et al., 2010; Derhovanessian E et al., 2011) that appears 
accelerate immune aging (Pawelec G et al., 2005; Akbar AN and Fletcher 
JM, 2005). The relation between CMV infection and poor health status 
was assessed in OCTO/NONA longitudinal studies (Wikby A et al., 1994 
Wikby A et al., 2002) in Swedish population. It has been reported that 
CMV infection is part of a group of features called Immune Risk Profile 
(IRP) that are useful to predict mortality (Pawelec G et al., 2005). Other 
parameters that contribute to IRP are high levels of late stage 
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differentiated CD8+ T cells, low levels of CD4+cell count, poor T cells 
proliferative response to mitogens, inversion of CD4:CD8  ratio, low IL-
2 production  and decreased B cells count.  In addition, it has been 
reported the CMV seropositivity and high levels of IL-6 are predictor of 
frailty and mortality (Schmaltz HN et al., 2005; Wang GC et al., 2010). 
Moreover, it has also been demonstrated a correlation between CMV 
infection and the progression of AIDS (Griffiths PD et al., 2006). Besides, 
it has been suggested that in elderly people the inflamm-aging could be 
independent from CMV serostatus as demonstrated by a recent 
longitudinal study (Bartlett DB et al., 2012).  
 
 
 
1.2 The effects of aging on the immune system  
 
1.2.1 T lymphocytes 
- Structural and environmental changes in thymus 
The thymus is the lymphoid organ responsible for the development of 
self-restricted, self-tolerant, immunocompetent T cells that mature 
through a series of proliferation and differentiation stages dependent upon 
receiving instructions from the specialized thymic microenvironment 
(Anderson G, et al., 2001; Ma D et al., 2013).  
With advancing age, there is an involution of the thymus (Taub DD 
and Longo DL, 2005; George AJ et al., 1996; Lynch HE et al., 2009) and 
both intrinsic and extrinsic factors are thought to contribute toward this 
process. Indeed, structural, phenotypical, and architectural changes of 
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thymic microenvironment have been observed (Chinn IK, et al., 2012). 
These processes include down regulation of various thymic epithelial cell 
(TEC) markers such keratin, MHC class II together with alterations of 
cortical and medullary markers (Li L  et al., 2003; Bertho JM, et al., 1997; 
Palmer DB et al., 2013). Furthermore, the structural integrity of the 
thymic niche is disrupted with age, including disorganization of the 
cortical and medullary junction; together with an increase of fibrosis, 
adipose tissue, and the accumulation of senescent cells in the aged thymus 
(Gui J, et al., 2007; Dixit VD, 2010). The thymic involution occurs in two 
phases: the first is associated with the physiological growth and the 
second is linked to the age-related changes (Aw D et al., 2012). In 
particular, the kinetic of this process is not uniform throughout life. 
Indeed, it is characterized by a rapid early decline, after which it seems to 
proceed at a steady rate (Palmer DB et al., 2013; George AJ et al., 1996) 
and then perhaps may end in later life (Nasi M et al., 2006; Mitchell WA 
et al., 2010). 
- Age –related modifications in T cell subsets 
These age–related modifications result in a progressive decrease of the 
percentage and absolute number of circulating CD3+ T lymphocytes and 
CD4+ and CD8+ T cells subsets (Pawelec G et al., 2002; Cossarizza A et 
al.,1996). Moreover, it is also observed the decline in output of newly 
developed T cells. As a consequence, there is a reduction of number of 
circulating naive T cells that do not permit to replenish the naïve T cells 
lost in the periphery and also to maintain the size of T cell repertoire 
(Kohler S et al., 2005; Naylor K et al., 2005; Fulop T et al., 2013). In this 
way, aged subjects become less responsive to immune stimulation and 
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vaccination, and likely prone to develop cancer, autoimmune disorders 
and chronic inflammatory diseases (Fulop T et al., 2013).  
In addition, aging of acquired immunity is associated with 
accumulation of memory and effector T cells as result of lifelong exposure 
to new and persistent infections (Fulop T et al., 2013; Saule P et al., 2006). 
Particularly, several studies have suggested the increase of the number of 
highly differentiated CD28- T cells, especially within the CD8+ T-cell 
subset in the elderly. This subset, that lacks of CD28 expression, is 
considered a biomarker for immunosenescence (Effros RB et al., 1994; 
Pawelec G et al., 2008). In addition, CD8+ CD28- T cells exhibit reduced 
antigen receptor diversity, defective antigen-induced proliferation and a 
shorter replicative lifespan while showing enhanced cytotoxicity 
regulatory functions (Oviedo-Orta E et al., 2013; Weng NP, et al., 2009) 
and resistence to apoptosis (Pawelec G et al., 2008).  
There are several surface markers which can be used to classify T 
cells. The most utilized are CD28, CD27, CD45, CCR7, CD62L, CD95, 
CD95L (Gupta S et al., 2005). For long time, memory and naïve human 
T cells were discriminated on the basis of CD45RA antigen, expressed 
primarily on naïve T lymphocytes and CD45RO expressed on memory T 
cells. But it is noted that a population of late-differentiated memory T 
cells re-express CD45RA, so this marker is not entirely useful to 
discriminate naïve and memory T cells (Hamman D et al., 1997). 
Actually,  the most widely accepted phenotyping model for CD8+ T and 
CD4+ T includes Naïve T lymphocytes (N: CCR7+, CD27+++, CD28+++, 
CD45RA+), that are also characterized by the absence of CD95 and the 
expression of CD62L ; Central Memory cells (CM: CCR7+, CD27++, 
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CD28++, CD45RA−), principally located in the lymph nodes, they  
represent the lesser differentiated memory population (Nociari MM, et al., 
1999); Effector Memory cells (EM: CCR7−, CD27±, CD28±, CD45RA−), 
the  highly mature T cell population found in extranodal tissues and 
mucous membranes. Furthermore, this last subset of lymphocytes seems 
to be the responsible for the tissue damages in autoimmune disorders 
because EM T cells are found in inflamed non-lymphoid tissues where 
secrete high amounts of effector cytokines (INF-γ and TNF-α), 
chemokines (RANTES) and acquire cytotoxic activity via 
granzyme/perforin granule exocytosis pathway (Kaech SM et al., 2002; 
Wherry EJ et al., 2003).  Another interesting memory T cell population is 
named TEMRA: these are terminally differentiated memory lymphocytes 
re-expressing CD45RA (TEMRA: CCR7−, CD27−, CD28−, CD45RA+). It 
has been demonstrated a strong correlation between chronological age 
and the frequency and absolute number of this population in most humans. 
It has been suggested that many of these TEMRA cells are not able to 
produce cytokines, to mediate cytotoxic activity, besides they show 
senescence-related proliferative defects (Effross RB, 2011; Fulop T et 
al.,2013). However, it has been recently demonstrated that, in some 
circumstances, TEMRA might secrete cytokines and express high levels 
of granzyme B and perforin (Libri VR et al., 2011). So, they may be 
important for protection against certain infections in vivo (Bruns H et al., 
2009; Di Mitri D et al., 2011). 
Another classification of naïve/memory T cells is based on the 
expression of CD57 and KLRG1, two inhibitory receptors present on late-
stage differentiated cells and considered as markers of senescence. 
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Indeed, KLRG1 is expressed by CD4+and CD8+ T lymphocytes and NK 
cells; differently CD57 is mainly expressed  on CD8+and NK cells, and  
at lower levels, is express by CD4+ (Ouyang Q et al., 2003; Larbi A et al., 
2009; Pellicanò M et al., 2011). 
Many evidences have shown that CMV, which establishes persistent, 
usually asymptomatic, life-long infection, has an enormous impact on the 
distribution of T cell subsets in most old people, which show a clonal 
expansion of CMV-specific CD4 and CD8 T lymphocytes (Looney RJ et 
al., 1999; Chidrawar S et al., 2009; Almanzar G et al., 2005, Pawelec G 
et al., 2005). CMV-specific T cells typically display an effector memory 
phenotype of late-stage differentiation. CMV also modulates innate 
immunity and induces the production of cytokines and chemokines which 
affect T cell immunity. Therefore, the typical consequence of aging is the 
progressive filling of the “immunological space” by activated 
lymphocytes in response to chronic/continuous stress either from 
pathological or physiological antigenic stimuli (Goto M, 2008).  
In the aged, it is also observed a high frequency of  regulatory T (Treg) 
cells and an imbalance in Treg response and in production of IL-17.  Treg 
cells from elderly play an immunosuppressive role in vitro and express 
high levels of IL-10 and TGF-β (Simone R et al., 2008; Oviedo-Orta E et 
al., 2013). On the contrary, Th17 cells that act against bacteria, activating 
and recruiting neutrophils, are also reduced in the elderly (Lee JS et al., 
2011; Oviedo-Orta E et al., 2013). 
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1.2.2 B lymphocytes 
- Age-related modifications in B cell compartment  
The most of the literature on immunosenescence has focused on T cell 
impairment, but it has been also demonstrated the impairment of the B 
cell branch in aging. Indeed, B cell compartment is affected in elderly 
people, thus, humoral immune response is modified in aged both in the 
quality and quantity of the antibodies produced and in the size of 
developing B cells subsets (Cancro et al., 2009; Frasca D and Blomberg 
2011; Buffa S et al., 2011). Indeed, it has been abundantly demonstrated 
that the percentage and absolute number of total CD19+ B Cells decrease 
in aged (Colonna-Romano et al., 2003; Frasca D et al., 2008; Veneri D et 
al., 2009), although the B lymphopoiesis persists during adult life (Rossi 
MI et al., 2003). It seems that defects in hematopoietic stem cells (HSC) 
in bone marrow, is partly responsible for the B cell impairment (Kogut I 
et al., 2012; Bulati M et al., 2011).  Indeed, the lowered output of naïve B 
cells from aged might be caused by the shift toward the production of 
myeloid progenitors at expense of lymphoid progenitors. This 
phenomenon seems to be connected to the up-regulation of genes 
involved in myeloid differentiation (Rossi DJ et al., 2005; Chambers SM 
et al., 2007) and in the alteration of cytokine milieu in the bone marrow 
(e.g TGF-β), other than to the impaired of V-DJ rearrangement. (Challen 
GA et al., 2010; Gibson KL et al., 2009). Moreover, it has been suggested 
that the shrinkage of the B cell repertoire (Guerretaz LM et al., 2008) and 
the shortening of telomeres might be implicated (Warren LA et al., 2009; 
Weng NP et al., 2008). In humans, several studies have reported changes 
in B cells or in the antibody repertoire (Dunn-Walters DK et al., 2010), 
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particularly in the heavy chain of BCR. Indeed, upon encountering of 
antigen, mature naïve B cells migrate to secondary lymphoid organs 
where they organize germinal centres and undergo immunoglobulin 
affinity maturation (Carsetti R et al., 2004).  During this stage, class 
switch recombination (CSR) takes place, this leads to production of 
different isotypes (IgG, IgA, IgE) with diverse effector functions, and 
somatic hypermutation (SHM), in which the V domains of 
immunoglobulin may increase their affinity by accumulation of 
mutations. These processes, are both dependent on the expression of the 
enzyme activation-induced cytidine deaminase (AID) (Pan-
Hammarstrom Q, et al., 2007; Cagigi A et al., 2009) and are fundamental 
for the quality of the immune response and for the development of an 
efficient serologic memory to prevent re-infections. Indeed, Frasca D et 
al., (2008) have shown that the expression of E2A-encoded transcription 
factor E47 (E47) and AID in B cells progressively decrease with age. As 
a consequence, elderly people show a significant collapse both in 
repertoire diversity and clonal expansion. Indeed, an increased 
oligoclonality and a reduced frequency of somatic hypermutation in the 
elderly response to pneumococcal vaccination has been reported (Kolibab 
et al., 2005). This is linked with a poor health status, frailty and a reduced 
protective humoral immune responses (Cancro MP et al., 2009; Dunn-
Walters DK et al., 2010; Gibson KL 2009; Scholtz JL et al., 2013). These 
data indicate a relative deficit in the ability of elderly people to mount 
primary responses to newly encountered antigenic epitopes, and also 
suggest that, a decline in T cell help or innate immune functions could 
also contribute to this change (Thompson WW et al., 2003; Kogut I et al., 
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2012). Beside, with aging, the levels of total and specific serum Ig 
isotypes are modified. Indeed, although the number of total B 
lymphocytes is reduced, the amount of IgG, IgA and, to a lesser extent 
IgE, is augmented. In a different way, the levels of IgM decrease or not 
change, while those of IgD decline (Listì F et al., 2006; Frasca D et al., 
2010). 
The study of B cell subsets is complicated by ample differences 
between individuals, as well as the variety of phenotyphing approaches 
employed (Ademokun A, et al 2010). In particular, using CD19+, IgD and 
CD27 (core markers) the following major circulating B cell subsets can 
be distinguished (Kaminski et al.,2013; Wei C et al., 2011): naïve B cells 
(IgD+CD27-); unswitched memory (IgD+CD27+) B cells also referred to 
as natural effector B cells that express IgM too; classical switched 
memory B cells  (IgD-CD27+) that express IgG+ or IgA+ and Double 
Negative (DN) memory B lymphocytes (IgD-CD27-) (Colonna-Romano 
G et al., 2009; Shi Y et al., 2003)  Indeed, naïve B cells are IgD+, while 
classical memory B lymphocytes express switched immunoglobulins 
(IgG, IgA, IgE) (Klein U et al, 1998) and CD27, a typical marker of 
memory B cells correlated with the presence of somatic hypermutations 
in Ig genes (Agematzu K et al., 2000).  
It has been demonstrated that naïve B cells are significantly reduced 
in elderly subjects (Gupta s et al., 2005; Colonna-Romano G et al., 2008), 
although other authors have observed the increase of percentage but not 
in the absolute number with age of these cells (Shi Y et al., 2005; Frasca 
et al., 2008). Concerning memory B cells, that are the responsible for 
driving the rapid secondary antibody response, Frasca et al., (2012) have 
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shown a decrease of switched memory B lymphocytes both in percentage 
and in absolute number suggesting a defect to undergo class switch. 
Unlike the above-mentioned data, Colonna-Romano G et al., (2003, 2009) 
have reported no significant changes of memory B cells identified as 
CD19+CD27+ in the elderly, moreover Macallan DC et al., (2005) have 
shown an increased proliferative ability of switched memory B cells. 
Moreover, DN B cells are memory B cells which have down-regulated 
the CD27 marker (Anolik JH et al., 2004; Fecteau JF et al., 2006; Wei C 
et a., 2007; Colonna-Romano G et al., 2009; Cagigi A et al., 2009). In 
fact, for the most part of them, DN B cells have switched the heavy chain 
of immunoglobulin molecule in IgG+, others (more than 20%) in IgA+, 
whereas less than 10% are IgM+. Beside, these cells have low levels of 
ABCB1 transporter (Colonna-Romano G et al., 2009), a protein 
responsible for the transport of molecules across cell membranes (Efferth 
T et al., 2003) and very low levels of Bcl2 that should preserve cells from 
apoptosis. It has been also verified that DN not act as antigen presenting 
cells (APC) because express reduced levels of HLA-DR, CD80 and CD40 
that are useful for antigen presentation and T-B cooperation. It has also 
been described that shown that DN B cells of the elderly donors have very 
short telomeres compared to the same subpopulation of young donors. 
Moreover, these cells are not responder to CpG stimulation although can 
be activated with F(ab’)2 (anti-BCR) (Colonna-Romano G et al., 2009). In 
addition, keeping in mind that DN B cells from elderly subjects show an 
intrinsic in vitro activation, there is not a link between their capacity to 
proliferate and the ability to produce cytokines as TNF-α and IL-10 also 
when stimulated with strong stimuli (CpG/PMA/Ionomycin) (Buffa S et 
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al., 2011). However, others reported that DN B cells can be stimulated in 
vitro to secrete immunoglobulins against tetanus toxoid and influenza 
virus (Wirths and Lanzavecchia et al., 2005).  
Furthermore, it has been demonstrated that DN B lymphocytes are 
enlarged significantly in percentage but not in absolute number in healthy 
elderly (Colonna-Romano et al., 2009). The increased of these cells has 
also been demonstrated in healthy subjects challenged with respiratory 
syncityal virus (RSV) (Sanz I et al., 2008); in active Lupus patients (Wei 
C et al., 2007) and in HIV patients (Cagigi A et al., 2009) and it might be 
the result of persistent stimulation of immune system. In elderly people, 
DN B cells show a reduced rate of the mutations evaluated in the V region 
of IgG genes when compared with young (Buffa S et al., 2011). Thus, the 
increase of the double negative memory B cells in the elderly together 
with the reduced rate of mutation might be due to the disconnected 
generation of these cells from germinal centers, as it has been 
demonstrated that ageing negatively affects the germinal center formation 
in secondary lymphoid tissues (William J et al., 2002; Frasca D et al., 
2005) or might represent the first wave of memory B cells (Blink EJ et 
al., 2005; Inamine A et al., 2005) or terminally differentiated memory B 
cells. Alternatively, it has been hypothesized that the increase of these 
memory B cells subset might be also the manifestation of an age-related 
physiologic modification (elderly) or a pathologic deregulation (SLE 
patients) of the immune system (Bulati et al., 2011). 
 Among IgM memory B cells, it is also possible to distinguish 
IgM+IgD+CD27+ and IgM+IgD-CD27+ called “IgM only”. It is reported 
that IgM memory B cell subsets, that is the predominant B subset, is 
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reduced with age and might be involved in defective immune response 
against infections by encapsulated bacteria (Shi Y et al., 2005; Buffa S et 
al., 2011) so, increasing the predisposition to pneumococcal infection 
(Frasca D and Blomberg ., 2011; Buffa et al., 2011). 
Using additional markers, as CD24 and CD38 it is possible to identify 
a recently produced population (Transitional B cells) (Fecteau JF et al., 
2006; Palanichamy A et al., 2009; Blair PA et al., 2010; Berkowska MA 
et al., 2011). They express high levels of both CD24 and CD38 
(CD38hiCD24hi Transitional B cells). 
It has been demonstrated that the human immature transitional CD19+ 
CD24hiCD38hi B cells have regulatory function. Indeed, these 
lymphocytes, also called Breg, are the main interleukin-10-producing 
subset, that suppress the differentiation of T helper 1 cells (Blair et al., 
2010). It has been observed that they expand in patients suffering of 
lymphoma and autoimmune diseases, such as rheumatoid arthritis (RA) 
and SLE (Palanichamy A et al., 2009; Blair PA et al., 2010). In particular, 
Blair et al (2010) has also reported that in SLE patients, these cells loss 
their suppressive capacity, producing less IL-10. In association with 
previous evidence showing defects in Treg cell activity in SLE, the 
authors have suggested the impairment of regulatory cell functions in this 
and other autoimmune diseases.  
B lymphocytes and cytokine/chemokine production 
Interestingly, B cells have effector and regulatory functions other than 
antibody production such as T cell and dendritic cell regulation and 
cytokine and chemokine production (Sanz I et al., 2007; Martin F and 
Chan AC, 2006; Harris DP et al., 2011). Indeed, in literature, naïve and 
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memory B cells have been distinguished also by producing different pro- 
and anti-inflammatory cytokines. Particularly, naïve B cells produce anti-
inflammatory cytokines, whereas memory B cells are the main 
responsible for pro-inflammatory cytokines production (Duddy ME et al., 
2004, 2007; Sanz I et al., 2007, 2008; Lund FE, 2008). Buffa et al., (2011) 
has demonstrated that CD27+ and CD27- B cells from young and elderly 
subjects produce different kind of cytokines. Indeed, in both age-groups, 
the physiological (α-CD40/IL-4) stimulation induces a good IL-10 and 
TNF-α production by unswitched memory B cells. Fascinatingly, in older  
people, naïve B cells are also highly activated to produce cytokine under 
these conditions. On the other hand, it has been also demonstrated that a 
strong stimulation (CpG/PMA/Ionomycin) (Bouaziz JD et al., 2010) 
activates the production of IL-10 by both IgD+CD27- (classical naïve) and 
IgD+CD27+ (memory unswitched) B cells in young and elderly subjects. 
Thus, it has been suggested that naïve B cells from young donors need a 
sufficiently strong stimulus to be activated in vitro, while naïve B cells 
from elderly subjects are able to produce high basal levels IL-10 and TNF-
α  as they might be basically activated by bacteria  or viruses (such CMV). 
As a consequence, Buffa S et al.,(2011) have supposed that cytokines 
production in young subject might control the size of immune response 
while in the elderly, the higher production of cytokine by naïve B cells 
may be related to overstimulation of the immune system. In this regard, 
Rieger A and Bar-Or A (2008) have proposed that the IL-10 production 
by naïve B cells might be a control mechanism to prevent the exacerbation 
of inflammation in an autoimmune context, whereas IL-10 production by 
memory B cells might be participate in the resolution of the disease. 
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Due to the above reported data, the different distribution of B cell 
subpopulations in the elderly and their ability to produce pro- or anti-
inflammatory cytokines might play a central role in the generation of the 
inflammatory environment typical of age (Agrawall N and Gupta SK, 
2010; Licastro F et al., 2005).  
Moreover, another link between inflamm-aging and adaptive immune 
responses might be identified in the expression of chemokines’ receptors. 
Indeed, certain combination of chemokines and their receptors guide all 
the immune cells and also B lymphocytes to specific tissues (Kunkel EJ 
and Butcher EC, 2003). Accordingly, CXCR4, CXCR5, CCR6 and CCR7 
have been identified as receptor that drive B cells to lymph node attract 
by a combination of CXCL12, CXCL13, CCL20 and CCL19 respectively 
while CXCR3 leads B cells to sites of inflammation (Comeford I et al., 
2010; Welsh-Bacic et al., 2011). 
Recently, several lines of evidences have suggested that the 
combination of interleukin-21 (IL-21) and BCR stimulation, in absence 
of CD40 ligation, enables B cells to produce and secrete active form of 
cytotoxic serine protease granzyme B (GrB) that induces apoptosis of 
target cells independently from perforin, but using mannose-6-phosphate 
or fluid phase endocytosis (Hagn M et al., 2009; Kurschus FC et al., 2005; 
Gross C et al., 2003). It has been proposed that GrB-secreting B cells 
might exert cytotoxic functions and partecipate in early cell-mediated 
immune response during inflammatory and neoplastic process. Indeed, it 
has been demonstrated that GrB secretion by B cell might play a 
significant role in early antiviral immune responses, in the regulation of 
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autoimmune diseases and in cancer immunosorvelliance (Hagn M et al., 
2009).   
 
 
 
1.3 Centenarian offspring: a model of successful aging 
 
As previously discussed, healthy aging and lifelong has been also 
related with genetics (Roush W, 1996; Troen BR, 2003; Franceschi C et 
al., 2005; Candore G et al., 2006a; Salvioli S et al., 2006; De Benedictis   
and Franceschi C, 2007).  
Centenarians represent the  best example of extreme longevity in 
humans that have escaped neonatal mortality, illnesses in the pre-
antibiotic era (Candore G et al., 2010), and the major age-related diseases, 
such as cancer (Akushevich I et al., 2012; Pavlidis N et al., 2012),  
cardiovascular diseases, diabetes and dementia (Franceschi C and Bonafe 
M`, 2003; Terry DF et al., 2003, 2004),  so reaching the extreme limit of 
human life in healthy and good clinic conditions. For this reasons, they 
represent the best prototypes of successful aging (Franceschi C et al., 
1995) and are considered a good model for the study healthy aging. 
Studies on centenarians might allow the identification of key factors 
associated with exceptional longevity in humans. Moreover, centenarians 
are equipped with well-preserved and efficient immunological defense 
mechanisms, and optimal combinations of an appropriate lifestyle and 
genetic background (Franceschi C et al., 1995). Moreover, it has been 
demonstrated that they have a genetic predisposition to produce high 
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amounts of anti-inflammatory cytokine or lower level of pro-
inflammatory ones (Salvioli S et al., 2006; Franceschi C et al., 2007: 
Salvioli S et al., 2013).  However, it has been reported that they also 
produce high levels of IL-6 and other inflammatory markers (Gerly R et 
al., 2000; Gangemi S et al., 2005; Salvioli S et al., 2013). In order to 
explain this paradox, it has been suggested that, in these individuals, the 
balance between pro- and anti-inflammatory cytokine could be have 
positive role toward the development of those age-related diseases having 
a strong inflammatory pathogenetic component and might compensate the 
concomitant development of strong and effective anti-inflammatory 
responses (Candore G et al. 2006; Franceschi C et al. 2007; Vasto S et al. 
2008, 2009; Baggio G et al., 1998). Furthermore, centenarians are 
equipped with well-preserved and efficient immunological defense 
mechanism, and optimal combination of lifestyle and genetic background. 
Looking the immune system, some parameters, such as NK cell number 
and activity, are conserved in centenarians and similar to those found in 
young subjects. Nevertheless, centenarians show a decrease of B cells and 
naive T lymphocytes, accumulation of expanded clone of memory T cells, 
a progressive increase of CD28-cytotoxicT cells, the accumulation of 
expanded clones of memory T cells and a shrinkage of T cell repertoire 
as aged people. In addition, it is observed a complex reshaping of the 
cytokine network and an age-relate increase in adhesion molecules on the 
lymphocytes surface (Cossarizza A et al., 1996).   
According to epidemiological data in different populations, there is a 
familial component of longevity. Indeed, these studies demonstrate that 
parents, siblings and offspring of long-lived subjects have a significant 
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survival advantage, a high probability to have been or to became long-
living persons and to have a lower risk to undergo the most important age-
related diseases compared with the age-matched controls population 
(Terry DF et al., 2004a, 2004b). Especially, centenarian offspring (CO), 
have genetic and functional advantages that predispose them to healthy 
ageing and longer survival (Terry DF et al., 2004a, 2004b) and are 
considered the best example of successful aging (Franceschi C et al 1995; 
Franceschi C et al., 2008). These findings support the hypothesis that CO 
are a suitable target of ageing studies because  they have an appropriate 
control group, i.e. age-matched healthy elderly subjects, who haven’t a 
familial history of longevity (Derhovanessian E et al., 2010). It is also 
observed that CO as their controls share the same incidents of cancer, 
dementia, osteoporosis, Parkinson’s disease but lower risk of 
cardiovascular disease, myocardial infarction and stroke (Terry DF et al., 
2004a, 2004b).   
Data in literature on B cell branch demonstrate that CO do not show 
the typical naïve/memory shift observed in elderly (Colonna-Romano G 
et al., 2010). Indeed, although a decreased B cell count was observed both 
in CO and in their age-matched controls, in the offspring of centenarians, 
naïve B cells (IgD+CD27-) were more abundant whereas  DN B cells 
(IgD-CD27-) were significantly decreased, looking similar to the young 
(Colonna-Romano et al., 2010). It is well known that the quality and the 
size of the humoral immune response decline with age (Frasca D et al., 
2005; Miller JP and Cancro MP, 2007; Gibson KL et al., 2009; Dunn-
Walters DK et al., 2010; Bulati M et al., 2011) and that these changes are 
correlated by lower antibody responses and decreased production of high-
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affinity antibodies. The evaluation of IgM secreted in the serum by CO 
shows that the values are within the range of the levels observed in young 
subjects (Colonna-Romano et al., 2010). 
Taken together these data support the idea that centenarian offspring 
have an advantage both to fight the main age-related diseases and to 
properly respond against new infections, prolonging their life. 
Alternatively, immunogenetic profile may give this result.  
 
 
 
1.3 Alzheimer’s Disease (AD): 
a model of unsuccessful aging 
 
Alzheimer’s disease (AD) is the most common cause of dementia in 
elderly people. It is a progressive and irreversible neurodegenerative 
disease characterized by functional impairment, amnesia and other 
cognitive dysfunctions (Martin Prince RB, 2011). It can be considered as 
one of the most example of unsuccessful aging. Currently, AD is 
diagnosed by the presence of memory and cognitive impairment, early 
brain atrophy in several brain regions detected by structural MRI, a 
characteristic pattern of decreased glucose metabolism in parietal-
temporal association cortices shown by FDG-PET analysis (Fox NC et 
al., 2001; Sultana R et al., 2013) but, a firmness  diagnosis can be made 
only post-mortem analysis upon brain autopsy. With this analysis it has 
revealed that the two main neuropathologycal hallmarks of AD include 
extracellular deposit of senile plaques and neurofibrillary tangles (NFTs). 
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The former is characterized by the association of amyloid β-peptide, 
dystrophic neuritis, activated microglia and reactive astrocytes; while, the 
latter consist of iperphosphorylated tau-proteins that cause the collapse of 
microtubules (Nussbaum RL and Ellis CE, 2003). The production of Aβ 
plaques is the result of the cleavage of amyloid precursor protein (APP), 
a transmembrane glycoprotein expressed in an ubiquitous way, that is 
synthesized in the endoplasmatic reticulum and it is involved in the 
neuronal and dendritic growth and synapse formation (Priller C et al., 
2006). APP is processed by two different pathways: the physiological 
pathway and the pathogenic or amyloid pathway. The first involves the α-
secretase enzyme which cuts within the APP domain, generating two 
fragments, P3 and AICD, two γ-secretase substrates while the second 
pathway is due to the consecutive action of β and γ secretases, catalyzing 
the release of Aβ40 and Aβ42 fragments that will settle, joining into 
plaques (Selkoe, 2001; Bird TD, 2005. Alzheimer’s disease occurs 
predominantly after the age of sixty, although there are rare cases of onset 
between thirty-fifty years. Most cases of Alzheimer’s disease are sporadic 
even though there is a small subset of cases that have an earlier age of 
onset and have a strong genetic basis. It is accepted that there are many 
factors that increase the incidence of this disease. Indeed, a number of 
studies have found that mutations on APP, Presenilin-1 (PS1) and 
Presenilin-2 (PS2), enzymes/cofactors are involved in the APP digestion, 
lead to a preferential production of Aβ42, the toxic fragment, compared 
to the not toxic fragment Aβ40 (Bird TD, 2005). It is also known that 
Apoliproprotein E (ApoE) can bind amyloid beta peptide and localize in 
senile plaques, supporting the theory that this protein plays a key role in 
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the clereance of Aβ42 (Nussbaum and Ellis, 2003). Moreover, some 
researchers  have shown that cholesterol may influence APP degradation 
pathway inhibiting α-secretase activity but enhancing β- and γ-secretase 
functions (Crestini A et al., 2006; Grimm MO et al., 2011). The most 
important risk factor seems to be the age (Leuner K, et al., 2012). Indeed, 
the aging brain is exposed to a lifetime of changes and insults such as 
oxidative stress, trauma, damaged molecules, inflammation which may 
support the beginning of neurodegeneration. Furthermore, it has been 
observed that in very old women (over eighty years), the risk to 
developing this disease is greater than in males so it seems that gender 
may be considered another AD risk factor ( Nussbaum RL and Ellis CE, 
2003).  
Brain inflammation is a typical hallmark of Alzheimer’s disease. 
Microglia, astrocytes and neurons are responsible for inflammatory 
reactions. Indeed, inflammatory mediators could directly promote AD by 
interference in the APP-metabolism (Fassbender K et al., 2000). 
It has been shown that Aβ peptide is able to stimulate the synthesis 
and secretion of IL-1, IL-6 and IL-8 by microglial cells, activating the 
inflammatory response. In the nervous tissue, these cytokines induce APP 
and, as consequence, Aβ synthesis that, in turn, will increase cytokines 
production by glial cells and neurons. If the activation of cells persists and 
becomes chronic, these cytokines contribute to neurodegeneration 
(Akiyama H et al., 2000). Moreover, the combined action of TNF-α and 
IFN-γ not only stimulates Aβ42 synthesis, but leads to reduced secretion 
of soluble APP protein, generally considered as a protein with 
neuroprotective attitudes.  Inflammation induced by the accumulation of 
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Aβ peptide is not a local phenomenon that concerns only the brain of AD 
patients, but a systemic process that affects the entire organism (Britschgi 
M et al., 2007).  Therefore, a reciprocal relationship between Aβ42 and 
inflammatory mediators might exist (Griffin WS et al., 2002). Different 
studies have shown an increase in chemokines production, like MIP-1α, 
RANTES and MCP-1 by PBMC of AD patients and the expression of 
CCR5 on brain endothelial cells (Li M et al., 2009; Reale M et al., 2008). 
The expression of CCR2 and CCR5 on T cells and CCR5 on B cells on 
AD patients are increased after in vitro stimulation with r-Aβ peptide 
(Pellicanò M et al., 2010).     
It has been recently suggested that blood derived cells seem to 
accumulate in the AD brain and that immunological changes characterizes 
this pathology. Indeed it has been reported a different distribution and 
reactivity of immune cells and the presence of antibodies direct to CNS-
specific amyloid beta peptides (Rogers J et al., 1998; Fiala M et al., 2005; 
Monsonego A et al., 2003). According to this evidences, several studies 
have described a communication between central and systemic immune 
response. It has been suggested that neuroinflammation might induce the 
afflux of central nervous system proteins, as Aβ peptide, or inflammatory 
mediators across the blood-brain-barrel (BBB). This process might cause 
immune response and recruitment of myeloid or lymphocytic cell into the 
brain (Britchgi M and Wyss-Coray, 2007).  Moreover, it has been 
demonstrated that peripheral blood cells (PBMCs) from AD patients are 
able to produce high levels of cytokines, such as IL-1β,and IL-6 compared 
to PBMCs of controls subjects (Speciale L et al., 2007). Other studies 
have shown Aβ-peptide stimulates MIP-1α expression on peripheral T 
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cells and expression of its receptors CCR5 on brain endothelial cells. This 
modification promotes T cells crossing of BBB and migration towards 
brain (Man SM et al., 2006). 
Sign of a systemic involvement have been described in peripheral 
blood lymphocytes. Indeed, it has been reported a significant decrease in 
B and T cells numbers while the number of NK cells does not change 
(Ritchartz-Saltzburger E et al., 2007). Concerning T compartment, the 
most change is seen in CD4+ lymphocytes because, AD patients show a 
significant decline of naïve (CD45RA+CCR7+) and a simultaneous 
increase of effector memory (CD45RA-CCR7-) and TEMRA: (terminal 
effector memory RA) (CD45RA+CCR7-) T cells, when compared to age 
matched controls (Larbi A et al., 2009). Furthermore, recently it has been 
described an higher frequency of activated T cells (CD4+CD25+FoxP3-) 
in AD patients compared to old controls (Pellicanò M et al., 2011).  
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2. OUTLINE OF THE THESIS 
 
The progressive increase of lifespan and the consequent growth of the 
elderly population have focused the attention of scientific community on 
aging. Particularly, researchers have concentrate their efforts trying to 
understand the mechanisms that could lead to longevity. 
Aging is a natural process that occurs in cells, tissues and organs 
(Cevenini E et al., 2008; 2013). One of the most important characteristics 
of aging is the progressive deregulation of immune responses, resulting in 
an increased susceptibility to infectious diseases and pathological 
conditions relating to the inflammation and the onset of autoimmune 
diseases (Troen BR, 2003). The age related modifications in immune 
competence are called “immunosenescence” (Franceschi C et al., 1995; 
Pawelec G et al., 2005). This phenomenon is a complex process that 
involves both the innate and adaptive immune compartment (Franceschi 
C et al., 1995; Licastro F et al., 2005; Pawelec G et al., 2005). Lifelong 
and chronic antigenic load are the major driving force of 
immunosenescence. The consequences of this occurrence are the 
progressive filling of the immunological space by activated lymphocytes 
in response to chronic/continuous stressor agents, the constant decline in 
the number of naive T cells, the reduction of new B cell precursors, the 
extended survival of memory B and T cells, the increase in homeostatic 
proliferation and clonal expansion. All those factors contribute to the 
limited repertoire and the collapse of cell diversity that are frequently 
correlated with poor health status (Cancro MP et al., 2009; Gibson KL, 
2009; Dunn-Walters DK et al., 2010; Scholtz JL et al., 2013)..  
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Nevertheless, some people can reach the extreme limit of life-span in 
good clinical conditions, escaping major age-related diseases, as 
centenarians do. Indeed, they may represent the prototypes of successful 
aging Franceschi C et al., 2005; Terry DF et al., 2003; 2004). This event 
seems to be the result of balance between environmental and genetic 
factors (Franceschi C et al., 1995). Studies of centenarian pose the 
challenge of whom to use as control. Differently from their parents, 
Centenarian offspring (CO) have an appropriate control group, i.e. healthy 
elderly, who haven’t a familiar history of longevity (Derhovanessian E et 
al., 2010). Moreover, offspring of centenarians have a genetic background 
that could predispose them to healthy aging and longer survival rather 
their age-matched controls whose parents died at an average life 
expectancy (Terry DF et al., 2004). 
The aim of this thesis is to study the immunological profile of elderly 
people and a group of people “genetically advantaged” for longevity 
(CO), to evaluate if exist a correlation between familial longevity and the 
immune system, focusing our attention on the B cell branch and 
particularly on double negative (DN) B cells. 
As a model of unsuccessful aging, we focused our attention on 
immune system patients suffering by Alzheimer’s disease (AD). 
In chapter 3 (“A novel B cell population revealed by a CD38/CD24 
gating strategy: CD38(-)CD24(-) B cells in centenarian offspring and 
elderly people”, 2013) we show a different distribution of naïve/memory 
B cell subsets in the elderly and in centenarian offspring. We also 
characterize a novel population of late memory B cells and perform 
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functional analysis to evaluate cytokines productions induced by in vitro 
activation with CpG/PMA/Ionomycin.  
In chapter 4 (“Evidence for Less Marked Potential Signs of T-Cell 
Immunosenescence in Centenarian Offspring Than in the General Age-
Matched Population”, 2013) we show a phenotypic analysis of the T-cell 
arm of adaptive immunity in a group of centenarian offspring comparing 
them with equally elderly people without a familial history of longevity. 
In particular, we have analyzed the expression of CD27, CD28, CD45RA, 
CD45RO and CD57 on CD4+ and CD8+ to evaluate the different stage of 
differentiation of CD4+ and CD8+ subsets between young, elderly, 
centenarian offspring and age-matched controls. The aim of this study is 
to evaluate some possible differences that can be related with the 
increased lifespan expectancy of centenarian offspring. 
In chapter 5 (“Trafficking phenotype and production of Granzyme B  
by Double Negative B cells (IgG+IgD-CD27-) in the elderly”, 2014) we 
investigate the expression of CCR7, CCR6,CXCR4, CXCR5 and CD62L 
on naïve/memory B subpopulations in young and elderly subjects to 
evaluate if the pro-inflammatory status, typical of aged people, could 
influence the trafficking phenotype of these cells.  Furthermore, in order 
to evaluate whether DN memory B cells are able to act as Granzyme B 
(GrB) producing cells, we study their ability to respond to the 
simultaneous in vitro stimulation with IL-21 and the triggering of BCR 
with anti-human IgG, in young and elderly subjects.  
In chapter 6 (“Double Negative (CD19+IgD-CD27-) B lymphocytes: 
a new insight from telomerase activity in healthy elderly, in centenarian 
offspring and in Alzheimer’s disease patients”, manuscript in 
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preparation) we analyze cell surface expression of two BCR-inhibitory 
receptors, CD307d and CD22 to evaluate whether the low proliferative 
ability of Double Negative (DN) B cells might be related to over-
expression of these receptors. Furthermore, in order to evaluate whether 
DN B lymphocytes might play any role in the immune response we 
assessed the proliferative response of these cells after stimulation in vitro 
with different kind of stimuli. Because of DN B cell are capably to 
vigorously proliferate after CpG/α-IgG/CD40 in vitro, we analyzed 
whether this stimulus might modifies telomerase activity in young and 
elderly subjects. In addition, to verify if relative activity of telomerase 
(RTA) might be a useful test to evaluate the efficiency of immune system 
we also performed the test using B cells obtained from genetically 
advantage people, centenarian offspring, and unsuccessfully aged people, 
as patient affected by severe Alzheimer’s disease.  
In chapter 7 (“Immunophenotype and trafficking profile in 
Alzheimer’s disease patients”, manuscript in preparation) we evaluate 
the different distribution of the circulating B cells subpopulation in the 
two different groups of AD patients object of the study (Severe and Mild) 
comparing them one each other and with their age-matched healthy 
controls. Moreover, we analyze the expression of CCR7, CCR6, CXCR3, 
CXCR4 and CXCR5 chemokines receptors on healthy elderly donors, 
severe AD and mild AD patients, in order to evaluate whether in AD 
patients, IgD-CD27- DN B cells show the pro-inflammatory trafficking 
profile.  
In chapter 8 (“Immunosenescence, inflammation and Alzheimer’s 
disease”, 2012) we present a review about the modifications of the 
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immune system with aging (immunosenescence), showing 
immunological changes on cellular and humoral branches. Moreover, we 
focus on changes of some immunoinflammatory parameters observed in 
patients affected by AD.  
In chapter 9 (“Genetics of longevity. data from the studies on Sicilian 
centenarians”, 2012) we report current literature data on centenarians. 
We discuss about genetic background and immune system of these 
subjects that reach the extreme limits of human life.  In particular, we also 
report our data gathered for 10 years in Sicilian centenarians, concerning 
the relationship between gender and longevity, the role of some immune 
and inflammatory genes or epigenetic age-related modifications and 
ageing and longevity. 
In chapter 10 (“Centenarian Offspring: a model for Understanding 
Longevity”,2013) we summarize several aspects that permit to consider 
centenarian offspring a suitable model to understand successful aging. We 
discuss their genetic background, cardiovascular and immunological 
profile and cognitive status. 
Finally, in chapter 11, a summary and general discussion of the 
results are presented.  
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Palermo, Italy 
 
Abstract 
Immunosenescence is characterized by the impairment of both 
cellular and humoral immunity, so elderly people show a reduced ability to 
respond against new infections and vaccines. Moreover, ageing is associated 
with decrease of B lymphocyte percentage and absolute number. We and 
others have previously demonstrated a significant increase of Double 
Negative (DN) (CD19+IgG+IgD-CD27-) B cells in elderly people and in 
chronic stimulated subjects (HIV, SLE, RSV).In previous works, we have 
demonstrated that DN B cells of elderly donors have very short telomeres 
compared to the same subpopulation of young donors, show a low frequency 
of somatic mutation and are not responder to CpG stimulation, although they 
can be weakly activated with F(ab’)2 (anti-BCR). In order to understand 
whether the low attitude to proliferate after the in vitro stimulation of DN B 
cells depends on the expression of inhibitory receptors, we have assessed the 
expression of CD307d and CD22 on naïve/memory B cell subsets focusing 
our attention on DN B cells. Then, we have evaluated the proliferative 
response of DN B cells after different kinds of stimuli in young and elderly 
donors. We have demonstrated that the refractoriness to proliferate of DN B 
cells does not depend on the expression of inhibitory receptors, but it is 
limited to certain stimulators. Indeed, when DN B cells are stimulated 
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engaging contemporarily BCR and TLR9, they become able to proliferate and 
reactivate the relative telomerase activities (RTA). In the present study we 
also compared the telomerase reactivation activity in a group of people 
genetically advantaged for longevity as Centenarian offspring are and in a 
group of severe Alzheimer’s disease patients who represent an example of 
unsuccessful ageing model. In conclusion, we suggest that the monitoring of 
DN B cells might be a useful parameter to evaluate the quality of aging 
process.   
Introduction 
Advancing age yields numerous immune system changes, as 
evidenced by blunted primary and recall response, feeble vaccine efficacy and 
increased prevalence of inflammatory pathologies (Frasca et al. 2004; 
Schenkein et al. 2008; Cancro et al. 2009; Shaw et al., 2010; Frasca et al. 
2011). Accordingly, the knowledge of how age impacts the production and 
the behaviour of B cells, as well as the modulation of the humoral immune 
response, are fundamental to understanding the age-related phenomenon 
known as immunosenescence. B cells are key mediators of immunity having 
effector and regulatory functions, other than antibody production (Harris et 
al., 2000; Martin and Chan, 2006; Sanz et al., 2007), through the secretion of 
different cytokines. These in turn play an important role in the regulation of 
normal immune responses, but also contributing to human autoimmune 
diseases (Youinou et al., 2005; Harris et al., 2005a,b). 
Nowadays B cell branch has been extensively studied and different B 
cells subsets, such as transitional, naïve, memory and plasmablasts have been 
identified by using of different cellular markers, for instance IgD, CD27, 
CD24, CD38 although do not exist a general consensus to classify B cell 
subpopulation in humans (Kaminski et al., 2012). However, it has been 
suggested a kind of classification to identify “core” subsets on peripheral 
CD19+ B cells which could represents an useful biomarker in some 
autoimmune disease (Kaminski et al., 2012). To this perspective,naïve and 
different memory B cells subsets have been described (Shi et al., 2003; 
Tangye and Hodgkin 2004; Fecteau et al., 2006, Wei et al., 2007; Bulati et al. 
2011). In particular, in humans, peripheral blood naïve and memory B cells 
can be divided, on the basis of differential expression of IgD and CD27, into 
different functional cell subsets: naïve IgD+CD27- cells; memory unswitched 
IgD+CD27+ cells, (some of which are the so called “IgM memory” 
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IgM+IgD+CD27+), classical switched memory B cells IgD-CD27+ that also 
include the IgM+IgD-CD27+ (IgM only) and finally - Double Negative (DN) 
memory B lymphocytes  IgD-D27- (Shi et al., 2003; Colonna-Romano et al., 
2009). 
Advanced age is per se a condition characterized by lack of B 
clonotypic immune response to new extracellular pathogens. It is to note that 
aging affects the humoral branch of the immune system because the B cell 
number is reduced in the elderly (Faria et al., 2008; Frasca et al., 2008; Veneri 
et al., 2009). Indeed, it is known that the proportion of different subsets is also 
altered (as reviewed by Bulati et al., 2011).We and others (Colonna-Romano 
et al., 2003; Gupta et al., 2005) have shown that in the elderly there is a 
significant decrease in naïve (IgD+CD27-) B cells and no significant 
reciprocal increase of CD27+ memory B lymphocytes (Klein et al., 1998; 
Agematsu et al., 2000). Moreover, our and other groups have also 
demonstrated the increase in percentage but not in absolute number of 
CD19+IgG+IgD-CD27- (DN) B cells in different cohort of subjects. Indeed, 
this B cell population is expanded both in the elderly (Colonna-Romano et 
al., 2009; Bulati et al., 2011) and in patients suffering of chronic immune 
inflammation, such as chronic HIV infections (Cagigi et al., 2009), systemic 
lupus erythematosus (SLE) (Anolik et al., 2004; Wei et al., 2007) and in 
healthy subjects challenged with respiratory syncytial virus (RSV) (Sanz et 
al., 2008). (Fecteau et al., 2006; Wei et al., 2007; Sanz et al., 2008; Cagigi et 
al., 2009; Colonna-Romano et al., 2009; Bulati et al., 2011). 
However, not all subjects or population groups are equally susceptible 
to the effects of long-term chronic stimulation of the immune system. 
Recently, we have reported that in a genetically advantaged cohort of 
centenarian offspring (CO), distribution of naïve/memory B cells subsets is 
more similar to that observed in young subjects instead of their age-matched 
(AM) controls (70-80 years old) that have not a background of longevity. 
Indeed, CO do not show the typical naïve/memory shift observed in the 
elderly and DN B cells are not increased, while naïve B cell subset is well 
preserved. These data on centenarian offspring support the hypothesis of a 
“familiar youth” of the immune system, due to their favorable genetic 
background, that can be a big advantage both to fight the main age-related 
diseases and to properly respond to vaccinations, also suggesting a good bone 
marrow cell reservoir. Recently, we have evaluated the distribution of 
naïve/memory B cell subset in a Sicilian cohort of Alzheimer’s disease (AD) 
patients. Our preliminary results corroborate data from literature that 
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indicates a reduction both in percentage than absolute number of total B cells 
(Speciale L et al., 2007; Xue et al., 2009; Pellicanò et al., 2010) but 
interestingly, DN B cells are significantly increased in severe AD patients, 
when compared to age-matched healthy elderly donors, suggesting the effect 
of chronic stimulation on the humoral B cell branch (manuscript in 
preparation).  
In our previously paper, we have estimate the ability of DN B cells to 
go toward cycle of replication evaluating the telomere length. As “classical 
memory” IgD-CD27+ B cells, also DN B cells show features of memory 
lymphocytes with short telomeres. We have also demonstrated that DN B 
cells of elderly donors have very short telomeres compared to the same 
subpopulation of young donors (Colonna-Romano et al., 2009). Moreover, 
these cells are not responder to CpG stimulation, although they can be weakly 
activated with F(ab’)2 (anti-BCR)(Colonna-Romano et al. 2009). In addition, 
keeping in mind that DN B cells from elderly subjects show an intrinsic “in 
vitro” activation, there is not a link between their capacity to proliferate and 
the ability to produce cytokines as TNF-α and IL-10 also when stimulated 
with strong stimuli (CpG/PMA/Ionomycin) (Buffa S et al., 2011). 
Recently, a new memory B lymphocyte population was discovered by 
Moir et al. (2008) in HIV-viremic individuals. This subset (CD20+CD27-
CD21-), called tissue-like memory B cells, lacks the expression of CD27 and 
shows a typical profile of pro-inflammatory trafficking receptors that is in 
agreement with migration to chronically inflamed tissues and away from 
lymphoid tissues that favour the cooperation between B and T cells. Similarly 
to DN B lymphocytes, these cells express significantly high levels of some 
chemokine receptors that drive cells to the inflamed tissues (Bulati et al., 
2014). Furthermore, tissue-like memory cells are characterized by high levels 
expression of inhibitory receptors, compared with memory and naïve B cells,  
such as CD307d, CD22 and CD72 that, probably, do not allow high levels of 
proliferation ability of these B cells in response to  B cell stimuli (Moir et al., 
2008).  
In the present study, we have evaluated in young and elderly donors, 
the proliferative response of DN B cells after different kinds of stimuli. In 
order to understand whether the low attitude to proliferate after the in vitro 
stimulation of DN B cells depends on the expression of inhibitory receptors, 
such as exhausted tissue-like memory B lymphocytes in HIV-viraemic 
individuals (Day et al., 2006; Trautmann et al., 2006), we have decided to 
investigate cell surface expression of CD307d and CD22 in naïve and 
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memory B cells in young and elderly donors. Our results demonstrate that, 
although DN cells of elderly donors are per se poorly responders, we show 
that the refractivity to proliferate of DN B cells does not depend on the 
expression of inhibitory receptors, but it is limited to certain stimulators. 
Indeed, in the present paper we observed that engaging contemporary both 
the innate (to which they are not sensitive) and the adaptive receptors, DN B 
cells are able to proliferate. As consequence, we compared the potential 
relationship between proliferation and relative telomerase activities (RTA) in 
DN B cells in young and elderly subjects in order to understand the biology 
of these cells and the age-related modulation of response.  
In conclusion, an adequate stimulation might render DN B 
lymphocytes active players in the immune response. Noteworthy, here we 
also report data obtained from CO and severe AD patients that suggest us that 
the evaluation of the reactivity of DN cells might be a useful parameter to 
evaluate the quality of ageing process. 
Materials and methods 
Subjects 
A total of 63 Sicilian subjects were included in the study:  20 young (age 
range 25-40 years) and 20 elderly (age range 78-90 years), 8 Centenarian 
Offspring (CO) (age range 60-70), 7 age-matched controls (AM) (age range 
63-74) and 8 Alzheimer’s disease patients (AD) (age range 69-76). Among 
this group we have performed phenotype analysis, to evaluate the BCR-
inhibitory receptors (CD307d and CD22) expression in B cell subpopulations 
(20 young and 20 elderly) and we have also performed functional analysis (B 
cell proliferation and relative telomerase activity, RTA, after in vitro 
stimulation on total B cells and DN subset) (10 young, 10 elderly, 8 
Centenarian Offspring (CO), 7 age-matched controls (AM) and 8 Alzheimer’s 
disease patients (AD). 
AD subjects included in the study were assessed with a multidimensional 
protocol including: demographic characteristics, medical history, 
pharmacological treatments, clinical, neuropsychological and neurological  
examination, standard laboratory blood tests and neuro-imaging study with 
CT and/or MRI scan. The exclusion criteria were: a diagnosis of severe 
systemic disorder, the presence of psychosis, a history of significant head 
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injury or substance abuse. Diagnosis of probable AD was according to 
standard clinical procedures and followed the DSM-IV criteria [American 
Psychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV (Text Revision). Washington, American Psychiatric 
Association, 2000] and the diagnosis of AD was based on the criteria of the 
National Institute for Neurological and Communicative Disorders and 
Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann et al.,1984). Cognitive perfor mance and alterations 
were measured according to the Mini Mental State Examination (MMSE) and 
the Global Deterioration Scale.  
Healthy controls (HC), randomly selected from the same population as the 
patient cohort, had complete neurological examinations and were judged to 
be in good health based on their clinical history and blood tests (complete 
blood cell count, erythrocyte sedimentation rate, glucose, urea nitrogen, 
creatinine, electrolytes, liver function tests, iron, proteins, cholesterol, 
triglycerides). The University Hospital Ethics Committee approved the study, 
and informed consent was obtained from all guardians of patients and controls 
according to Italian law. Whole blood was collected by venopuncture in 
vacutainer tubes containing ethylenediamine tetraacetic acid. The samples 
were kept at room temperature and used within 2 h for the various 
experiments. 
B lymphocytes immunomagnetic separation 
Peripheral blood mononuclear cells (PBMCs) were isolated by use of density-
gradient Ficoll-Lympholyte (Cedarlane Laboratories Limited, Ontario, 
Canada) centrifugation. PBMCs were adjusted to 1*106/ml in RPMI 1640 
medium (Euroclone, Devon, UK) supplemented with 10% heat-inactivated 
Fetal Bovin Serum (Euroclone), 1% penicillin/streptomicin, 10 mM HEPES, 
and 1 mM L-Glutamin. B lymphocytes were separated from PBMCs by 
immunomagnetic sorting, as described by Miltenyi et al. (1990) using anti-
CD19 magnetic microbeads (MACS CD19 Multisort Microbeads; Miltenyi 
Biotec, Aubum, CA, USA). Cells obtained from immunomagnetic sorting 
were >98% CD19+ lymphocytes, as determined by flow cytometry analysis. 
Antibodies and Flow Cytometry for phenotypic analysis 
Purified B cells were stained with different combinations of the following 
monoclonal antibodies: anti-IgDFITC, anti-CD27PE or anti-CD27APC, anti-
CD22PE-Cy5(BD, Pharmingen) and anti-CD307dPE (FcRL4) (BioLegend).  
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Cells were washed twice and analyzed. All measurements were made with a 
FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) with 
the same instrument setting. At least 104 cells were analyzed using 
CellQuestPro (Becton Dickinson, San Jose, CA, USA) software.  
Stimulation of B cells in vitro  
Purified B cells (1x105/200 µl) were cultured in 96-well round-bottom plates, 
in complete RPMI medium with 10% Fetal Bovin Serum in absence or 
presence of 2 µg/ml of anti-BCR [F(ab’)2] (Jackson ImmunoResearch 
Laboratories, Inc, Philadelphia) 3µg/ml of CpG-B 2006 
oligodeoxynucleotide (TIB Molbiol, Genova, Italy), and 500ng/ml of anti-
human CD40 purified (BD, Pharmingen) for 72h, at 37°C in 5% CO2. 
 
Proliferation assay 
Cell proliferation assay was performed by Ki67 evaluation. Cultured cells, 
stimulated or not, were washed and stained with anti-IgDPE or anti anti-IgGPE, 
anti-CD19PECy5 and anti-CD27APC for 30 minutes at 4°C. Then cells were 
washed twice and re-suspended with 250 µl of BD Fixation/Permeabilization 
solution for 20 minutes at 4°C. After two wash in BD Perm/Wash solution 
buffer, cells were stained in the dark for 30 minutes on ice with 20µl of anti-
Ki67FITC (Becton Dickinson). Subsequently, cells were washed twice and the 
Ki67 positive cells were analyzed. All measurements were made with a 
FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) with 
the same instrument setting. At least 104 Cells were analyzed using 
CellQuestPro (Becton Dickinson, San Jose, CA, USA) software.   
 
DN B (CD19+IgG+CD27-) lymphocytes sorting with FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, CA, USA)  
After 72hrs of culture, B  cells, stimulated and not stimulated as above 
mentioned, were stained with 20µl of anti-IgGFITC, anti-CD27PE and anti-
CD19APC (Pharmingen, BD Bioscience, Mountain View, CA, USA) for 30 
min at 4°C. Next, cells were washed and 1 ml of PBS/BSA (4%) was added. 
After defining the sorting region gate of CD19+IgG+CD27- (Double Negative, 
DN B cells) population, we optimized the sample concentration, verifying the 
event rate and the sort rate to maximize the efficiency of cell separation. 
Finally, DN B lymphocytes were collected in cytometry tubes and used for 
telomerase activity measurements. 
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Detection  of telomerase activity by TRAP assay  
For quantitative analysis of telomerase activity, a Telomeric Repeat 
Amplification Protocol (TRAP) (Kim et al., 1997) and a photometric enzyme 
immunoassay were performed using TeloTAGGG Telomearse PCR ElisaPlus 
kit (Roche Diagnostics, Indianapolis, USA), according to the manufacture’s 
protocol. This precisely involved elongation and amplification of telomerase 
reaction products to allow highly sensitive detection of telomerase activity by 
a photometric enzyme immunoassay. In addition, cellular extracts from 
human CD19+ or DN B lymphocyte cultures under baseline conditions or 
activated, incubated for 72hrs  and sorted (as above described) were utilized.  
Briefly, we firstly obtained pellets of sorted CD19+IgG+CD27- cells at 
3,000g for 5 min at 2-8°C. They were lysed directly in sterile reaction tubes 
using the lysis buffer provided in the kit.  Protein lysate was kept on ice for 
30 min and centrifuged at 16,000g for 20 min at 2-8°C. Protein concentration 
was measured by standard methods. Subsequently, the supernatants obtained 
were utilized in quantity of 0.5-10 µg total protein for the TRAP reaction, 
having the assurance to prepare for each sample a negative control by heat 
inactivation of its aliquot at 85°C for 20 min. In performing the TRAP 
reaction,  high control template (concentration 0.1 amol/µl; quantity used for 
each reaction 1µl), a reaction mixture (25 µl for each sample), an Internal 
standard (IS;5 µl for each sample) provided in the kit were also utilized. Thus, 
sterile tubes (each containing a total of 30µl of the master mix-25 µl of 
reaction mixture and 5 µl of IS- and a suitable volume of each negative or 
positive sample or  1 µl of control template) were transferred to thermal cycler 
(MyCycler, Biorad). A combined primer elongation/amplification reaction 
was performed by the following protocol:  primer elongation 10-30 min at 25 
°C 1 cycle; telomerase inactivation 5 min at 94°C 1 cycle; amplification 
(denaturation 30s at 94°C; annealing 30s at 50 °C; polymerization 90s 72°C 
) for 30 cycles; 10 min at 72 °C for 1 cycle; hold 4°C. During the  reaction, 
telomerase add   telomeric repeats (TTAGGG)  to the 3’end of the biotin-
labeled primer. The elongation products, as well as the IS included in the same 
reaction tube, are then amplified. The PCR products were split into two 
aliquots, denatured, bound to a streptavidin-coated 96-well plate and 
hybridized to a digoxigenin (DIG)-labeled telomeric repeat-specific probes, 
specific for the telomeric repeats and IS. The resulting products were 
immobilized via the biotin label  to streptavidin-coated 96-well microplate. 
Immobilized amplicons were then detected with an antibody against 
digoxigen that is conjugated to horseradish peroxidase (anti-DIG-HRP) and 
the sensitive peroxidase substrate TMB. . Sample absorbance was measured 
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at 450 nm (reference wavelength 690 nm) using an ELISA plate reader within 
30 min after the addition of the stop reagent. Absorbance values were then 
utilized to calculate the relative telomerase activity of each sample using an 
appropriate formula provided in the kit ‘s protocol.   
 
Statistical analysis 
All statistical analyses were performed with Graph Pad Prism 4.0 using the 
Mann-Whitney nonparametric U test to compare two independent groups. 
Statistical significance was expressed as P<0.05 (*), P<0.01 (**), and 
P<0.001 (***) as shown in the figures. All values are expressed as mean± 
standard error of the mean (SEM). 
 
RESULTS 
Expression of BCR- inhibitory receptors (CD307d and CD22) in B cell 
subpopulations 
To evaluate if any analogy exists between tissue-like memory B cells 
described in the blood of HIV-viraemic individuals and DN B cells observed 
in our models of aging, we have evaluated the expression of two BCR-
inhibitory receptors,CD307d (FcRL4) and CD22. Indeed, it has been 
suggested that the low proliferative capacity of tissue-like memory B cells 
and their reduced replication history in vivo might be related to the over-
expression of inhibitory receptors (Moir et al., 2008).As we have previously 
demonstrated, DN B cells, that are increased in the elderly, proliferate less 
than naïve B cells when stimulated in vitro with different stimulators. The 
evaluation of these inhibitor receptors on naïve/memory B cells identified on 
the basis of IgD/CD27 expression revealed a different situation from data 
described in literature. As shown in table 1, both in young and elderly donors, 
CD307d is mainly expressed on memory unswitched B cells and it is 
significantly reduced on naïve B cells and lost by memory switched and 
double negative B cells. Intriguingly, memory unswitched B cells from old 
donors show significantly higher levels of this molecule compared to memory 
unswitched B cells from young donors. 
Concerning CD22 analysis, its expression is not related to the different ability 
of the four  B cell subpopulations to proliferate. Indeed, our analysis revealed 
a higher degree of expression in all B cell subpopulations independently from 
the age of donors and so, no significant difference was observed between 
young and elderly subjects (Table 1). 
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Taken together these data suggest that there is not a relationship between the 
expression of the two inhibitory receptors and the ability to proliferate of DN 
B cells. 
 
Total CD19+B cells and DN B cells are strongly activated by the 
simultaneous triggering of adaptive (BCR) and innate (TLR9) immune 
receptors 
The attitude of total CD19+ B cells to proliferate, after stimulation with a 
combination of different stimuli, was evaluated in a group of young and 
elderly donors to assess whether any difference could be related to the age of 
the subjects or, differently due to the kind of stimulation. As known, during 
aging the B cell branch of the immune system is impaired resulting in a loss 
of function and a less protective effect against a variety of pathogens. So, the 
correlation stimulus-activation might be helpful to understand the biology of 
these cells and the effector mechanisms. We tested total CD19+ B cells to the 
proliferative effects of TLR9 ligand CpG alone, or with α-IgG/α-CD40 that 
engages the adaptive receptor BCR. Moreover, we have also engaged both 
the innate and the adaptive receptors culturing the cells with both the 
stimulators. Our data confirm the reluctance of CD19+ B cells of elderly 
subjects to properly respond against innate and adaptive stimulation. On the 
contrary, in young donors the same stimuli induce a feeble but growing 
response. Interestingly, when contemporary engaged, the innate and adaptive 
receptors of total B cells cause a strong proliferation both in young than 
elderly subjects (Figure 1). As we are interested on DN B cells and to assess 
whether these cells of the elderly might play any role in the immune response, 
we have evaluated their ability to be activated by different kinds of stimuli. 
As total B lymphocytes, also DN B cells of elderly donors are able to 
proliferate by the contemporary engagement of the innate and adaptive 
receptors (Figure 1). 
Relative Telomerase Activity (RTA) in CD19+B lymphocytes upon 
“different” in vitro stimulation 
As known, chronic stimulation of immune cells and ageing are characterized 
by telomere erosion: this phenomenon causes the reduced proliferative ability 
of immune cells together with the reduction of clonal expansion after antigen 
stimulation. To verify whether the ability to respond to the stimulation with 
CpG, α-IgG and α-CD40 modifies telomerase expression in total B cells and 
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in naive/memory B cells subsets, we cultured B cells of our different groups 
of study with different stimuli. Our preliminary results demonstrate that RTA 
evaluation seem to be a very sensitive method to evaluate the size of 
activation of B cells: indeed as shown in figure 2, activation of total B cells 
with 2 different concentration of CpG alone, or with α-IgG and α-CD40 or, 
finally with CpG,  α-IgG and α-CD40, causes a telomerase activation that is 
dependent on the quality and on the quantity of the stimulation (Figure 2).  
Relative Telomerase Activity (RTA) in DN B cell subset upon “triple” in 
vitro stimulation 
To verify if RTA might be a useful test to evaluate the efficiency of immune 
system in the elderly, we also performed the test using B cells obtained from 
genetically advantaged people, as Centenarian offspring (CO) are (Colonna-
Romano et al., 2010) and unsuccessfully aged people as patient affected by 
severe Alzheimer’s disease (AD).  
As depicted  in Figure 3, the evaluation of RTA in DN obtained from young, 
old, CO and severe AD patients shows that the activation of telomerase in DN 
cells by the combined stimulation of innate and adaptive stimuli mirrors the 
“immunological” age of the donors. In fact old donors show a reduce RTA 
when compared with young donors, CO, as described in other models are in 
the middle between Y and O and finally severe AD patients show very low 
levels of RTA. 
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INHIBIT
ORY 
RECEPT
OR 
Median       
(P25-P75) 
 
Naive 
(IgD+CD
27-) 
 
Memory 
Unswitc
hed 
(IgD+CD
27+) 
 
Memory 
Switched 
(IgD-
CD27+) 
 
Double 
Negative 
(DN)        
(IgD-
CD27-) 
 
p1 
 
p2 
 
p3 
 
p4 
 
p5 
 
p
6 
 
 
YOUNG 
68.6                 
(66.2-71) 
205.5                  
(168.6-
242.5) 
19.3                     
(16.9-
21.8) 
15.7                  
(14.6-
16.7) 
0.04 0.05 0.00
4 
0.002 0.00
1 
N
S C
D
307d
 
ELDERL
Y 
85.8                 
(64.8-
118) 
577.4                  
(526.6-
877) 
30.7                    
(29.9-
35.4) 
21.2                       
(20-27.8) 
0.00
5 
0.05 0.04 0.002 0.00
1 
N
S 
p Young 
vs Elderly 
NS 0.03 NS NS   
 
YOUNG 
421.3      
(383.5-
443.2) 
436.9                       
(366.9-
459.7) 
289.6                    
(246.6-
307.1) 
353.3       
(299.7-
437.5) 
NS NS NS 0.01 NS N
S 
C
D
22
 ELDERL
Y 
449.5                 
(437.6-
570) 
562.2                    
(411-
581.8) 
248.3                 
(231.9-
287.9) 
359.7      
(232.9-
378) 
NS 0.00
1 
0.00
8 
0.009 0.02 N
S 
p Young 
vs Elderly 
NS NS NS NS   
 
Table 1.Evaluation of BCR-inhibitory receptors (CD307d and CD22) expression on B cell 
subpopulations obtained from 20 Young (age range 25-40) and 20 Elderly donors (age range 
78-90). Purified B lymphocytes were stained with anti-IgD and anti-CD27to identify the four 
IgD/CD27 B cell subsets. Subsequently, naïve/memory B cells were evaluated for CD22 and 
CD307 (FcRL4) expression. Both in young and elderly donors, CD307d (FcRL4) is mainly 
expressed on memory unswitched B cells and it is significantly reduced on naïve B cells and 
lost by memory switched and double negative B cells. Memory unswitched B cells from 
elderly subjects show significantly higher levels of this molecule compared to memory 
unswitched B cells from young donors. CD22 is well expressed at in all B lymphocytes 
subpopulations both in young and elderly donors. Values are expressed as median and range 
of mean fluorescence intensities (MFI) ± SEM. p1= Naïve Vs Memory Unswitched; p2= 
Naïve Vs Memory Switched; p3= Naïve Vs DN; p4= Memory Unswitched Vs Memory 
Switched; p5= Memory Unswitched Vs DN; p6= Memory Switched Vs DN. NS=Not 
Significant. Statistical analysis were evaluated by Mann-Whitney nonparametric U testing 
are indicated by p (GraphPad Prism 4). 
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Figure 1. Intracitoplasmatic expression of Ki67 onCD19+B cells and Double Negative (DN) 
B cells cultured in RPMI, CpG,α-IgG/CD40 and CpG/α-IgG/CD40 for 72hr in 10 young 
(age-range 25-40) and 10 elderly (age-range 78-90) subjects. Purified B lymphocytes were 
cultured with different stimuli and then were stained with Ki-67, anti-IgD, anti-CD19 and 
anti-CD27 to assess proliferative ability after in vitro stimulation. (A) Total CD19+ B cells 
from young donors (left side of the figure) slightly proliferate to different stimuli but at higher 
levels with combination of adaptive and innate stimulation;total CD19+ B cells from elderly 
people (right side of the figure) are less responder to the stimulation with CpG and α-
IgG/CD40 but are well activate by the “triple” stimuli CpG/α-IgG/CD40. (B) DN cell from 
young subjects (left side of the figure) maintain the same trend of proliferation of the total 
CD19+ B cells, indeed these cells show a significant level of Ki67 expression when stimulated 
with CpG/α-IgG/CD40; DN B lymphocytes from elderly donors (right side of the figure) 
proliferate significantly with CpG/α-IgG/CD40, even though these cells have higher in vitro 
basal level of activation. Values are expressed as median and range of mean fluorescence 
intensities (MFI) ± SEM. Significant differences are evaluated by Mann-Whitney 
nonparametric U testing and are indicated by *p ≤ .05, **p ≤ .01, ***p ≤ .001. Moreover, we 
reported significant differences between the proliferative ability of DN B cells in young vs 
elderly subjects in not stimulated culture (p<0.0015) and after stimulation with α-IgG/CD40 
(p<0.03), whereas we did not observed significant differences between the proliferative 
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ability of DN B cells in young vs elderly subjects after stimulation with CpG and CpG/α-
IgG/CD40. 
 
 
Figure 2. Relative Telomerase activity (RTA) (mean and SEM) evaluatedin 
CD19+lymphocytes from (5) young subjects (age-range 25-40) purified by immunomagnetic 
sorting and activate withdifferent stimuli: CpG (10µl/ml), CpG (3µl/ml), a-IgG/CD40 and 
CpG/α-IgG/CD40). Telomerase activity was measured by TRAP assay as described in 
Materials and Method. Values are shown in log10 scale. Significant differences are evaluated 
by Mann-Whitney nonparametric U testing (GraphPad Prism 4).   
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Figure 3. The Relative Telomerase Activity (RTA) in Double Negative (DN) B lymphocytes 
(IgG+IgD-CD27-) was measured in not stimulated and stimulated culture with CpG/α-
IgG/CD40 for 72h in 7 young controls(Y) (age-range 25-40), 8 elderly subjects (E) (age-
range 78-90), 8 Centenarian Offspring (CO) (age range 60-70),7 age-matched controls 
(AM)(age range 63-74) and 8 Alzheimer’s disease patients (AD) (age range 63-74). DN B 
cells were separated from other subsets by sorting with FACSCalibur flow cytometer.Values 
are expressed as mean of MFI±SEM.Significant differencesvaluated by Mann–Whitney 
nonparametric U testing (GraphPad Prism 4). In the right side of the figure are represented 
the fold of increase between stimulated and unstimulated culture. The p values are: p<0,0003 
(young), P<0,0002 (elderly), P<0,0003 (Centenarianoffspring), <0,0006 (Age-Matched) and 
<0,0006 (Alzheimer’s disease).  
 
Discussion 
It is well established that both innate and adaptive immunity in the elderly are 
impaired and related to the increased susceptibility to infectious disease, 
autoimmunity and cancer. T and B cell branch are involved in 
immunosenescence (Ouyang et al. 2003; Pawelec et al., 2005; Pawelec and 
Larbi., 2008; Frasca et al., 2004, 2010, 2011; Schenkein et al., 2008; Cancro 
et al., 2009; Bulati et al., 2011; Frasca and Blomberg 2011). In the elderly we 
have demonstrated the increase in percentage,  but not in absolute number, of  
a “Double negative” (IgG+IgD-CD27-) memory B cells population (Colonna-
Romano et al., 2009) and the contemporary reduction of naïve (IgD+CD27-) 
B lymphocytes (Colonna-Romano et al., 2009; Gupta et al., 2005), that is 
crucial for the response to new antigens. However, there are controversial 
findings about the increase, decrease or no change in the naïve/memory B 
cells, as we have reviewed (Bulati et al., 2011). The increase of DN B 
lymphocytes in the old subjects might be associated with their typical 
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inflammatory micro-environment (Licastro et al., 2005; Vasto et al., 2007; 
Singh and Newman, 2011), characterized by a general increase in plasma 
levels of pro-inflammatory cytokines and other inflammatory mediators. 
Moreover, this B cell subset has also been described in patients affected by 
HIV, SLE and challenged with RSV (Fecteau et al., 2006; Wei et al., 2007; 
Sanz et al., 2008; Cagigi et al., 2009). Accordingly with this evidence, their 
increase could be the consequence of pathologic-long-enduring stimulation 
or, alternatively, it might be related to the exhaustion of memory B cells 
chronically stimulated in the elderly (Colonna-Romano et al., 2009).  
A link between “Inflamm-aging” and adaptive immune responses may be 
identified in the expression of chemokine receptors. Recently, we have shown 
that naïve and memory B cells from young and elderly donors  express 
different chemokine receptors. Focusing on DN B cells, we have described 
the higher expression of CCR6 and CCR7 in elderly donors, while the same 
subset obtained by young subjects have revealed the sole expression of 
CXCR3 (Bulati et al., 2014). The meaning of the changing in the chemokine 
receptors profile might be related to the inflammatory environment, typical 
of ageing, rendering these cells more sensitive to pro-inflammatory molecules 
and cytokines (Singh and Newman, 2011; Salvioli et al., 2013) and in this 
way DN B cells become able to migrate in inflamed sites (Bulati et al., 2014).   
Moreover, we have hypothesized that DN might be an exhausted pool of 
memory B cells  (Colonna-Romano et al., 2009) because of their low 
replicative ability after in vitro stimulation with physiological (α-CD40/IL-4; 
CpG ) or not-physiological strong stimulus (CpG/PMA/Ionomycin). 
Recently, we have shown as these cells are not able to produce cytokines such 
as TNF-α and IL-10 (Buffa et al., 2011), even if others reported that DN B 
cells can be stimulated in vitro to secrete immunoglobulins against tetanus 
toxoid and influenza virus  (Wirths and Lanzavecchia et al., 2005).  
Two different groups (Moir et al., 2008; Hao et al., 2011) have described other 
two exhausted B cell populations. The first group have observed, in HIV-
viraemic patients, the increase of a population of memory, tissue-like memory 
B cells (CD20+CD27-CD21-), that express significantly high levels of 
CXCR3 and CXCR6, and low levels of CCR7, CD62L and CXCR5 than 
classical memory or naïve B cells. Furthermore, tissue-like cells are 
characterized by the expression at high levels of inhibitory receptors, 
compared with memory and naïve B cells,  such as CD307d, CD22 and CD72 
that, probably, prevent the proliferation capacity of these B cells in response 
to B cell stimuli (Moir et al., 2008). Hao’s group (2011) has described a 
mature B cell subset that accumulates with age in old mice. They lack the 
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expression of CD21/35, CD23, CD43 and AA4.1, and are also IgD negative. 
Moreover, these cells express low levels of CD62L and CXCR5 and high 
levels of CXCR4. This population is not activated, because of low levels of 
MHC-II and CD86 expression and they seem to be refractory to activation by 
adaptive immune receptors. Indeed this cells poorly respond to BCR and 
CD40 triggering, but they yet respond to TLR9 or TLR7 ligation and 
proliferate most actively to combined TLR and BCR stimuli (Hao et al., 
2011). In the present study, to better understand whether the low proliferative 
capacity of DN B cells after in vitro stimulation may be related to the 
expression of inhibitory receptors, such as exhausted tissue-like memory B 
lymphocytes in HIV-viraemic individuals (Day et al., 2006; Trautmann et al., 
2006), we have decided to analyze cell surface expression of CD307d and 
CD22 in naïve and memory B cells in young and elderly donors. In particular, 
CD307d (FcRL4), is a protein that has the capacity to inhibit BCR signaling 
by binding to SHP-1 and SHP-2 (Ehrhardt et al., 2005), that is exclusively 
presents on B cells, although it is not found in the earliest stages of bone 
marrow B cell development. Low level of CD307d has been found on mature 
and germinal centre B cells, but higher expression of this molecule has been 
observed in a subpopulation of memory B cells (Matesanz-Isabel et al., 2011). 
It has been suggested that CD307d+ B cells could represent a specialized 
tissue subpopulation of memory B cells (Ehrhardt et al., 2005). Thus, it would 
be interesting to determine whether CD307d is a good marker for identifying 
different memory B-cell subsets. In this regard,  Moir et al. (2008) report that 
a population of memory B cells (CD20+CD27-CD21-) positive for FcRL4 
(CD307d+) have an increased frequencies in the peripheral blood of human 
HIV-viraemic patients and have an “exhausted” phenotype. But, in healthy 
individuals FcRL4+ B cells are largely restricted to mucosal tissues and 
mesenteric lymph nodes, and are very rare in peripheral blood, lymph nodes 
and the spleen (Ehrhardt et al., 2005). These cells do not express the typical 
memory B cells marker, CD27, almost all of them have undergone class 
switching, mainly to IgG, whereas a smaller proportion express IgA and they 
lack the expression of markers that identify germinal centre B cells and 
plasma cells (Ehrhardt et al., 2005; Falini et al., 2003). The CD307d+ B cells 
detected by Moir et al. (2008) share many phenotypic features with the tissue-
based FcRL4+ memory B cells, indicating that, in the disease situation of 
viraemic HIV-positive patients, FcRL4+ B cells might exit from mucosal 
tissues and circulate through the blood. Another intriguing feature is that 
reported by Cagigi et al. (2009). Indeed they also found a significant increase 
in percentage of a not classical IgG+CD27- or IgA+CD27-  memory B cell 
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population in HIV-infected patients, that could be the same population, 
identified with different phenotypic markers by Moir et al. (2008).  
Concerning CD22, is a type I membrane protein that is expressed at 
low levels on pre- and immature B cells and maximally on mature B cells 
(Nitschke et al., 1997). Furthermore, it is an inhibitory coreceptor of the BCR 
(Sieger et al., 2013) and, like other co-receptors, is required to modulate the 
antigen receptor signal in response to the stimuli coming from the local 
microenvironment (Cyster  and Goodnow, 1997). This molecule was 
originally identified as a B-cell-associated adhesion protein that appeared to 
function in the regulation of B-cell activation, but the ability of CD22 to 
inhibit antigen-induced signaling depends upon its proximity to the BCR 
(Walker and Smith, 2008). Indeed, while CD22 appears to inhibit signals that 
derive from the BCR, it might also initiate positive signals when react to itself, 
or perhaps with other surface receptors (Walker and Smith, 2008). 
The evaluation of the expression of BCR inhibitory receptors CD307d 
and CD22 in all B subpopulations in young and elderly donors revealed that 
there are not differences between the two age groups studied, with the 
exception of for CD307d on memory unswitched from elderly subjects. In 
this way, the reduced ability of B lymphocytes from old donors to respond to 
immune challenge cannot be fully attributed to a mechanism lying on the 
expression of these molecules. It is interesting to note that, differently to 
tissue-like B cells identified by Moir et al.,(2008), DN B cells do not express 
CD307d. This result might suggest that tissue-like B cells and DN B cells are 
differently controlled in their ability to proliferate after BCR engagement.  
As DN B lymphocytes do not express inhibitors receptors, to 
understand whether these cells might be a by-product of B cell activation or 
whether they might play any role in the immune response, we have decided 
to stimulated B cells in vitro by CpG alone, then α-IgG/CD40 and also the 
contemporary engagement of adaptive and innate immune receptors (BCR 
and TLR9). Our results show that in young subjects total CD19+ cells and all 
B subsets respond after stimulation in vitro albeit at different levels. Indeed, 
they proliferate at higher levels with triggering of BCR/TLR9, respectively 
less with adaptive or innate stimuli. In old donors, the situation is different 
because CD19+ lymphocytes and naïve, memory unswitched and double 
negative B cells do not proliferate after physiological stimuli (CpG alone, 
then α-IgGCD40) but proliferate with the double stimulation although al 
lower levels observed in young donors. This could reflect that simultaneous 
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BCR and TLR stimulation might activate some pathway involved in immune 
function.  
Telomerase is a ribonucleoprotein enzyme that plays an essential role in cell 
proliferation by compensating for the loss of telomere (Greider et al, 1998) 
and protecting chromosomes (Epel et al., 2010). Its activity is highly 
regulated, indeed it is constitutively expressed in germ line cells (Atzmon G 
et al., 2010; Martens et al., 2002; Weng et al., 1997) and in tumor cells while 
is absent in most of human somatic cells (Atzmon G et al., 2010; Kim et al., 
1994), exceptlymphocytes that are the unique cellular population 
characterized by high telomerase expression even during advanced phases of 
differentiation.Moreover, during resting phases B and T subpopulations 
express h-TERT at low levels, but upon activation a significant increase is 
observed (Lobetti-Bodoni et al., 2010; Son et al., 2003;Weng et al., 1997; 
Donaldson et al., 1999). Additionally, it is known that the chronic life stress 
(Damjanovic et al., 2007; Epel et al., 2004) is cause of shortening of telomeres 
and both raised (Damjanovic et al., 2007) and decrease of telomerase activity 
(Epel et al., 2004). Nowadays, the meaning of this paradox is unclear. 
Generally, telomerase activity is under dynamic control. For example, the 
acute stress, e.g. cortisol (Choi et al., 2008) may compromise its activity while 
mitogenic stimulation, e.g. antigen stimulation for B lymphocytes (Igarashi 
and Sakaguki, 1997), may induce itself (Epel et al.,  2010). In fact, telomerase 
activation occurs in conjunction with cell activation after the encounter with 
a cognate antigen (Dolcetti and De Rossi, 2012). 
It is also known that B lymphocytes have longer telomeres and higher 
telomerase activity than T cells (Dolcetti and De Rossi, 2012; Martens et al., 
2002; Weng et al., 1997). In particular, with regard to B subtype, germinal 
centre B cells, a subpopulation with extensive clonal expansion and antigen-
driven selection, show longer telomeres than those of naïve and memory 
lymphocytes and also that CD27+ memory B cells have longer telomeres than 
CD27- population (Dolcetti and De Rossi, 2012; Martens et al., 2002; Weng 
et al., 1997). 
In agreement with these evidence, our group have demonstrated that DN B 
cells and memory B cells have shorter telomeres than naïve B cells. Especially 
in elderly people, classical memory (IgD-CD27+) and double-negative B cells 
(IgD-CD27-), that have a very similar telomere length, have shorter telomere 
compared to young subjects (Colonna-Romano et al., 2009). An open debate 
about the role of shortened telomeres and decrease telomerase activity in the 
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aging of immune system is the main aim of investigations in 
immunosenescence (Lobetti-Bodoni et al., 2010; Son et al., 2000). For this 
reason, and because of it is believed that the up-regulation of telomerase 
might play a role in maintaining lymphocytes replicative potential and 
function (Son et al., 2003) we have examined whether relative telomerase 
activity was induced after stimulation with CpG/α-IgG/CD40 in CD19+ cells 
in young  donors and in DN B lymphocytes in young and elderly subjects. 
We have seen that in stimulated B cells from young people the relative 
telomerase activity approximately increased about 200 fold and also that in 
double negative B cells the levels of induced telomerase activity was higher 
in young than elderly. Further, we have expanded this study to centenarian 
offspring and subject affected by a severe form of Alzheimer’s disease. It is 
known that the CO are a good model to study successful aging inasmuch have 
favourable background, escaping the main age-related disease. Indeed, they 
have a good reservoir of naïve B cells that allow them to keep fighting off 
new infections. As we have previously demonstrated, CO also have less 
double negative B lymphocytes than their age-related counterpart that are not 
genetically advantaged for longevity (Colonna-Romano et al., 2010). On the 
other hand, Alzheimer’s disease is the most common cause of dementia in the 
elderly subjects and it is estimated that the number of affected individuals is 
predicted to triplicate by 2050 (Wimo et al., 2003; Rubio-Perez et al., 2012; 
Hebert et al., 2000; Martorana et al., 2012). Moreover, it has been 
demonstrated that AD patients show many modifications of immune and 
inflammatory systems (Pellicanò et al., 2012; Larbi A et al., 2009; Richartz-
Salzburger E et al., 2007). Particularly, our group and others (Martorana A et 
al., 2012; Pellicanò et al., 2010; Speciale L et al., 2007; Xue et al., 2009) have 
reported a decrease both in percentage and absolute number of total B cells 
from AD patients when compared to their age-matched healthy controls. 
Recently, we have also observed the increase of DN B cells in severe AD 
subjects (manuscript in preparation). Furthermore, it is known that telomerase 
seems to be protect neurons from amyloid Aβ-induced apoptosis (Zhu et al., 
2000; Panossian et al., 2003) and that there are a significant telomeres 
shortening in PBMC from AD than age-matched controls (Panossian et al., 
2003). Here, we have observed that, after stimulation, telomerase activity of 
double negative B cells in centenarian offspring was higher than healthy 
elderly and lower than young subjects so we confirm that they behave halfway 
between young and elderly people. Differently, we have seen that stimulation 
induced telomerase reactivation of double negative B cells of AD patients but 
at lower level than other groups studied.  
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Taken together, our data suggest that if properly stimulated, DN B cells 
acquire the ability to begin new cellular cycles as demonstrated by RTA 
values. Age is not per se a limiting factor for the telomerase function, 
although it has influence on the level of expression of this enzyme. The 
monitoring level of the enzymatic function such as other functional analysis 
(cytokine and chemokine expression, production of pro- and anti-
inflammatory mediators, cytotoxic activity, etc) might represent a rapid and 
immediate additional tool for monitoring the physiologic and pathological 
ageing process. 
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Abstract 
Alzheimer’s Disease (AD) is the most common cause of dementia. It is 
known that, other than age, the systemic inflammation represent one of 
the risk factor for this pathology. Recent evidences suggest that it is not 
only the central nervous system (CNS) that can be blamed for 
inflammatory response in AD, but also cells from periphery. The chronic 
stimulus given by the accumulation of Amyloid β, that characterize the 
Alzheimer’s disease, may trigger the immune reactions inducing a chronic 
inflammation. In the brain tissue, there is an activation of adaptive 
immunity, that try to eliminate the initially insult both from brain and 
periphery. This inflammatory scenario could lead towards a recruitment 
of myeloid and lymphocytic cells into the CNS. As the immune status in 
the periphery is strictly linked with the brain environment, the study of 
the different peripheral lymphocyte subpopulations in AD, results to be 
important. In our previously study, it has been demonstrated a decrease of 
total CD19+ B cells in AD patients when compared with their healthy age-
matched controls, suggesting the involvement of B cells in AD. 
Moreover, we have demonstrated a different distribution of B lymphocyte 
subpopulations in elderly subjects, in which the pro-inflammatory milieu 
seems to influence the profile of trafficking receptor in the increased 
Double Negative (DN, IgD-CD27-) B cell population. Thus, in this study 
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we have assessed the distribution of specific naïve/memory B lymphocyte 
subpopulations in severe and mild AD patients comparing them with their 
age-matched controls. Furthermore, we have evaluated in DN B cells, the 
expression of some chemokine receptors involved in cell migration 
toward inflamed tissue in AD patients and in healthy elderly age-matched 
controls. Here, we show that there is a significant decrease of naïve  
(IgD+CD27-) B cells and a significant increase of DN B cells in severe 
AD subject compared with healthy age-matched control, while mild AD 
subjects behave as their age-matched healthy controls. Besides, we also 
show that DN B cells in AD patients have an enhanced pro-inflammatory 
trafficking profile. Indeed, the increased expression of the chemokine 
receptor CCR6 seems to depend on the severity of the pathology, while 
CCR7, increase only in severe AD patients, supporting the hypothesis that 
the increase of DN B cells is correlated with chronic inflammation. Thus, 
we conclude that AD status might affects the distribution of specific naïve 
and DN memory B cells and that might also influence the pro-
inflammatory profile of trafficking receptor in DN B cells, driving these 
lymphocytes to inflamed brain tissue. 
 
Introduction 
Alzheimer’s disease is the most common cause of dementia involving about 
13 million people worldwide. This pathology, that leads a loss, usually 
progressive and severe, of brain function, does not represent only a medical 
but also a social problem. The economic impact of dementia is enormous. 
Globally, costs for people with dementia is over than 1% of gross domestic 
product (GDP) (Wimo et al., 2010; de Vugt and Verhey, 2013). 
The single greatest risk factor for Alzheimer's disease is age. While the 
disease can occur in younger people, even in their 30s and 40s, the risk grows 
considerably after age 65, and it is estimated that 50% of those who pass their 
eightieth birthday will be stricken. Indeed, during aging, brain is massively 
exposed to a great variety of stressors, such as trauma, oxidative stress, tissues 
damages, inflammation, which may be correlated with the beginning of the 
neuro-degeneration (Fulop et al., 2013a, 2013b). Pathological changes in the 
AD brain include neuronal and synapse loss, senile plaques and 
neurofibrillary tangles, that are normally present in normal brain aging, but in 
AD they are more severe and, at the beginning,  the degeneration involves 
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specific regions of the cerebral cortex, as hippocampus, entorhinal and 
temporoparietal cortex (Sardi et al., 2011). These  areas are  important not 
only for memory, but also for other cognitive functions. The crucial step in 
AD pathogenesis is the production of amyloid beta (Aβ), that is  the result of 
cleavage of a larger peptide, named amyloid precursor protein (APP), which 
is overexpressed in AD (Griffin, 2006). The highly insoluble and proteolysis-
resistant fibrillar 42-aminoacid form of β-amyloid (Aβ42 peptide), leads to a 
formation of senile plaques that accumulate and deposit in the parenchyma 
brain of the AD patients. Even if the elderly are the most involved population, 
aging alone cannot be considered as the only cause of this disease. There are 
other risk factors besides age: family history of Alzheimer's, stress, serious 
illness or injury, inadequate physical and social activity and poor diet (Fulop 
et al., 2013a, 2013b). A number of additional pathogenic mechanisms that 
overlap with Aβ plaques and neurofibrillary tangles include inflammation 
(Strous and Shoenfeld, 2006), oxidative damage (Evseev  et al., 2001), iron 
deregulation (Combarros  et al., 2005), mitochondrial dysfunction 
(Arshavsky, 2006). Inflammation clearly occurs in pathologically vulnerable 
regions of the AD brain, indeed senile plaques result from the accumulation 
of several other proteins and a chronic inflammatory reaction around deposits 
of amyloid. Microglia, astrocytes, and neurons are responsible for the 
inflammatory reaction. Activated cells strongly produce inflammatory 
mediators such as pro-inflammatory cytokines, chemokines, macrophage 
inflammatory proteins, monocyte chemo-attractant proteins, prostaglandins, 
leukotrienes, thromboxanes, coagulation factors, reactive oxygen species, 
nitric oxide, complement factors, proteases, protease inhibitors, pentraxins, 
and C-reactive protein (Veneri et al., 2009; Appay et al., 2011; Bulati et al., 
2011; Frasca et al., 2012; Pawelec et al., 2012).  The microglia activation can 
be due to local or systemic inflammation. In fact, a strong local inflammatory 
stimulus, such as a previous head trauma, is a risk factor for AD and several 
epidemiological studies clearly show that blood elevations of acute phase 
proteins, markers of systemic inflammatory stimuli, may be risk factors for 
cognitive decline and dementia. For a long time lymphocytes were not 
considered as major players in brain immunity and consequently in 
neurodegenerative diseases. Recent evidences suggest that it is not only the 
central nervous system (CNS) that can be blamed for inflammatory response 
in AD, but also cells from periphery (Bonotis et al., 2008; Ciccocioppo et al., 
2008; Miscia et al., 2009; Liu et al., 2010; Pellicanò et al., 2010, 2012; 
Martorana et al., 2012). It is also known that in AD, the integrity of blood 
brain barrier (BBB), which normally act protecting and isolating the brain 
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from organism’s immune reactions, is compromised by multiple 
microtrauma, microvascular pathologies and inflammation. This results in an 
increased permeability of BBB that leads to the abolition of the 
immunological privilege of CNS. It is now well accepted that adaptive 
immunity plays a role in normal brain physiology as well as in 
neurodegenerative diseases (Kipnis et al., 2004, 2008; Schwartz and 
Schechter, 2010). The chronic stimulus given by the accumulation of Aβ, or 
other insults that characterize the Alzheimer’s disease, may trigger the 
immune reactions inducing a chronic inflammation, not only in the brain 
tissue but also in periphery. Herein, the immune system seeks to eliminate the 
overproduced Aβ by mounting an acute inflammatory response (Feng and 
Sun, 2011). This results in an activation of adaptive immunity, production of 
specific antibodies and T cells activation to eliminate the initially insult both 
from brain and periphery. This inflammatory scenario could lead towards a 
recruitment of myeloid and lymphocytic cells into the CNS (Britschgi and 
Wyss-Coray, 2007). So, in this context it has been demonstrated the presence 
of both CD4+ and CD8+ T lymphocytes in brain parenchyma of AD patients 
(Town et al., 2005; Li et al., 2009; Fulop et al., 2013a, 2013b). The overall 
immune response and the persistent microglial activation could result in a 
chronic inflammation process contributing to AD development and 
progression (Fulop 2013a, 2013b).   
The “peripheral lymphocytes” topic, as a different tool for early diagnosis of 
AD, has been examined by different groups, even if with conflicting results 
(Britschgi and Wyss-Coray, 2007; Speciale et al., 2007; Larbi et al., 2009; 
Pellicanò et al., 2010). A reduction of total CD3+ T cells were demonstrated 
(Xue et al., 2009). Specific lymphocyte subpopulations have also been 
investigated, although there are many discordant results (Britschgi and Wyss-
Coray, 2007; Speciale et al., 2007; Larbi et al., 2009; Xue et al., 2009; 
Pellicanò et al., 2010 ). The involvement of B cells in the complex cellular 
interactions active in AD patients is suggested by the modification of their B 
cell compartment when compared with healthy age-matched controls. We 
have previously demonstrate a decrease, both in percentage and in absolute 
number, of total CD19+ B cells in AD patients when compared with their 
healthy age-matched controls (Pellicanò et al, 2010). In this paper we focused 
on the naïve/memory B cell subsets identified with the combination of the 
“core” IgD and CD27 surface markers (Kaminski et al., 2012), trying to 
assess whether the involvement of the B cell branch in AD patients also 
affects the distribution of specific lymphocyte subpopulations. This is also 
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based on our previous paper (Colonna-Romano et al., 2009; Buffa et al., 2011; 
Bulati et al., 2011) in which we showed a different distribution of B 
lymphocyte subpopulations in elderly subjects, in particular a significant 
decrease of naïve (IgD+CD27-) B cells and a significant increase of Double 
Negative (DN, IgD-CD27-) memory B cells. Moreover, as we have 
demonstrate in healthy elderly subjects a pro-inflammatory profile of 
trafficking receptor in DN B cells (Bulati et al., 2014), we evaluated the 
expression of some chemokine receptors involved in cell migration in AD 
patients and in healthy elderly age-matched controls. It is known that the 
combinations of chemokines and their receptors guide the immune cells, and 
also B cells, to specific tissues. In particular CXCR4, CXCR5, CCR6 and 
CCR7 have been identified as receptors that drive B cells to lymph node and 
allow B cells to recirculate, while CXCR3 leads B cells to sites of 
inflammation (Kunkel and Butcher, 2003). Moreover, many authors report 
the involvement of CCR6 in the recruitment of immune system cells in sites 
of inflammation (Schutyser et al., 2003; Comerford et al., 2010; Welsh-Bacic 
et al., 2011). Concerning the role of CCR7 as pro-inflammatory receptor, its  
involvement has been shown in autoimmune and infectious diseases, such as 
rheumatoid arthritis, Helicobacter pylori-induced gastritis, and Sjögren's 
syndrome (Müller and Lipp, 2003). Besides, the CCR7/CCL19/CCL21 
chemokine axis  involvement in the development of tertiary lymphoid tissue 
(TLT), has been recently demonstrated in the chronically inflamed intestine 
of a mouse model of Crohn's-like ileitis (McNamee et al., 2013).  
Surprisingly, both in mild and in severe AD patients, we found a trafficking 
phenotype of DN B cells consistent with the migration of these cells into the 
inflamed tissues.  
 
Materials and methods 
 
1. Subjects studied 
 
Fifty Sicilian subjects were studied, 20 severe (age range 65-85 years) and 15 
mild (age range 65-91 years) Alzheimer’s Disease (AD) patients and 15 
healthy age-matched controls (age range 65-81 years). None of the selected 
subjects had neoplastic, infectious, autoimmune diseases, or received any 
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medications influencing immune function at the time of the study. All 
subjects, or their care-givers,  gave informed consent according to the Italian 
law.  
Healthy controls (HC), randomly selected from the same population as the 
patient cohort, had complete neurological examinations and were judged to 
be in good health based on their clinical history and blood tests (complete 
blood cell count, erythrocyte sedimentation rate, glucose, urea nitrogen, 
creatinine, electrolytes, liver function tests, iron, proteins, cholesterol, 
triglycerides). The University Hospital Ethics Committee approved the study, 
and informed consent was obtained from all guardians of patients and controls 
according to Italian law. Whole blood was collected by venopuncture in 
vacutainer tubes containing ethylenediamine tetraacetic acid. The samples 
were kept at room temperature and used within 2 h for the various 
experiments. 
AD subjects were assessed with a multidimensional protocol including: 
demographic characteristics, medical history, pharmacological treatments, 
clinical, neuropsychological and neurological  examination, standard 
laboratory blood tests and neuro-imaging study with CT and/or MRI scan. 
The exclusion criteria were: a diagnosis of severe systemic disorder, the 
presence of psychosis, a history of significant head injury or substance abuse. 
Dementia was diagnosed according to DSM-IV criteria [American 
Psychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV (Text Revision). Washington, American Psychiatric 
Association, 2000] and the diagnosis of AD was based on the criteria of the 
National Institute for Neurological and Communicative Disorders and 
Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann G et al.,1984). According to Mini-Mental State 
Examination [MMSE] (Folstein et al., 1975), 20 patients were affected by 
severe dementia (score < 17), whereas 15 were affected by mild-to-moderate 
grade of dementia (score >17< 24). Patients with vascular dementia were not 
included in the study. Since treatment with acetyl-cholinesterase inhibitors 
may modulate cytokine expression (Reale et al., 2004), patients were included 
before starting that therapy. The clinical protocol included the following: 
cognitive assessment, functional and behavioural assessment, evaluation of 
vascular risk factors (VRF) and somatic co-morbidity. 
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2. Cell preparation 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous 
blood by density gradient centrifugation on Ficoll-Lympholyte (Cedarlane 
Laboratories Limited, Ontario, Canada). PBMCs were adjusted to 1x106/ml 
in RPMI 1640 medium (Euroclone, Devon, UK) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (Euroclone), 1% 
penicillin/streptomicin, 10 mM HEPES, and 1 mM L-Glutamin.  
3. Antibodies and Flow Cytometry panels 
 
 PBMCs were stained with different combinations of the following 
monoclonal antibodies: anti-IgDFITC, anti-CD196PE (CCR6), anti-CD197PE 
(CCR7), anti-CD183APC (CXCR3), anti-CD184PE (CXCR4, Fusin), anti-
CD185PE-Cy7 (CXCR5) (BD, Pharmingen), anti-CD19PB, anti-CD27AlexaFluor750 
or anti-CD27PE-Cy7 (Beckman Coulter, Miami, FL, USA). Cells were washed 
twice and analyzed. All measurements were made with a CyAN ADP flow 
cytometer (Beckman Coulter, Miami, FL, USA) with the same instrument 
setting. At least 104 cells were analyzed using FlowJo (Tree Star) software.  
 
4. Statistical analysis 
 
Values are given as median and range of mean fluorescence intensities 
(MFI) and are compared using Mann-Whitney nonparametric U test. 
Differences are considered significant when a p value <0.05 was obtained 
by comparison between the different groups. 
 
Results 
Naïve(IgD+CD27-) B cells are decreased and Double Negative (IgD-CD27-) 
B cells are increased in Severe Alzheimer’s Disease Patients. 
We have evaluated the different distribution of the circulating B cells 
subpopulation in the two different groups of AD patients studied (Severe and 
117 
 
Mild) comparing them one each other and with their age-matched healthy 
controls. First, as shown in Figure 1, we confirm (Pellicanò et al., 2010) a 
significant decrease, both in percentage and in absolute number, in total B 
cell population in severe AD subjects compared to healthy elderly, but no 
significant difference between these last ones and mild AD patients. 
 
 
 
 
Figure 1. Evaluation of percentage and absolute number of CD19+ B lymphocytes in 
peripheral blood of healthy elderly, severe AD and mild AD patients. Data are expressed 
as mean ± SD. Statistically significant differences was evaluated with Mann-Whitney 
test and is indicated on the top of the histogram, only when it occurs. 
Concerning the four B cells subpopulations, identified with the “core” 
markers IgD and CD27, we have found, in severe AD subjects, a further 
significant decrease in (IgD+CD27-) naïve B cells (Figure 2, panel A), both in 
percentage and absolute number, and a connected marked increase in Double 
Negative (IgD-CD27-) memory B cells (Figure 2, panel B), in percentage but 
not in absolute number, compared to age-matched healthy donors,. We did 
not find any significant differences on Unswitched (Figure 2, panel C) and 
Switched (Figure 2, panel D) memory B lymphocytes in severe AD patients, 
while Mild AD patients behave as healthy elderly subjects. 
(A) 
0.01 0.03 
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Figure 2. Percentage and absolute number of the four B cell subpopulation, identified by 
using the “core” markers IgD and CD27, in healthy elderly donors, severe AD patients 
and mild AD patients. Data are expressed as mean ± SD. Statistically significant 
differences was evaluated with Mann-Whitney test and is indicated on the top of the 
histogram, only when it occurs. (A) IgD+CD27- Naïve B cells. (B) IgD-CD27- Double 
Negative (DN) B cells. (C) IgD+CD27+ Unswitched Memory B cells. (D) IgD-CD27+ 
Switched Memory B cells. 
 
Profile of trafficking receptors in DN B cell subpopulation. 
 
In order to evaluate whether also in AD patients, IgD-CD27- DN B cells 
show the typical pro-inflammatory trafficking profile (Bulati et al., 2014), 
we have assessed, on these population of lymphocytes, the expression of 
CCR7, CCR6, CXCR3, CXCR4 and CXCR5 chemokines receptors on 
healthy elderly donors, severe and mild AD patients. Concerning CXCR4 
and CXCR5, we have found, in both groups of AD patients (severe and 
mild), exactly similar results to those of their age-matched controls, 
indeed these two chemokines receptors are not present in DN B cells (data 
not shown). The pro-inflammatory CXCR3 chemokine receptor of all 
groups studied shows no significant differences between them (data not 
shown). Surprisingly, we found intriguing results for the other two pro-
inflammatory chemokines receptors CCR6  and CCR7. Concerning 
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CCR6 we show (Figure 3) a significantly increased expression (p= 0.008 
healthy elderly vs mild AD; p= 0.006, healthy elderly vs severe AD) of 
this chemokine receptor related to the severity of Alzheimer’s disease. 
CCR7 expression is significantly increased (Figure 4) in severe AD 
patients, but not in mild AD subjects (p= 0.02, severe AD vs healthy 
elderly; p= 0.009, severe AD vs mild AD). A similar behaviour is 
mirrored in total B cells (Figure 5), suggesting that the expression of these 
chemokines receptors could be influenced by the pro-inflammatory milieu 
of AD patients, and that, CCR6 and, probably, CCR7 could drive B cells 
to inflamed brain tissue. 
 
 
Figure 3. Evaluation of CCR6 expression on IgD-CD27- DN B cells of healthy elderly, 
severe AD patients and mild AD patients. Data are expressed as mean ± SD of Mean 
Fluorescence Intensity (MFI). Statistically significant differences was evaluated with 
Mann-Whitney test and is indicated on the top of the histogram, only when it occurs. 
 
0.006 0.008 
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Figure 4. Evaluation of CCR7 expression on IgD-CD27- DN B cells of healthy elderly, 
severe AD patients and mild AD patients. Data are expressed as mean ± SD of Mean 
Fluorescence Intensity (MFI). Statistically significant differences was evaluated with 
Mann-Whitney test and is indicated on the top of the histogram, only when it occurs. 
 
 
 
 
Figure 5. Evaluation of CCR6 and CCR7 expression on CD19+ B cells of healthy elderly, 
severe AD patients and mild AD patients. Data are expressed as mean ± SD of Mean 
Fluorescence Intensity (MFI). Statistically significant differences was evaluated with 
Mann-Whitney test and is indicated on the top of the histogram, only when it occurs. 
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0.006 0.008 0.03 0.04 
122 
 
Discussion 
 
Although Alzheimer’s disease is a neurodegenerative pathology, it has been 
widely demonstrated the involvement of a dysregulation of the  immune 
response in AD pathogenesis. Even if it is still unclear whether the 
inflammatory processes are a primary or a subsequent event, it has been 
suggested that flogistic process has an important role in disease development 
(Sardi et al., 2011). It is also known that in the elderly there is a low-grade 
chronic and systemic inflammation (inflamm-aging), which is always 
controlled and asymptomatic, and it can constitute a major determinant of 
frailty and age-associated diseases (Gupta and Pansari, 2003; Sardi et al., 
2011; Salvioli et al., 2013). A growing body of evidences demonstrates that 
Aβ-plaques induce an inflammatory reaction in the brain (Vom Berg et al., 
2012; Heneka et al., 2013; Monsonego et al., 2013), whereas the oligomeric 
forms of Aβ42 exert synaptotoxicity (Haass and Selkoe, 2007; Walsh and 
Selkoe, 2007).  It has also been shown the pathological effects of Aβ on brain 
vasculature, that lead to  the “cerebral amyloid angiopathy”, a phenomenon 
that causes vascular inflammation, brain haemorrhages, compromised 
perivascular drainage and altered blood flow (Thal et al., 2008). Moreover, 
the loss of integrity of  BBB, may lead to a passage of proteins in cerebro 
spinal fluid (CSF), causing a compromised role of BBB in preserving the 
brain as an “immune sanctuary” (Sardi et al., 2011). Inflammatory processes 
such as microgliosis, astrocytosis, dystrophic microglia, complement 
activation, cytokine elevation and acute-phase protein changes are thought to 
represent a response to the accumulation of Aβ in the vasculature and 
parenchyma of the brain (Monsonego et al., 2013). The compromised 
immune system associated with aging may substantially impact on these 
processes and lead to compromised brain function and neuronal repair 
processes, which enhance the progression of AD (Monsonego et al., 2013). 
In AD patients there is an evident systemic inflammation, indeed they present 
higher than normal levels of pro-inflammatory cytokines and chemokines 
both in the periphery as well as in the brain (Reale et al., 2008; Lee et al., 
2009). So immune system cells can be stimulated by these pro-inflammatory 
mediators, including also Aβ and various other agents, and the result may be 
an enhanced immune cell differentiation (Pellicanò et al., 2010, 2012; 
Goldeck et al., 2013). So, it is clear that there is a link between immune status 
in the periphery and the brain. Indeed, in AD patients, immune cells migrate 
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along a chemokine gradient from the periphery through the BBB into the 
brain (Fiala et al., 1998), or they are recruited in the CNS by other pro-
inflammatory mediators, such as Aβ, produced in the inflamed brain of AD 
(Britschgi and Wyss-Coray, 2007). For these reasons, an accurate study of the 
phenotype of the different peripheral lymphocytes subpopulation in AD, 
results to be important for monitoring the stage and the severity of the 
pathology. To this day, the only way to confirm a diagnosis of Alzheimer's is 
by autopsy of brain tissue. However, physical, psychological, and 
neurological examination can lead to a relatively accurate diagnosis, partly 
by eliminating other possible causes of dementia and partly by identifying the 
key signs or manifestations of Alzheimer's. Indeed severe and mild-to-
moderate AD subjects were included in the study by using cognitive, 
functional and behavioural assessment and the evaluation of vascular risk 
factors and somatic co-morbidity. In our previously studies on 
immunosenescence of the B cell branch, we have demonstrated a significantly 
decrease in total CD19+ B lymphocytes, both in percentage and in absolute 
number, and a remodeling of the B cell subpopulation with ageing (Colonna 
Romano et al., 2009; Bulati et al., 2011). Indeed, we have reported a 
significantly decrease, in percentage, of the IgD+CD27- naïve B cells  and a 
simultaneous increase, in percentage, of the IgD-CD27- double negative (DN) 
memory B lymphocytes. We characterized these DN B cells as a population 
of switched (IgG+/IgA+) memory B cells with short telomeres and they are 
poorly responder to conventional stimuli, indicating them as senescent cells 
(Colonna Romano et al., 2009; Buffa et al., 2011). It has been also 
demonstrated that the increase of these cells is correlated to the chronic 
stimulation of the immune system, as in Systemic Lupus Erythematosus or 
HIV patients and healthy subjects challenged with Respiratory Syncytial 
Virus (Wei et al., 2007; Sanz et al., 2008; Cagigi et al., 2009). DN B cells 
have also a pro-inflammatory phenotype of trafficking receptors, as they 
express elevated levels of CCR6 and CCR7, indicating that the typical age-
associated chronic-inflamed milieu influence the leukocytes migration 
(Bulati et al., 2014). Moreover, if adequately stimulated, these cells are able 
to proliferate and reactivate telomerase (Martorana et al., manuscript in 
preparation), and, in the presence of IL-21, they produce Granzyme B (Bulati 
et al., 2014). In the present paper we investigate on the B cell arm of the 
adaptive immune system of a cohort of AD patients in two different stages of 
the pathology, severe and mild AD patients, compared them each other and 
with their age-matched healthy controls. We show a decrease of CD19+ B 
cells, both in percentage and in absolute number, in severe AD patients when 
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compared with their age-matched healthy controls. Concerning the B cell 
subpopulation identified by using the “core” markers IgD and CD27, we show 
a significantly decrease, both in percentage and in absolute number, of naïve 
(IgD+CD27-) B cells in severe AD subject compared with healthy age-
matched controls. Besides, there is a significant increase, only in percentage, 
of DN (IgD-CD27-) B cells in severe AD subject compared with healthy age-
matched controls. Mild AD subjects behave as their age-matched healthy 
controls. This data is very interesting because, due to the inflammatory nature 
of AD, it supports the hypothesis that the increase of DN B cells is correlated 
with chronic inflammation. Another intriguing data is that obtained from the 
trafficking phenotype. Indeed, concerning the pro-inflammatory chemokine 
receptor CCR6, its increase depends on the severity of the pathology. 
Recently it has been observed an increase of this chemokine receptor also in 
T cells obtained from AD patients (Goldeck et al., 2013). Other authors report 
that, together with adhesion molecules, like selectins and integrins, CCR6 
influences T cell migration through the choroid plexus into the CSF (Sallusto 
et al., 2012). Moreover, in a mouse model of AD-like disease, it has been 
shown a higher CCR6 expression both in brain and in periphery of these mice, 
which the authors suggested was due to the systemic inflammation in AD 
(Subramanian et al., 2010). Besides, CCR7 expression is significantly 
increased only in severe AD patients, but not in mild AD subjects. These data 
suggest that the expression of these two pro-inflammatory chemokines 
receptors could be influenced by the pro-inflammatory milieu of AD patients, 
and that, CCR6 and, probably, CCR7 could drive B cells to inflamed brain 
tissue. 
 
Conclusions 
 
Alzheimer’s Disease is a progressive, irreversible and debilitating disease 
and, currently, there is no effective preventive or disease modifying therapy 
or treatments available. Immunotherapy represents a potentially disease 
modifying strategy aimed at reducing the pathological lesions of AD and 
facilitating cognitive improvement. Many clinical trials are currently 
underway (Madeo and Frieri, 2013). The main goal of these therapies is to 
reduce the production of and/or enhance the clearance of cerebral Aβ plaques. 
Although mouse models of AD have shown promising results for both passive 
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and active immunotherapy, more investigations are needed before this 
approach can be applied in practice in humans (Fu et al., 2010). Clinical trials 
have not yet shown a significant effect on cognitive decline for A-beta 
immunotherapy despite a reduction is plaque burden (von Bernhardi, 2010; 
Aisen and Vellas, 2013). Another issue is how to monitor therapeutic 
progress. For this reasons, the use of different biomarkers could be important 
to detect pre-clinical disease, select individuals with mild cognitive 
impairment (MCI) and predict which patients may benefit most from therapy. 
So, biomarkers could be useful for the determination of disease risk but are 
also invaluable in establishing a diagnosis.  For example, complement 
proteins show promise as possible biomarkers and seem to be linked to AD 
pathology (Thambisetty et al., 2011). Nowadays, there are several types of 
peripheral biomarkers under investigation, but more work is required before 
they can be considered clinically useful (Mayeux and Schupf 2011). Thus, 
also the phenotypic studies of the peripheral lymphocyte subpopulations 
might be useful as biomarkers of AD for monitoring the effectiveness of 
therapeutic interventions. In this view, the results discussed in this paper 
could be used as additional empirical support aimed at developing standard 
operating procedures for AD biomarkers in the diagnostic routine and clinical 
trial. 
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11. Summary and general discussion 
The aging of the immune system is a gradual and dynamic process that 
modifies some immunological functions. These changes are known as 
“immunosenescence” (Franceschi C et al., 1995; Pawelec G et al., 2005) 
that have a great impact on immune performance in late life, contributing 
to the decreased ability of the elderly people to respond to emerging 
pathogens and to the decreased responsiveness to vaccinations (Grubeck-
Loebenstein B et al., 2009; Thompson WW et al., 2003; Fulop T et al., 
2013). Both the innate and the adaptive immune functions are affected in 
the aged. In particular, with aging, the acquired compartment of the 
immune system shows significant modifications in both T and B cell 
branches. Lifelong and chronic antigenic load are the major driving forces 
of this process, resulting in the reduction of the number of virgin antigen-
non experienced T cells (Franceschi C et al., 2007) and, contemporarily, 
in the filling of the immunological space with expanded clones of memory 
and effector, experienced cells (Franceschi C et al., 2000; Miller JP, and 
Cancro MP, 2007).  
It is known that the adaptive immune response of elderly people is 
qualitatively and quantitatively reduced when compared with the immune 
response of young people. Many studies have focused on T cells but B 
cell compartment is also affected with age. It has been demonstrated that, 
although the number of B cells is diminished, the levels of serum IgG, 
IgA and, to a lesser extent IgE increase while IgM and IgD are decreased 
(Listì F et al., 2006). Thus, it is suggested the possible shift from naïve 
toward memory compartment (Gupta S et al., 2005; Listì F et al., 2006; 
Colonna-Romano G et al., 2008).  
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A typical feature of aging is a chronic low grade of pro-inflammatory 
status, named “Inflamm-aging”, observed in the old people. This 
phenomenon, under genetic controls, is associated with a general increase 
in the production of pro-inflammatory cytokines and inflammatory 
markers (Cevenini E et al., 2010; Cevenini E 2013, Fulop T et al 2004, 
2013) that render elderly people prone to frailty (Balistreri CR et al., 2008; 
Franceschi C et al., 2005).  
It has been suggested that chronic antigenic stimuli, such as herpes 
virus infections (e.g.CMV), play a relevant role in exhaustion of the 
immune system, accelerating immune aging (Pawelec G et al., 2005; 
Akbar AN and Fletcher JM, 2005). Furthermore, the continuous attrition 
caused by chronic antigenic load results in the generation of inflammatory 
responses involved in age-related diseases (Pawelec G et al., 2005; Vasto 
S et al., 2007). 
A typical pathology, correlated to aging, is Alzheimer’s disease (AD). 
It is considered the most common form of age-related cognitive failure. 
Extracellular deposits of amyloid beta peptide trigger inflammatory 
reaction in the brain (Weiner et al., 2006). Moreover, changes in 
lymphocytes distribution and in cytokine levels in the plasma of AD 
patients have been reported (Richartz-Salzburger E et al., 2007; Speciale 
L et al., 2007; Larbi A et al., 2009; Pellicanò M et al., 2011). 
On the other hand, centenarians represent an example of successful 
aging because they have delayed diseases that normally cause mortality 
in the general population (Franceschi C, Bonafè M, 2003). In addition, 
centenarian offspring (CO) have a genetic advantage that could 
predispose them for longevity as they are preserved from age-associated 
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diseases, in particular cardiovascular diseases, stroke, myocardial 
infarction, and diabetes mellitus (Terry DF et al., 2004 a,b).   
The aim of this thesis is to study changes in immune system with age, 
also focusing on people genetically advantaged for healthy ageing 
(Centenarian Offspring) or unsuccessfully aged patients (Alzheimer’s 
Disease) affected paying attention principally on the naïve/memory B cell 
compartments.   
In chapter 3, we have shown our recent work about the naïve/memory 
B cells characterization based on two developmentally regulated markers, 
CD38 and CD24. We discussed about a new population of late memory 
B cells, CD19+CD38-CD24-, that is increased in elderly people compared 
to young and contemporarily reduced in centenarian offspring when 
compared to age-matched controls. We evaluated the production of pro- 
and anti-inflammatory cytokines by CD38/CD24 B cell subsets, 
confirming data in literature which affirm that CD19+CD38hiCD24hi 
(Breg) is the main IL-10-producing B cell population. We have also 
observed a high production levels of TNF by CD19+CD38-CD24+ and 
CD19+CD38-CD24- B cells. Despite the increase of the number of 
markers using for characterization, we confirmed that centenarian 
offspring (CO) have the B cell branch similar to young people but 
different to their healthy age-matched controls. The immunological 
profile of centenarian offspring could guarantee them a protection against 
the risk of infection and the inflammatory processes of ageing.  
In chapter 4 we show our data obtained in a recent study on the T-
cell immune profile of centenarian offspring (CO), their age-matched 
(AM) controls, healthy elderly and young subjects. We have studied the 
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distribution of CD4+ and CD8+ T cells within CD3+ T cell population. 
Here, we observed that CO have a slight increase of percentage CD4+ and 
a lower percentage of CD8+ T cells, compared to AM controls, so the 
CD4:CD8 results higher than AM subjects. Then, it was performed the 
analysis of costimulatory molecules, CD27 and CD28 on CD4+ and CD8+ 
T cells, to identify the stage of differentiation of T cell branch. We have 
shown that, young subjects have the higher percentage and absolute 
number of early differentiated CD4+CD27+ lymphocytes when compared 
to any of older groups (CO, AM and elderly donors). However, CO have 
the higher but not significant percentage and absolute number of these 
two cell subsets within elderly population. A similar pattern was observed 
within CD8+ T cells. Indeed, in young donors there were the highest 
percentage of CD27+ and CD28+ cells compared the other donors 
analyzed; differently, the  mean of percentage of CD27+ T cells and the 
percentage and absolute number of CD28+ were higher in CO than AM 
controls. Moreover, we have also identified the naïve/memory 
distribution within CD4+ and CD8+ populations. Our results show the 
most frequent percentage and absolute number of 
CD27+CD28+CD45RA+CD45RO- naïve cells within the CD4+ and  
CD8+ subsets in centenarian offspring, compared with their age-matched 
controls. Moreover, we have reported the reduction of CD28-CD27-
CD45RA+CD45RO+ late differentiated memory T cells in CO when 
compared with age-matched controls and old people. Next, we have also 
demonstrated that CO have a lower levels of potentially senescent 
CD8+CD57+ cells when compared with AM and elderly people. It is 
possible conclude that CO seems to have a similar phenotype to the young 
186 
 
subjects than that of AM controls. Thus, T cell arm appears resistant to 
major infections and might contribute to reach the extreme limits of life. 
In chapter 5 we have studied the expression of some chemokine 
receptors in peripheral naïve/memory B cell, from young and elderly, to 
evaluate whether the inflammatory milieu could influence B cell subsets 
trafficking. We have observed that naïve and memory unswitched B cells 
have a “lymph node phenotype”, while memory switched B cells express 
molecules useful to leave the lymphoid organs. Indeed, our data show a 
different expression of these chemokine receptors on peripheral naïve and 
memory B cells between the two groups studied. In particular, in young 
donors, naïve B cells express CCR7, CCR6 and CXCR4 allowing B cells 
to circulate. Thereafter, both memory unswitched and memory switched 
modulate the expression of CD62L and CXCR5 necessary to cooperate 
with cells in lymphoid organs. Memory unswitched and DN B cells from 
young subjects show also high levels of CXCR3, a chemokine receptor 
that consent to reach the inflammatory sites. Thus, it seems that both 
memory unswitched and DN B cells are able to migrate into the inflamed 
sites in a common flogistic reaction. With aging, naïve/memory B cell 
populations show some modifications on the expression of the studied 
receptors. Indeed, due to the expression of CXCR3, memory unswitched 
B cells retain the capacity to migrate to the sites of inflammation, while 
DN B cells lose the expression of this molecule, but express CCR6 and 
CCR7, that are also implicated in the migration to the inflammatory sites. 
Further, we investigated also whether total B cells and DN memory B 
lymphocytes are able to act as granzyme B (GrB) producing cells. We 
have shown that, after stimulation, both in young and elderly people, total 
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B cells produce GrB when compared to the not stimulated cells without 
differences between the two groups. Next, we focused on DN B cells, 
observing that also this particular memory population, under the same 
conditions, shows a GrB producing ability without differences between 
the two age groups studied. We hypothesize that the inflammatory 
environment, typical of aging, in some ways changes the trafficking 
ability of B cells and renders them more sensitive both to the cytokines 
and to the pro-inflammatory molecules which are over-produced in the 
elderly. Moreover, these data suggest that DN B cells, which are increased 
in old subjects and show a different pro-inflammatory trafficking profiles, 
in young and elderly subjects are able, if properly stimulated, to migrate 
into inflammatory sites,  to cooperate with other immune cells(i.e. 
memory unswitched B cells), to produce GrB.    
In chapter 6 we show our data (manuscript in preparation) about the 
expression of two inhibitory receptors (CD307d and CD22) on 
naïve/memory B cell subsets from young and elderly donors. We have 
observed that, both in young and elderly subjects, CD307d is mainly 
expressed on memory unswitched B cells and it is significantly reduced 
on naïve B cells and lost by memory switched and DN B cells. 
Interestingly, memory unswitched B cells from old donors, show 
significantly high levels of this molecule compared to memory 
unswitched B cells from young donors. Differently, CD22 is expressed at 
high level in all B cell subsets, independently from the age of donors and 
no significant differences were observed between young and elderly 
subjects. Thus, we conclude that DN B cells do not express a unique 
pattern of inhibitory receptors. Moreover, we have stimulated B cells in 
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vitro with the TLR9 ligand CpG alone, or with α-IgG/CD40, that engages 
the adaptive receptor BCR or with the contemporary engagement of 
adaptive and innate immune receptors (BCR and TLR9). We have 
reported that, in young subjects, total CD19+ cells and DN B lymphocytes 
respond to all stimuli used, albeit at different levels. Indeed, they 
proliferate at high levels with the triggering of BCR/TLR9, and at lower 
levels engaging BCR alone or TLR9. In old donors, the situation is 
different, because CD19+ lymphocytes and DN B cells do not proliferate 
after physiological stimuli (CpG alone, nor α-IgGCD40) but proliferate 
with the double stimulation (CpGα-IgGCD40), although al lower levels 
than those observed in young donors. This could reflect that, the 
simultaneous BCR and TLR stimulation might activate some pathway 
involved in immune function.  Furthermore, we have evaluated the 
relative telomerase activity (RTA) in young and in different groups of 
elderly subjects (CO, AM and elderly donors) to verify whether the ability 
to respond to the stimulation with CpG, α-IgG and CD40 could modify 
telomerase expression in DN B cells. We have reported that, the 
contemporary innate and adaptive stimulation induces the activation of 
telomerase in DN B cells from old and young. Moreover, we have also 
evaluated the induction of telomerase activity in groups of CO and AD 
subjects. Here, again, the contemporary engagement of innate and 
adaptive immune receptors activate telomerase although at different 
levels in the different groups. Indeed, old subjects show a reduced RTA 
when compared with young donors and CO subjects. So, we confirm that 
CO behave halfway between young and elderly subjects. Differently, 
severe AD patients show very low levels of RTA. This findings 
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demonstrated that, DN B cells can proliferate with appropriate stimulation 
and also that healthy aging does not annul the ability to induce telomerase 
activity in DN B cells but influences the level of expression of this 
enzyme.  
In chapter 7 we illustrate data from a manuscript in preparation, about 
the evaluation of naïve/memory B cell distribution, identified with the 
combination of the “core” IgD and CD27 surface markers (Kaminski et 
al., 2012), in the two different groups of AD patients object of the study 
(Severe and Mild), comparing them each other and with their age-matched 
healthy controls. We have confirmed (Pellicanò et al., 2009) a significant 
decrease, both in percentage and absolute number, in total B cell 
population in severe AD subjects, compared to healthy elderly, but no 
significant difference between elderly and mild AD patients. Moreover, 
we have found a significant decrease both in percentage and absolute 
number of (IgD+CD27-) naïve B cells, and a marked increase in 
percentage of Double Negative (IgD-CD27-) B cells, compared to age-
matched healthy donors. Differently, Mild AD patients seem behave as 
healthy elderly subjects. Further, we have assessed the expression of 
CXCR3, CXCR4, CXCR5, CCR6, and CCR7, chemokine receptors, on 
DN B lymphocytes in healthy elderly donors, severe and mild AD 
patients. We have demonstrated that DN B cells from AD patients do not 
express CXCR4 and CXCR5. Concerning CXCR3, we have observed 
high expression of this receptor in DN B cell in all groups studied, with 
no significant differences between them. On the other hand,  CCR6 is a 
significantly increased both in mild and severe AD patients, while CCR7 
expression is significantly increased in severe AD patients, but not in mild 
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AD subjects. Thus, we conclude that severe AD status might affects the 
distribution of specific naïve and DN B cells and that might also influence 
the pro-inflammatory profile of trafficking receptor in DN B cells, driving 
these lymphocytes to inflamed brain tissue. 
In chapter 8, we have discussed about the literature and previous data 
from our group, regarding the involvement of immunological 
modifications in Alzheimer’s disease (AD). We conclude that changes in 
innate and acquired immune system, genetic background and other risk 
factors contribute to the AD pathogenesis.  Indeed, it is suggested that Aβ 
peptides induce a persistent stimulation of the immune system that causes 
chronic T and B cells inflammatory responses and the release of 
inflammatory mediators. These events seem to contribute to 
neurodegeneration. On the other hand, genetic background, such as 
polymorphisms of genes involved in the immune-inflammation, might 
play a role in the generation of AD. Beside, other risk factors, such as 
hormones, levels of education and environmental events could be related 
to this age-related disease. In conclusion, it is considered relevant to 
identify a new method that allows the use of peripheral blood from AD 
patients to identify prognostic or disease markers. Until now, different 
factors, that might be useful at this purpose, has been identified although 
there are many discordant results. 
 
In chapter 9 we have reviewed our and literature data on Sicilian 
centenarians. We conclude that both a well preserved immune function 
and genetic background have a crucial role in aging and longevity and that 
centenarians represent the optimal model to understand successful and 
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unsuccessful aging. Indeed, it has been demonstrated that people 
genetically enriched for longevity possess immune different signatures 
respect to those general population. This suggests the idea of “familiar 
youth”. At this regard, centenarian offspring (CO) do not show a typical 
T naïve/memory shift observed in their age-matched (AM) controls. 
Moreover, also the B cell compartment of CO results similar to that young 
subjects than elderly donors. Indeed, although a decrease in B cell count 
was observed in centenarian offspring and their age-matched controls, it 
has been verified that naïve B cells (IgD+CD27-) were more abundant and 
double negative (DN) B cells (IgD-CD27-) were significantly decreased 
when compared with in young people. In this review, we suggest that 
there are other factors that contribute to longevity, such as, gender, 
environmental conditions, the low pro-inflammatory status, diet and 
genetics variants in TLR4, CCR5 Cox2 genes and also in cytokine 
(e.g.INF-γ, IL-10) genes that, regulating the immune response, seem to 
increase the chances to attain longevity.  
In chapter 10 we review literature data and the results of our studies 
about centenarian offspring (CO). We discussed about the biological 
mechanisms involved in determining the long-lived phenotype and the 
role that these investigations might have in developing of anti-aging 
therapies, drugs and modulating aging rate. We conclude that, CO may 
represent a model for understanding exceptional longevity. Indeed, they 
have a protective genetic background and may have inherited genetic 
variations, from their long-lived parents that protect them from ageing 
processes and hypertension, cancer, diabetes, cardiovascular disease 
(CVD). Moreover, CO show favorable lipid (i.e. high levels of HDL-C, 
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low levels of LDL-C), cardiovascular and an optimal immune profile (i.e. 
high levels of naïve B cells, decrease of DN B cells and high levels of 
serum IgM.). Furthermore, centenarians and their offspring, also, escape 
and/or postpone cognitive decline, dementia and have a reduced incidence 
for AD when compared to their AM controls. These data suggest that, the 
exceptional longevity might be the result of a concomitant action of 
phenotypic and genotypic characteristics, transmitted in long-lived 
families. 
 
11.1 Conclusions 
It is known that the lifelong exposure to new and persistent infections 
(Fulop T et al., 2013; Saule P et al., 2006), typical of aging, affects the 
adaptive immune reactions. Thus, modifications in both T and B cell 
compartments has been demonstrated (Pawelec et al., 2002; 2008; 2013; 
Miller and Cancro, 2007; Colonna-Romano G et al., 2009). Regarding T 
cell branch, these age-related changes result in progressive decrease of 
circulating CD3+, CD4+ and CD8+ T lymphocytes and in the 
accumulation of late stage differentiated CD8+ T cell subset in elderly 
people (Pawelec G et al., 2002). Particularly, several studies suggested 
the increase of the number of highly differentiated CD28- T cells, 
especially within the CD8+ T-cell subset in aged subjects (Effros RB et 
al., 1994; Pawelec G et al., 2008). These (CD28-CD8+) T cells exhibit 
reduced antigen receptor diversity, defective antigen-induced 
proliferation and a shorter replicative lifespan while showing enhanced 
cytotoxicity regulatory functions (Oviedo-Orta et al., 2013; Weng NP, et 
al., 2009) and resistance to apoptosis (Pawelec G et al., 2008). Another 
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interesting memory T cell population increased with aging is TEMRA 
(CCR7−, CD27−, CD28−, CD45RA+). It has been suggested that many of 
these TEMRA cells are not able to produce cytokines, to mediate 
cytotoxic activity and also they show senescence-related proliferative 
defects (Effross RB, 2011; Fulop T et al.,2013). However, it has been 
recently demonstrated that, in some circumstances, these cells might 
secrete cytokines and express high levels of granzyme B and perforin 
(Libri VR et al., 2011). So, they may be important for protection against 
certain infections in vivo (Bruns H et al., 2009; Di Mitri D et al., 2011). 
 As previously described, it has been also reported the impairment of 
the B cell branch with aging (Colonna-Romano G et al., 2003; Miller JP 
and CancroMP, 2007; Frasca D et al., 2008). Indeed, the time-enduring 
stimulation seems induce in elderly people, the decrease of naïve B cells 
(Gupta s et al., 2005; Colonna-Romano G et al., 2008), although other 
authors have observed the increase of percentage but not in the absolute 
number with age of these last cells (Shi Y et al., 2005; Frasca et al., 2008). 
Concerning memory B cell population, Frasca et al., (2012) have shown 
a decrease of both percentage and absolute number of switched memory 
B lymphocytes, suggesting a defect to undergo to class switch. Unlike the 
above-mentioned data, our group (Colonna-Romano G et al., 2003, 2009) 
has reported no significant changes of memory B cells identified as 
CD19+CD27+ in the elderly whereas a population of DN 
(CD19+IgG+IgD-CD27-) B cells is increased in the elderly (Colonna-
Romano G et al., 2009). Beside, the levels of total and specific serum Ig 
isotypes are modified. Indeed, although the number of total B 
lymphocytes is reduced the amount of IgG, IgA and, to a lesser extent 
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IgE, is augmented. In a different way, the levels of IgM decrease or not 
change, while those of IgD decline (Listì F et al., 2006; Frasca D et al., 
2010).  
Most of scientific research on immunosenescence has focused on the 
mechanisms that could lead to longevity. Thus, it is important to study the 
complex process of aging of the immune system in the elderly, in 
successful and unsuccessful models aging, to identify biomarkers of 
human healthy aging that could be potentially useful for the evaluation of 
anti-aging treatments or to improve the quality of life of the growing 
elderly population. Generally, centenarian offspring (CO), that are 
genetically advantaged for longevity, represent a model for understanding 
longevity, while Alzheimer’s disease patients are useful to study 
unsuccessful aging (Terry et al., 2004a, 2004b; Derhovanessian et al., 
2010). Our studies show that CO have a T cell branch more similar to that 
of young people than in their age-matched (AM) controls. Accordingly, 
in these subjects, also the naïve/memory B cell compartment is more 
similar to that of young people than elderly donors. Indeed, naïve B cells 
are increased and DN B cells are reduced when compared to their AM 
controls. Thus, these interesting data indicate that naïve B lymphocytes 
and DN B cells could represent two hallmarks of aging process. The 
relevant role of DN B cells, as biomarker of human life, also results from 
studies conducted on immune system of Alzheimer’s disease patients. 
Indeed, we have demonstrated the decline of naïve B cells and an increase 
of percentage of Double Negative B cells in severe AD subjects, 
compared to age-matched healthy donors; whereas, mild AD patients 
seem behave as healthy elderly subjects. Therefore, it is possible to 
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suppose that the evaluation of the percentage of DN B cells could indicate 
both the chronological age and the biological age of immune system and 
also the performance of immune response against pathogens. Indeed, it 
has been reported that DN B pool is enlarged in chronically stimulated 
individuals, such as healthy subjects challenged with respiratory syncityal 
virus (RSV) (Sanz I et al., 2008), active Lupus patients (Wei C et al., 
2007) and in HIV patients (Cagigi A et al., 2009). Thus, the increased of 
these cells could be the result of persistent stimulation of immune system. 
Furthermore, we have evaluated whether DN B cells represent only a 
marker of aging or whether they are related to systemic inflammation 
because it is known that both elderly and AD patients are characterized 
by an inflammatory milieu that is not typical of CO (Terry DF et al., 2006; 
Salvioli S et al., 2013).  For this purpose, we have studied the expression 
of some chemokine receptors that drive the cells to inflamed tissues, in 
peripheral naïve/memory B cell from young and elderly. These 
experiments have suggested that the inflammatory milieu could influence 
B cell subsets trafficking. Indeed, naïve and memory B cell subsets 
express different pattern of chemokine receptors. The most important 
difference is represented by DN B lymphocytes. Indeed, DN B cells from 
young subjects show high levels of CXCR3, a chemokine receptor that 
consent to reach the inflammatory sites. Differently, in aged people, DN 
B cells lose the expression of this molecule, but show high levels of CCR6 
and CCR7, that are also implicated in the migration to the inflammatory 
sites. In addition, the same analysis has been realized in severe and mild 
AD and it has demonstrated that in patients with severe status of 
Alzheimer’s disease, DN B cells show significant high expression of 
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CCR6 when compared with mild AD subjects, whereas the CCR7 
expression is significantly increased in severe AD patients, but not in mild 
AD subjects. Thus, it seems that the increase of expression of CCR6 
depends on the severity of the pathology. Recently it has been observed 
an increase of CCR6 also on T cells obtained from AD patients (Goldeck 
et al., 2013). A similar behaviour is mirrored in total B cells, suggesting 
that the expression of these chemokines receptors could be influenced by 
the pro-inflammatory milieu of AD patients, and that, CCR6 and, 
probably, CCR7 could drive B cells to inflamed brain tissue. Until now, 
it is known that DN B cells might migrate into tissues with inflammation, 
although their role in these sites is unidentified. Nevertheless, it has been 
demonstrated that, with adequate stimulation, DN B cells secrete 
immunoglobulins against tetanus toxoid and influenza virus (Wirths and 
Lanzavecchia et al., 2005). Moreover, it has been demonstrated that both 
total B cells and DN B lymphocytes, might exert cytotoxic functions. 
Indeed, these cells, when stimulated with α-IgG and IL-21, that is 
increased in aged people, become GrB producing cells that might play a 
significant role in early antiviral immune responses, in the regulation of 
autoimmune diseases and in cancer immunosorvelliance (Hagn M et al., 
2009; Kurschus FC et al., 2004; Gross C et al., 2003). Additionally, we 
have demonstrated that both total B cells and DN B cell become able to 
produce granzyme B, after adequate stimulation, without no differences 
between young and elderly people. Thus, we conclude that DN B cells, 
that show a pro-inflammatory trafficking profile, in young and old 
subjects, if properly stimulated, might migrate into inflammatory sites 
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and, cooperating with other immune cells (e.g. memory unswitched) 
might produce GrB (Bulati M et al., 2014). 
Furthermore, it is known that DN B cells of the elderly donors have 
very short telomeres compared to the same subpopulation of young 
donors and that are not responder to CpG stimulation, although can be 
activated with F(ab’)2 (anti-BCR) (Colonna-Romano et al., 2009). We 
have demonstrated that the engagement of BCR and of TLR9 induces the 
proliferation of DN B cells and also the reactivation of telomerase in DN 
B cells from young and, progressively lesser, in CO, old people and AD 
subjects. This process permits the maintenance of length of telomeres or 
induces replications. 
In conclusion, in the present thesis I show data obtained studying some 
aspects of immune system in young and elderly donors, comparing the 
data obtained from these subjects with the data obtained studying a cohort 
of “genetically advantaged” for long-life subjects (CO) and elderly people 
affected by AD. The presented data suggest that the study of 
naïve/memory B and T cell compartments may be relevant in the 
evaluation of biological ageing of the immune system.  
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12. Sommario e discussione generale 
I cambiamenti progressivi e cumulativi del sistema immunitario con 
l’età, conosciuti con il termine di “Immunosenescenza” (Franceschi C et 
al., 1995; Pawelec G et al., 2005), hanno un grande impatto sulle 
performance del sistema immune nella tarda età, contribuendo alla ridotta 
abilità degli anziani di rispondere in maniera adeguata nei confronti di 
nuovi patogeni e vaccini (Grubeck-Loebenstein B et al., 2009; Thompson 
WW et al., 2003; Fulop T et al., 2013). Durante tale processo, sia le 
risposte innate che quelle adattative subiscono delle modificazioni. In 
particolar modo, con l’invecchiamento, il compartimento acquisito del 
sistema immunitario presenta evidenti variazioni e sia nella branca B che 
in quella T. La stimolazione antigenica cronica rappresenta la causa 
principale di tale processo, che comporta la riduzione del numero di 
cellule T vergini che non hanno mai incontrato l’antigene (Franceschi C 
et al., 2007) e, contemporaneamente, il riempimento dello spazio 
immunologico con cloni espansi di cellule memoria ed effettrici che 
hanno già incontrato l’antigene (Franceschi C et al., 2000; Miller JP, 
Cancro MP, 2007).  
La risposta umorale delle persone anziane è qualitativamente e 
quantitativamente ridotta rispetto a quella presente nei giovani.  Molti 
studi si sono concentrati sulle disfunzioni dei linfociti T e B, che risultano 
essere compromessi con l’invecchiamento. E’ stato dimostrato che, 
sebbene il numero di cellule B si riduca, i livelli sierici di IgG, IgA e, in 
misura minore di IgE aumentano, invece quelli di IgM e IgD 
diminuiscono (Listì F et al., 2006). Pertanto, è stato suggerito un possibile 
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passaggio dalle cellule vergini verso quelle memoria (Gupta S et al., 2005; 
Listì F et al., 2006; Colonna-Romano G et al., 2008).  
Un elemento caratteristico dell’invecchiamento è rappresentato dallo 
stato di infiammazione cronica basale, definito “Inflamm-aging”, 
osservato negli anziani. Tale processo, che è sotto controllo genico, è 
correlato con un aumento generale della produzione di citochine pro-
infiammatorie e marcatori infiammatori (Cevenini E et al., 2010; 
Cevenini E 2013, Fulop T et al 2004, 2013)  che predispone gli anziani 
alla fragilità (Balistreri CR et al., 2008; Franceschi C et al., 2005).  
E’ stato ipotizzato che stimoli antigenici cronici, come l’infezione da 
parte di virus erpetici (es. CMV), svolgono un ruolo rilevante nel rendere 
il sistema immunitario “esausto”, accelerando l’invecchiamento 
immunologico (Pawelec G et al., 2005; Akbar AN and Fletcher JM, 
2005). Inoltre, il logoramento continuo del sistema immunitario, causato 
dalla stimolazione antigenica cronica, genera risposte di tipo 
infiammatorio che sono implicate nelle malattie età-correlate (Pawelec G 
et al., 2005; Vasto S et al., 2007). 
Una tipica patologia, correlata all’età, è la malattia di Alzheimer (AD), 
che è considerata la causa più comune dei problemi cognitivi negli 
anziani. Depositi extracellulari di beta amiloide innescano una reazione 
infiammatoria nel cervello (Weiner et al., 2006). Inoltre, nei pazienti con 
AD sono stati osservati dei cambiamenti nella distribuzione linfocitaria e 
nei livelli di citochine plasmatiche (Richartz-Salzburger E et al., 2007; 
Speciale L et al., 2007; Larbi A et al., 2009; Pellicanò M et al., 2011). 
Diversamente, i centenari rappresentano un esempio di 
invecchiamento con successo, poiché sono sopravvissuti alle malattie che 
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normalmente causano mortalità nella popolazione generale (Franceschi C, 
Bonafè M, 2003). Inoltre, i figli di centenari (CO) hanno un background 
genetico che potrebbe predisporli alla longevità, poiché sembrano essere 
protetti contro le principali malattie associate all’età, come per esempio 
patologie cardiovascolari, infarto, infarto del miocardio e diabete mellito 
(Terry DF et al.,2004 a,b).  
L’obiettivo di questa tesi è di studiare i cambiamenti del sistema 
immunitario durante l’invecchiamento, focalizzando l’attenzione su 
quegli individui che sono “geneticamente avvantaggiati” per 
l’invecchiamento in buono stato di salute (Centenarian Offspring) oppure 
nei confronti di soggetti che mostrano un invecchiamento senza successo 
(Alzheimer’s disease patients), prestando attenzione principalmente ai 
linfociti B naive e memoria.   
Nel capitolo 3, abbiamo presentato un nostro lavoro recente sulla 
caratterizzazione dei linfociti B vergini/memoria basata sull’espressione 
di due marcatori di sviluppo, CD38 e CD24. Abbiamo discusso di una 
nuova popolazione di linfociti B della memoria tardivi, CD19+CD38-
CD24-, che è incrementata negli anziani rispetto ai giovani ed è, 
contemporaneamente, ridotta nei figli dei centenari, quando confrontati 
con i controlli della stessa età. Abbiamo valutato la produzione di 
citochine pro- e anti-infiammatorie da parte delle popolazioni 
CD38/CD24, confermando i dati presenti in letteratura, i quali affermano 
che, la popolazione CD19+CD38hiCD24hi (Breg) è la principale 
popolazione B responsabile della produzione di IL-10. Abbiamo anche 
osservato che le popolazioni CD19+CD38-CD24+ e CD19+CD38-CD24- 
sono le principali cellule responsabili della produzione di TNF. 
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Nonostante, l’incremento del numero di marcatori utilizzati per la 
caratterizzazione, confermiamo che i figli di centenari (CO) hanno una 
branca B linfocitaria simile a quella dei giovani ma differente da quella 
dei loro controlli sani della stessa età. Quindi, il profilo immunologico dei 
figli dei centenari potrebbe garantire loro una maggiore protezione contro 
il rischio di infezioni e dai processi infiammatori tipici dei soggetti 
anziani. 
Nel capitolo 4 abbiamo mostrato i nostri dati ottenuti studiando il 
profilo immunologico dei linfociti T dei figli di centenari (CO), dei loro 
controlli coetanei (AM), dei soggetti anziani sani e dei soggetti giovani. 
Abbiamo studiato la distribuzione dei linfociti T CD4+ e CD8+ dentro la 
popolazione dei linfociti CD3+. In tale studio, abbiamo osservato che i 
CO hanno un debole incremento della percentuale di CD4+ ed una ridotta 
percentuale di cellule T CD8+, per cui il rapporto CD4+:CD8+ risulta 
essere maggiore di quello osservato nei controlli  di pari età. Inoltre, è 
stata effettuata l’analisi delle molecole costimolatorie CD27 e CD28 sui 
linfociti CD4+ e CD8+, per identificare lo stadio di differenziamento dei 
linfociti T. Abbiamo dimostrato che, i soggetti giovani mostrano una 
percentuale ed un numero assoluto di cellule CD4+CD27+  precocemente 
differenziate maggiore rispetto a quella osservata negli altri gruppi 
studiati (CO, AM e anziani). Tuttavia, i CO esprimono  una percentuale, 
anche se non significativa, e un numero assoluto di queste due 
sottopopolazioni cellulari più elevati rispetto agli AM e anziani sani. 
Un pattern simile è stato osservato nella popolazione dei linfociti T 
CD8+.  Infatti, i donatori giovani mostravano una percentuale di CD27+ e 
CD28+ maggiore rispetto a tutti gli altri soggetti studiati; diversamente, la 
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percentuale media di linfociti T CD27+ e sia la percentuale che numero 
assoluto di CD28+ erano maggiori nei CO rispetto gli AM. Inoltre, 
abbiamo anche identificato la distribuzione di cellule naive/memoria 
all’interno delle popolazioni di CD4+ e CD8+. I nostri risultati mostrano 
che i figli di centenari hanno, sia nell’ambito dei CD4+ che dei CD8+, i 
valori percentuali e numero assoluto delle cellule T naive 
CD27+CD28+CD45RA+CD45RO-  maggiore rispetto agli AM. Per di più, 
i CO presentano una riduzione delle cellule T CD28-CD27-
CD45RA+CD45RO+ (late differentiated memory) rispetto sia i controlli 
di pari età che gli anziani sani. Oltre a ciò, abbiamo dimostrato che i figli 
dei centenari hanno un livello basso di cellule potenzialmente senescenti 
CD8+CD57+, rispetto a quello osservato negli AM e nelle persone 
anziane. Quindi, è possibile concludere che i CO presentano un fenotipo 
più simile a quello dei soggetti giovani rispetto ai controlli coetanei. Così, 
il compartimento cellulare T sembra essere più resistente alle principali 
infezioni e potrebbe contribuire al raggiungimento degli estremi limiti 
della vita. 
Nel chapter 5 abbiamo studiato l’espressione di alcuni recettori 
chemochinici in cellule B naïve/memoria di sangue periferico, di soggetti 
giovani ed anziani, per valutare se l’ambiente infiammatorio  influenza il 
traffico cellulare. Abbiamo osservato che i linfociti B naive e memoria 
unswitched hanno un fenotipo linfonodale, mentre le cellule memoria 
switched esprimono molecole utili per lasciare gli organi linfonodali. 
Infatti, i nostri dati dimostrano una espressione diversa di questi recettori 
chemochinici sulle cellule B naive e memoria tra i due gruppi studiati. In 
particolar modo, nei donatori giovani, le cellule B naïve esprimono il 
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CCR7, CCR6 e CXCR4 che consentono ai linfociti B di ricircolare. 
Inoltre, sia le cellule memoria unswitched che quelle switched modulano 
l’espressione del CD62L e CXCR5, necessari a cooperare con le cellule 
negli organi linfoidi. Le cellule B memoria unswitched e le cellule doppio 
negative (DN) dei soggetti giovani mostrano anche livelli elevati di 
espressione del CXCR3, un recettore chemochinico che consente di 
raggiungere i siti infiammatori. Quindi, sembra che sia le cellule memoria 
che le DN siano in grado di migrare nei siti infiammati in una reazione 
flogistica comune. Con l’invecchiamento, le cellule B naive/memoria 
mostrano alcune modificazioni nell’espressione dei recettori studiati. 
Infatti, a causa dell’espressione di CXCR3, le cellule memoria B 
unswitched conservano la capacità di migrare nei siti di infiammazione, 
mentre le cellule B DN perdono l’espressione di questa molecola, ma 
esprimono CCR6 e CCR7, che a loro volta sono anche coinvolti nella 
migrazione ai siti con infiammazione. Successivamente, abbiamo cercato 
di capire se le cellule B totali e le cellule B DN fossero in grado di agire 
come cellule produttrici di granzima B. A questo scopo, abbiamo 
stimolato in vitro le cellule di soggetti giovani ed anziani, con IL-21, che 
è incrementata nelle persone anziane, e con anti-IgG. Abbiamo dimostrato 
che, dopo la stimolazione, le cellule B totali di persone giovani e anziane, 
producono GrB, senza notare alcuna differenza tra i due gruppi.  In 
seguito, abbiamo focalizzato la nostra attenzione sulle cellule B DN, 
osservando che anche questa popolazione particolare di cellule memoria, 
nelle stesse condizioni, produce granzima B, senza alcuna differenza tra i 
due gruppi studiati. Abbiamo ipotizzato che l’ambiente infiammatorio, 
tipico dell’invecchiamento, in qualche modo cambia le abilità di 
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ricircolare (trafficking) delle cellule, rendendole più sensibili sia alle 
citochine e alle molecole pro-infiammatorie che sono over-prodotte 
nell’anziano. Inoltre, questi dati suggeriscono che le cellule B DN, che 
sono aumentate nei soggetti anziani e mostrano un profilo di trafficking 
pro-infiammatorio, in soggetti giovani ed anziani che consente loro, con 
la stimolazione adeguata, di migrare nei siti infiammati, per cooperare con 
le altre cellule del sistema immunitario (es. le cellule memoria B 
unswitched), per produrre il GrB.    
Nel capitolo 6 abbiamo studiato l’espressione di due recettori inibitori 
(CD307d and CD22) sulle cellule B naïve/memory in soggetti giovani e 
anziani. Abbiamo osservato che, sia nei giovani che negli anziani, il 
CD307d è principalmente espresso dalle cellule B memoria unswitched, 
ridotto in modo significativo nelle cellule B naïve B e non espresso dalle 
cellule B memoria switched e anche dalle DN. Un dato molto interessante 
è rappresentato dalle cellule B memoria unswitched dei soggetti anziani, 
le quali mostrano livelli elevati e significativi di questa molecola rispetto 
alle cellule B memoria unswitched nei soggetti giovani. Diversamente, il 
CD22 è espresso a livelli elevati da tutte le sottopopolazioni cellulari B, 
in modo indipendente dall’età dei donatori e senza differenze significative 
tra soggetti giovani ed anziani. Quindi, possiamo concludere che le cellule 
B DN non esprimono un unico pattern di recettori di inibizione. Inoltre, 
abbiamo stimolato le cellule B in vitro con il CpG, ligando del TLR9, o 
con α-IgG/CD40, per stimolare il recettore BCR oppure abbiamo 
stimolato contemporaneamente i recettori dell’immunità acquisita e 
innata (BCR e TLR9). Abbiamo riportato che, nei soggetti giovani, le 
cellule CD19+ totali e i linfociti B DN rispondono a tutti gli stimoli 
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utilizzati, sebbene a differenti livelli. Infatti, queste cellule proliferano a 
livelli elevati stimolando sia il BCR che il TLR9, e a bassi livelli 
stimolando solamente il BCR oppure il TLR9. Nei donatori anziani, la 
situazione è differente, perchè i linfociti CD19+ tot e quelli DN non 
proliferano dopo stimolazione fisiologica (CpG o α-IgGCD40) ma 
proliferano con la doppia stimolazione (CpGα-IgGCD40), sebbene a 
livelli inferiori rispetto a quelli osservati nei donatori giovani. Questo 
potrebbe indicare che, stimolando contemporaneamente il  BCR e  il TLR, 
potrebbe essere attivato qualche pathway coinvolto nelle funzioni 
immunologiche.  Inoltre, abbiamo anche saggiato l’attività relativa della 
telomerasi (RTA) in giovani e anche in diversi gruppi di soggetti anziani 
(CO, AM e anziani sani) per verificare se la capacità di rispondere alla 
stimolazione con CpG, α-IgG e CD40, potesse essere in grado di 
modificare l’espressione della telomerasi nelle cellule B DN. Abbiamo 
dimostrato che, utilizzando simultaneamente uno stimolo innato ed uno 
specifico si induce l’attivazione delle telomerasi nelle cellule B DN di 
soggetti giovani e anziani. Per di più, abbiamo anche saggiato l’attività 
della telomerasi nei figli di centenari e nei soggetti con malattia di 
Alzheimer. Anche in questi altri due gruppi di individui, la stimolazione 
di recettori dell’immunità innata ed acquisita attivano la telomerasi anche 
se a differenti livelli nei diversi gruppi. Infatti, i soggetti anziani mostrano 
una RTA ridotta quando paragonati con i giovani e i figli di centenari.  Di 
conseguenza, confermiamo che i CO hanno un comportamento 
immunologico intermedio tra quello dei giovani e degli anziani. Invece, i 
soggetti con AD in forma grave mostrano bassi livelli di RTA. Questi 
risultati dimostrano che, le cellule B DN possono proliferare con una 
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stimolazione appropriata e anche che il processo di invecchiamento non 
annulla l’abilità di indurre l’attività della telomerasi nelle cellule B DN 
ma influenza i livelli di espressione di questo enzima.  
Nel capitolo 7 abbiamo riportato i dati, inseriti in un lavoro in 
preparazione, in merito alla valutazione della distribuzione delle cellule B 
naïve e memoria, identificate con una combinazione di due marcatori di 
superficie, IgD e CD27 (Kaminski et al., 2012), in due diversi gruppi di 
pazienti con malattia di Alzheimer (gravi e lievi), paragonandoli l’un 
l’altro e con i soggetti sani di controllo loro coetanei. Abbiamo 
confermato (Pellicanò et al., 2009) una riduzione significativa, sia della 
percentuale che del numero assoluto delle cellule B totali nei soggetti con 
AD in forma grave, rispetto agli anziani sani, senza trovare alcuna 
differenza tra gli anziani e i pazienti con AD in forma lieve. Inoltre, 
abbiamo trovato una riduzione significativa sia della percentuale che del 
numero assoluto delle cellule B naive (IgD+CD27-), ed un significativo 
incremento della percentuale delle cellule B DN (IgD-CD27-) rispetto i 
controlli sani di pari età. Diversamente, i pazienti con AD lieve sembrano 
comportarsi in modo simile agli anziani sani. Inoltre, abbiamo saggiato 
l’espressione di alcuni recettori chemochinici, quali CXCR3, CXCR4, 
CXCR5, CCR6, e CCR7 da parte delle cellule B DN in soggetti anziani 
sani e pazienti con AD grave o lieve.  Abbiamo dimostrato che le cellule 
B DN dei soggetti con AD in forma grave non esprimono CXCR4 e 
CXCR5. Per quanto riguarda il CXCR3, abbiamo dimostrato 
un’espressione elevata di questo recettore nelle cellule B DN di tutti i 
gruppi studiati, senza osservare alcuna differenza significativa tra loro. 
Sorprendentemente, il CCR6 è aumentato in modo significativo sia nei 
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pazienti con AD in forma grave che in quelli con forma live, invece il 
CCR7 è aumentato in modo significativo nei pazienti con AD in forma 
grave, ma non in quelli con forma lieve. Quindi, concludiamo che la 
gravità della malattia di Alzheimer potrebbe influenzare la distribuzione 
delle cellule naïve e delle cellule B DN, ed anche il profilo dei recettori di 
trafficking pro-infiammatorio nelle cellule B DN, guidando questi 
linfociti nel tessuto cerebrale infiammato.  
Nel capitolo 8, abbiamo discusso alcuni dati nostri ed altri presenti in 
letteratura riguardanti il coinvolgimento delle modifiche del sistema 
immunitario nella malattia di Alzheimer (AD).  Dall’esame di questi, 
abbiamo dedotto che i cambiamenti nel sistema immunitario innato e 
acquisito, il background genetico ed altri fattori di rischio, contribuiscono 
alla patogenesi di questa patologia. Infatti, è stato suggerito che il peptide 
Aβ induce una stimolazione persistente del sistema immunitario che causa 
risposte infiammatorie croniche da parte delle cellule T e B ed anche il 
rilascio di mediatori infiammatori. Questi eventi sembrano contribuire 
alla neurodegenerazione. Per quanto riguarda il background genetico, è 
stato dimostrato che i polimorfismi dei geni coinvolti nel processo di 
infiammazione del sistema immunitario, potrebbero avere un ruolo nella 
generazione dell’AD. Inoltre, altri fattori di rischio, come ormoni, il 
livello di istruzione e fattori ambientali potrebbero essere associati a 
questa malattia età-correlata. In conclusione, è stato considerato di 
importanza rilevante, identificare un metodo nuovo che consenta l’uso del 
sangue periferico di pazienti con AD per identificare marcatori 
prognostici o associati alla malattia. Sino ad oggi, sono stati identificati 
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diversi fattori che possono essere utili a tale scopo, sebbene ci siano molti 
risultati discordanti. 
Nel capitolo 9 abbiamo commentato nostri dati e alcuni di letteratura 
riguardanti i centenari siciliani. Dalla riflessione su questi dati, è possibile 
concludere che, sia una funzione immunitaria ben preservata che il 
background genetico svolgono un ruolo cruciale nell’invecchiamento e 
nella longevità ed anche che, i centenari rappresentano il modello migliore 
per comprendere l’invecchiamento con e senza successo. Infatti, è stato 
dimostrato che le persone avvantaggiate geneticamente per la longevità 
possiedono delle caratteristiche immunologiche differenti rispetto quelle 
della popolazione generale. Questo suggerisce l’ipotesi della “giovinezza 
familiare”. A tal proposito, i figli dei centenari (CO) non possiedono il 
tipico profilo delle cellule T naive e memoria osservato nei controlli di 
pari età (AM). Inoltre, anche il compartimento cellulare dei linfociti B dei 
CO risulta essere più simile a quello osservato nei soggetti giovani rispetto 
a quello degli anziani. Infatti, sebbene nei figli dei centenari e nei loro 
controlli di pari età sia stato osservata una riduzione nel numero delle 
cellule B, è stato dimostrato che le cellule B naïve  (IgD+CD27-) 
aumentano e che le cellule B DN (IgD-CD27-) si riducono in modo 
significativo quando paragonate con le persone giovani. In questo lavoro, 
noi ipotizziamo che esistono altri fattori che contribuiscono alla longevità, 
come il genere, condizioni  ambientali, lo stato pro-infiammatorio, la dieta 
e le mutazioni nei geni per il TLR4, CCR5 Cox2 ed anche in quelli per le 
citochine (es. INF-γ, IL-10) che regolano la risposta immunitaria. Tali 
fattori aumentare le possibilità per il raggiungimento della longevità. 
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Nel capitolo 10 abbiamo esaminato i dati presenti in letteratura 
insieme ai risultati dei nostri studi riguardanti i figli dei centenari (CO). 
Abbiamo discusso dei meccanismi biologici che contribuiscono al 
raggiungimento di un fenotipo longevo ed anche il ruolo che queste 
ricerche potrebbero avere nello sviluppo di terapie anti-invecchiamento, 
farmaci e nel controllo della velocità del processo di invecchiamento. 
Concludiamo che, i figli dei centenari (CO) potrebbero rappresentare un 
modello di invecchiamento per comprendere la longevità. Infatti, essi 
hanno un background genetico protettivo e potrebbero avere ereditato 
delle varianti geniche, dai loro genitori longevi, che li proteggono dal 
processo di invecchiamento e dall’ipertensione, cancro, diabete, patologie 
cardiovascolari (CVD). Inoltre, i CO mostrano un profilo cardiovascolare 
e lipidico favorevoli (es. alti livelli di HDL-C, bassi livelli di LDL-C) ed 
un profilo immunologico ottimale (es. alti livelli di cellule B naïve, 
diminuzione di cellule B DN ed alti livelli di IgM sieriche). Inoltre, i 
centenari ed i loro figli, sfuggono o posticipano il declino cognitivo, la 
demenza ed hanno una ridotta incidenza per l’AD rispetto ai loro controlli 
di pari età (AM). Questi dati suggeriscono che, l’eccezionale longevità 
potrebbe essere il risultato di un’azione concomitante di caratteristiche 
fenotipiche e genotipiche, trasmesse nelle famiglie longeve. 
 
12.1 Conclusioni 
E’ noto che l’esposizione duratura alle infezioni nuove e persistenti 
(Fulop T et al., 2013; Saule P et al., 2006), tipiche degli anziani, 
influenzano le reazioni immunitarie acquisite. Infatti sono state 
dimostrate modifiche nel compartimento cellulare sia dei linfociti T che 
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in quello dei B (Pawelec et al., 2002; 2008; 2013; Miller and Cancro, 
2007; Colonna-Romano G et al., 2009). Per quanto concerne la branca 
cellulare dei linfociti T, i cambiamenti correlati all’età risultano in una 
riduzione progressiva dei linfociti T CD3+, CD4+ e CD8+ T circolanti e 
nell’incremento delle cellule T CD8+ terminalmente differenziate (late 
stage differentiated) nelle persone anziane (Pawelec G et al., 2002). In 
particolar modo, diversi studi hanno suggerito l’incremento del numero 
di cellule T CD28- altamente differenziate (highly differentiated), 
specialmente nell’ambito dei linfociti T CD8+ nei soggetti anziani (Effros 
RB et al., 1994; Pawelec G et al., 2008). Queste cellule T (CD28-CD8+) 
mostrano una ridotta diversità recettoriale, proliferazione difettiva indotta 
dall’antigene, breve vita replicativa e un’aumentata funzione citotossica 
(Oviedo-Orta et al., 2013; Weng NP, et al., 2009) e resistenza all’apoptosi 
(Pawelec G et al., 2008). Un’altra popolazione di linfociti T memoria 
interessante, che incrementa con l’età, è rappresentata dalle cellule T 
memoria effettrici terminalmente differenziate, TEMRA (CCR7−, CD27−, 
CD28−, CD45RA+). E’ stato suggerito che molte di queste cellule 
TEMRA non siano in grado di produrre citochine, di mediare attività 
citotossiche, e sembrano mostrare difetti proliferativi associati alla 
senescenza (Effross RB, 2011; Fulop T et al.,2013). Tuttavia, di recente, 
è stato dimostrato che in alcune circostanze queste cellule possono 
secernere citochine ed esprimere alti livelli granzima B e perforina (Libri 
VR et al., 2011). Quindi, queste cellule potrebbero essere importanti per 
la protezione contro alcune infezioni in vivo (Bruns H et al., 2009; Di 
Mitri D et al., 2011). Come discusso precedentemente, nel compartimento 
cellulare dei linfociti B sono stati dimostrati dei cambiamenti correlati 
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all’età (Colonna-Romano et al., 2003; Miller JP and Cancro MP, 2007; 
Frasca D et al., 2008). Infatti, la stimolazione persistente sembra indurre 
nelle persone anziane, la diminuzione delle cellule B CD19+ totali 
(Colonna-Romano et al., 2003; Frasca D et al., 2008; Veneri D et al., 
2009) e delle cellule naive (Gupta s et al., 2005; Colonna-Romano G et 
al., 2008), sebbene altri gruppi di ricerca abbiano osservato l’incremento 
della percentuale ma non del numero assoluto di queste ultime con l’età 
(Shi Y et al., 2005; Frasca et al., 2008). Per quanto riguarda la popolazione 
di cellule B memoria, il gruppo di ricerca della Frasca (Frasca et al.,, 
2012) ha dimostrato una diminuzione sia della percentuale che del numero 
assoluto dei linfociti B memoria switched, suggerendo un difetto delle 
cellule nel compiere lo switch di classe. Diversamente da quanto riportato 
prima, il nostro gruppo (Colonna-Romano G et al., 2003, 2009) non ha 
riportato nessun cambiamento significativo nelle cellule B memoria, 
identificate come CD19+CD27+ nell’anziano, ma un incremento 
significativo della popolazione di linfociti B DN(CD19+IgG+IgD-CD27-) 
in tali soggetti (Colonna-Romano G et al., 2009). Inoltre, i livelli sierici 
di immunoglobuline totali e degli isotipi specifici subiscono modifiche 
con l’età. Infatti, sebbene il numero dei linfociti B totali si reduca con 
l’età, i livelli di IgG, IgA , e in misura minore di IgE, sono aumentati. 
Diversamente, i livelli di IgM diminuiscono oppure non cambiano, 
mentre quelli di IgD si riducono (Listì F et al., 2006; Frasca D et al., 2010).  
La maggior parte delle ricerche scientifiche sull’immunosenescenza 
hanno focalizzato l’attenzione sui meccanismi che potrebbero portare alla 
longevità. Per cui, si ritiene importante studiare il complesso processo 
dell’invecchiamento del sistema immunitario negli anziani ed anche in 
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modelli di studio dell’invecchiamento con e senza successo, per 
identificare biomarcatori di invecchiamento in buona salute, che 
potrebbero essere utili per valutare i trattamenti di anti-invecchiamento 
oppure migliorare la qualità della vita della popolazione anziana che è in 
aumento. In generale, i figli dei centenari (CO), che sono avvantaggiati 
geneticamente per la longevità, rappresentano un modello per 
comprendere la longevità, invece i pazienti con malattia di Alzheimer 
sono utili per studiare l’invecchiamento senza successo (Terry et al., 
2004a, 2004b; Derhovanessian et al., 2010). I nostri studi dimostrano che 
i CO hanno un compartimento cellulare dei linfociti T molto più simile a 
quello dei soggetti giovani che ai loro controlli di pari età (AM). Inoltre, 
in questi soggetti, anche il compartimento cellulare dei linfociti B naïve e 
memoria è più simile quello delle persone giovani rispetto a quello delle 
persone anziane. Infatti, le cellule B naive sono aumentate e i  linfociti B 
DN sono ridotti rispetto ai loro controlli AM. Di conseguenza, questi dati 
interessanti indicano che i linfociti B naïve e le cellule B DN potrebbero 
rappresentare due marcatori del processo di invecchiamento. Il ruolo 
rilevante delle cellule B DN, come biomarcatori di vita umana, risulta 
anche da studi condotti sul sistema immunitario dei pazienti con malattia 
di Alzheimer. Difatti, abbiamo dimostrato il declino delle cellule B naïve 
e un incremento della percentuale di cellule B DN in soggetti con AD 
grave, rispetto ai donatori coetanei in buone condizioni di salute; invece, 
i pazienti con AD lieve sembrano comportarsi come gli anziani sani. 
Quindi, è possibile supporre che la valutazione della percentuale delle 
cellule B DN potrebbe indicare sia l’età cronologica che quella biologica 
del sistema immunitario ed anche le prestazioni delle risposte immunitarie 
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contro i patogeni. Infatti, è stato riportato che il pool di cellule B DN è 
espanso in individui stimolati cronicamente, come soggetti sani infettati 
con virus respiratorio sinciziale (RSV) (Sanz I et al., 2008), pazienti con 
Lupus (Wei C et al., 2007) ed in soggetti con HIV (Cagigi A et al., 2009).  
Di conseguenza, l’incremento di queste cellule potrebbe essere il risultato 
di una stimolazione persistente del sistema immunitario.  Inoltre, abbiamo 
anche cercato di comprendere se le cellule B DN possono essere 
considerate un marcatore di invecchiamento oppure se queste cellule sono 
correlate all’infiammazione sistemica, poiché è noto che sia gli anziani 
che i pazienti con AD sono caratterizzati da un’infiammazione sistemica 
che non è tipica dei CO (Terry DF et al., 2006; Salvioli S et al., 2013). A 
tale scopo, abbiamo studiato l’espressione di alcuni recettori 
chemochinici che guidano le cellule verso i tessuti infiammati, nelle 
cellule B naive e memoria di sangue periferico di soggetti giovani e 
anziani. Questi esperimenti hanno suggerito che l’ambiente 
infiammatorio potrebbe influenzare il traffico delle cellule B. Infatti, le 
sottopopolazioni B naive e memoria esprimono differenti pattern di 
recettori chemochinici. La differenza più importante è rappresentata dai 
linfociti B DN. In particolar modo, le cellule B DN dei soggetti giovani 
esprimono livelli elevati di CXCR3, un recettore chemochinico che 
consente di raggiungere i siti infiammati. Differentemente, nelle persone 
anziane, le cellule B DN perdono l’espressione di questa molecola, ma 
mostrano livelli elevati di CCR6 e di CCR7, che sono anche implicati 
nella migrazione ai siti infiammati. Inoltre, la stessa analisi ha è stata 
realizzata in soggetti con AD grave o lievi. E’ stato dimostrato che nei 
pazienti con la forma grave di Alzheimer, le cellule B DN esprimono 
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elevati e significativi livelli di CCR6 rispetto i soggetti con AD lieve, 
mentre l’espressione del CCR7 è aumentata in modo significativo nei 
pazienti con AD in forma grave, ma non in quelli con la forma lieve della 
malattia. Quindi, sembra che l’incremento dell’espressione del CCR6 
dipenda dalla gravità della patologia. Di recente, è stato osservato un 
incremento di espressione del CCR6 anche da parte delle cellule T 
ottenute da pazienti con AD (Goldeck et al., 2013). Un comportamento 
simile è effettuato anche da parte delle cellule B totali, suggerendo che 
l’espressione di questi recettori chemochinici potrebbe essere influenzato 
dall’ambiente pro-infiammatorio dei pazienti con AD, e che, il CCR6 e, 
probabilmente, il CCR7 potrebbero giudare le cellule B verso il tessuto 
cerebrale infiammato. Ad oggi, è noto che le cellule B DN potrebbero  
migrare nei tessuti con infiammazione, sebbene il loro ruolo in questi siti 
non si conosca. Tuttavia, è stato dimostrato che, con un’adeguata 
stimolazione, le cellule B DN secernono immunoglobuline contro la 
tossina tetanica ed il virus influenzale (Wirths and Lanzavecchia et al., 
2005). Per di più, è stato dimostrato che sia le cellule B totali che i linfociti 
B DN, possono esercitare funzioni citotossiche. Infatti, queste cellule, 
quando stimolate con α-IgG e IL-21, che è aumentata nelle persone 
anziane, producono il granzima B (GrB) che può svolgere un ruolo 
significativo nelle fasi precoci della risposta immunitaria antivirale, nella 
regolazione delle patologie autoimmuni e nell’immunosorveglianza nel 
cancro (Hagn M et al., 2009; Kurschus FC et al., 2004; Gross C et al., 
2003). Inoltre, abbiamo dimostrato che sia le cellule B tot che le B DN, 
dopo adeguata stimolazione, diventano abili a produrre granzima B, senza 
nessuna differenza tra soggetti giovani e anziani. Quindi, concludiamo 
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che le cellule B DN, che mostrano un profilo di trafficking di tipo pro-
infiammatorio, in soggetti giovani e anziani, se adeguatamente stimolate, 
potrebbero migrare verso i siti infiammatori, cooperando con altre cellule 
del sistema immunitario (es.le cellule memoria unswitched), potrebbero 
produrre il GrB (Bulati M et al., 2014). 
Inoltre, è noto che le cellule B DN degli anziani hanno i telomeri corti 
rispetto la stessa sottopopolazione dei soggetti giovani e che non 
rispondono alla stimolazione con CpG, sebbene possano essere attivate 
con il F(ab’)2 (anti-BCR) (Colonna-Romano et al., 2009). Abbiamo 
dimostrato che la stimolazione del BCR e del TLR9 induce la 
proliferazione delle cellule B DN ed anche la riattivazione delle 
telomerasi nelle cellule B DN B di soggetti giovani, anziani, CO e soggetti 
con AD. Questo processo permette di mantenere la lunghezza dei telomeri 
o di indurre la replicazione. 
In conclusione, nella presente tesi ho mostrato i dati ottenuti studiando 
alcuni aspetti del sistema immunitario in soggetti giovani e anziani, 
paragonando i dati ottenuti da questi soggetti con quelli ottenuti studiando 
una coorte di soggetti “geneticamente avvantaggiati” per la longevità 
(CO) e persone anziane affette da AD. I dati riportati suggeriscono che lo 
studio dei compartimenti cellulari dei linfociti T e B naïve/memoria 
potrebbero essere rilevanti nella valutazione dell’invecchiamento 
biologico del sistema immunitario.  
 
  
218 
 
 
  
219 
 
 
 
 
 
References 
 
  
220 
 
13. REFERENCES 
• Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory 
B-cell marker.Immunol Today. 2000 May;21(5):204-6. 
• Agrawal N, Gupta SK. Birth weight, early weight gain, and risk of 
type 1 diabetes. Natl Med J India. 2010 Sep-Oct;23(5):289-90.  
• Akbar AN, HensonSM. Are senescence and exhaustion inter-twined 
or unrelated processes that compromise immunity? Nat RevImmunol 
(2011) 11:289–95. 
• Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence 
during aging. Curr Opin Immunol. 17(5):480-485 (2005) 
• Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell 
mediators of inflammation in the Alzheimer disease brain. Alzheimer 
Dis Assoc Disord. Suppl 1:S47-53. (2000) Review. 
• Akushevich I, Veremeyeva G, Kravchenko J, Ukraintseva S, Arbeev 
K, Akleyev AV, Yashin AI. New stochastic carcinogenesis model 
with covariates: an approach involving intracellular barrier 
mechanisms. Math Biosci. 2012 Mar;236(1):16-30.  
• Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-
Brandstetter D, Würzner R, Schönitzer D, Grubeck-Loebenstein B. 
Long-term cytomegalovirus infection leads to significant changes in 
the composition of the CD8+ T-cell repertoire, which may be the basis 
for an imbalance in the cytokine production profile in elderly persons. 
J Virol. 79:3675-3683 (2005) 
• Anderson G, Jenkinson EJ. Lymphostromal interactions in thymic 
development and function. Nat Rev Immunol (2001) 1:31–40.  
221 
 
• Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, 
Looney RJ, Sanz I. Rituximab improves peripheral B cell 
abnormalities in human systemic lupus erythematosus. Arthritis 
Rheumat. 40:3538-3590 (2004) 
• Aw D, Palmer DB. It’s not all equal: a multi phasic theory of thymic 
involution. Biogerontology (2012) 13:77–81.  
• Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, Dalla 
Vestra M, Previato L, Guido M, Pigozzo S, Cortella I, Crepaldi 
G, Franceschi C. Lipoprotein(a) and lipoprotein profile in healthy 
centenarians: a reappraisal of vascular risk factors. FASEB 
J. 1998 Apr;12(6):433-7. 
• Balistreri CR, Candore G, Caruso M, Incalcaterra E, Franceschi C, 
Caruso C. Role of polymorphisms of CC-chemokine receptor-5 gene 
in acute myocardial infarction and biological implications for 
longevity. Haematologica. 93:637-638 (2008) 
• Bartlett DB, Firth CM, Phillips AC, Moss P, Baylis D, Syddall H, 
Sayer AA, Cooper C, Lord JM.The age-related increase in low-grade 
systemic inflammation (Inflammaging) is not driven by 
cytomegalovirus infection.Aging Cell. 2012 Oct;11(5):912-5. 
• Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, 
Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der 
Burg M, van Dongen JJ, van Zelm MC. Human memory B cells 
originate from three distinct germinal center-dependent and -
independent maturation pathways. Blood. 118(8):2150-2158 (2011) 
• Bertho JM, Demarquay C, Moulain N, Van Der Meeren A, Berrih-
Aknin S, Gourmelon P. Phenotypic and immunohistological analyses 
222 
 
of the human adult thymus: evidence for an active thymus during adult 
life. Cell Immunol (1997) 179:30–40.  
• Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and 
age-related sarcopenia. Curr Opin Clin Nutr Metab Care. 2012 
Jan;15(1):12-22.  
• Bird TD. Genetic factors in Alzheimer's disease.N Engl J Med. 
352(9):862-4 (2005).  
• Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, 
Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit 
regulatory capacity in healthy individuals but are functionally 
impaired in systemic Lupus Erythematosus patients. Immunity. 
32(1):129-40 (2010) 
• Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, Tarlinton DM. 
Early appearance of germinal center-derived memory B cells and 
plasma cells in blood after primary immunization. J Exp Med. 2005 
Feb 21;201(4):545-54. 
• Bouaziz JD, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, 
Bensussan A, Musette P. IL-10 produced by activated human B cells 
regulates CD4(+) T-cell activation in vitro. Eur J 
Immunol. 2010 Oct;40(10):2686-91. 
• Britschgi M and Wyss-Coray T Systemic and acquired immune 
responses in Alzheimer's disease. Int Rev Neurobiol 82, 205-33 
(2007). 
• Bruns H, Meinken C, Schauenberg P, Härter G, Kern P, Modlin RL, 
Antoni C, Stenger S. Anti-TNF immunotherapy reduces CD8+ T cell-
223 
 
mediated antimicrobial activity against Mycobacterium tuberculosis 
in humans. J Clin Invest. 2009 May;119(5):1167-77. 
• Bruunsgaard H., “A high plasma concentration of tnf-α is associated 
with dementia in centenarians,” Journals of Gerontology. Series A, 
vol. 54, no. 7, pp. M357–M364, 1999. 
• Buffa S, Bulati M, Pellicanò M, Dunn-Walters DK, Wu YC, Candore 
G, Vitello S, Caruso C, Colonna-Romano G. B cell 
immunosenescence: different features of naive and memory B cells in 
elderly. Biogerontology. 2011 Oct;12(5):473-83. 
• Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, 
Pellicanò M, Wu YC, Colonna Romano G. B cells and 
immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged 
humans. Ageing Res Rev. 2011 Apr;10(2):274-84.  
• Cagigi A, Du L, Dang LV, Grutzmeir S, Atlas A, Chiodi F, Pan-
Hammarstrom Q, Nilsson A. CD27(-) B-cells produce class switched 
and somatically hyper-mutated antibodies during chronic HIV-1 
infection. PLos One. 4(5):e5427 (2009) 
• Campisi J. Aging and cancer cell biology, 2007. Aging 
Cell. 2007 Jun;6(3):261-3. Review. 
• Cancro MP, Hao Y, Scholz JL, Riley RL, Frasca D, Dunn-Walters 
DK, Blomberg BB. B cells and ageing: molecules and mechanisms. 
Trends Immunol. 30:313-318 (2009) 
• Candore G, Caruso C, Colonna-Romano G. Inflammation, genetic 
background and longevity. Biogerontology. 2010 Oct;11(5):565-73. 
• Candore G, Balistreri CR, Listì F, Grimaldi MP, Vasto S, Colonna-
Romano G, Franceschi C, Lio D, Caselli G, Caruso C. 
224 
 
Immunogenetics, gender, and longevity. Ann N Y Acad Sci. 
1089:516-37. (2006) Review b. 
• Candore G, Balistreri CR, Grimaldi MP, Vasto S, Listì F, Chiappelli 
M, Licastro F, Lio D, Caruso C. Age-related inflammatory diseases: 
role of genetics and gender in the pathophysiology of Alzheimer's 
disease. Ann N Y Acad Sci. 1089:472-86. (2006) Review a. 
• Carsetti R. Characterization of B-cell maturation in the peripheral 
immunesystem. Methods Mol Biol. 2004;271:25-35. 
• Cevenini E, Monti D, Franceschi C. Inflamm-ageing. Curr Opin Clin 
Nutr Metab Care. 2013 Jan;16(1):14-20. Review. 
• Cevenini E, Caruso C, Candore G, Capri M, Nuzzo D, Duro G, Rizzo 
C, Colonna-Romano G, Lio D, Di Carlo D, Palmas MG, Scurti M, 
Pini E, Franceschi C, Vasto S. Age-related inflammation: the 
contribution of different organs, tissues and systems. How to face it 
for therapeutic approaches. Curr Pharm Des. 16:609-618 (2010) 
• Cevenini E, Invidia L, Lescai F, Salvioli S, Tieri P, Castellani G, 
Franceschi C. Human models of aging and longevity. Expert Opin 
Biol Ther. 2008 Sep;8(9):1393-405. 
• Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct 
hematopoietic stem cell subtypes are differentially regulated by TGF-
beta1. Cell Stem Cell. 2010 Mar 5;6(3):265-78.  
• Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, Goodell 
MA. Aging hematopoietic stem cells decline in function and exhibit 
epigenetic dysregulation. PLoS Biol. 2007 Aug;5(8):e201. 
• Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, Moss 
P. Cytomegalovirus-seropositivity has a profound influence on the 
225 
 
magnitude of major lymphoid subsets within healthy individuals. Clin 
Exp Immunol. 155:423-432 (2009) 
• Chinn IK, Blackburn CC, Manley NR, Sempowski GD. Changes in 
primary lymphoid organs with aging. Semin Immunol (2012) 24:309–
20.  
• Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio 
D, Candore G, Caruso C. A double-negative (IgD-CD27-) B cell 
population is increased in the peripheral blood of elderly people. 
Mech Ageing Develop. 130(10):681-690 (2009) 
• Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, 
Di Bona D, Caruso C. Inflammation, genes and zinc in Alzheimer’s 
disease. Brain Res Rev. 58:96-105 (2008) 
• Colonna-Romano G, Bulati M, Aquino A, Scialabba G, Candore G, 
Lio D, Motta M, Malaguarnera M, Caruso C. B cells in the aged: 
CD27, CD5 and CD40 expression. Mech Ageing Dev. 124:389-393 
(2003) 
• Comerford, I., Bunting, M., Fenix, K., Haylock-Jacobs, S., Litchfield, 
W., Harata-Lee, Y., Turvey, M., Brazzatti, J., Gregor, C., Nguyen, P., 
Kara, E., McColl, S.R., 2010. An immune paradox: how can the same 
chemokine axis regulate both immune tolerance and activation?: 
CCR6/CCL20: a chemokine axis balancing immunological tolerance 
and inflammation in autoimmune disease. Bioessays 32(12), 1067-
1076. 
• Cossarizza A, Ortolani C, Paganelli R, Barbieri D, Monti D, Sansoni 
P et al. CD45 isoforms expression on CD4+ and CD8+ T cell 
226 
 
throughout life, from newborns to centenarians: implications for T cell 
memory. Mech Ageing Dev. 86:173-195 (1996) 
• Crestini A, Napolitano M, Piscopo P, Confaloni A, Bravo E. Changes 
in cholesterol metabolism are associated with PS1 and PS2 gene 
regulation in SK-N-BE. J Mol Neurosci. 30(3):311-322 (2006) 
• De Benedictis G, Franceschi C. The unusual genetics of human 
longevity. Sci Aging Knowledge Environ. 2006 Jun 
28;2006(10):pe20.  
• De Martinis M., Franceschi C., Monti D., Ginaldi L.: Inflamm-ageing 
and lifelong antigenic load as major determinants of ageing rate and 
longevity. FEBS Lett 579,2035-2039 (2005) 
• Derhovanessian E, Maier AB, Beck R, Jahn G, Hahnel K, Slagboom 
PE, de Craen AJ, Westendorp RG, Pawelec G. Hallmark features of 
immunosenescence are absent in familial longevity. J Immunol. 
185:4618-4624 (2010) 
• Derhovanessian E, Maier AB, Hähnel K, Beck R, de Craen AJ, 
Slagboom EP, Westendorp RG, Pawelec G. Infection with 
cytomegalovirus but not herpes simplex virus induces the 
accumulation of late-differentiated CD4+ and CD8+ T-cells in 
humans. J Gen Virol. 2011 Dec;92(Pt 12):2746-56. 
• Dewan SK, Zheng SB, Xia SJ, Bill K. Senescent remodeling of the 
immune system and its contribution to the predisposition of the elderly 
to infections. Chin Med J (Engl). 2012 Sep;125(18):3325-31.  
• Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay 
R, Kipling D, Soares MV, Battistini L, Akbar AN. Reversible 
227 
 
senescence in human CD4+CD45RA+CD27- memory T cells. J 
Immunol. 2011 Sep 1;187(5):2093-100. 
• Dixit VD. Thymic fatness and approaches to enhance thymopoietic 
fitness in aging. Curr Opin Immunol (2010) 22:521–8.  
• Duddy ME, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, 
Kim HJ, Bar-Or A. Distinct effector cytokine profiles of memory and 
naive human B cell subsets and implication in multiple sclerosis. J 
Immunol. 178:6092-6099 (2007) 
• Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell 
effector cytokines: a role in immune regulation? J Immunol. 
172(6):3422-3427 (2004) 
• Dunn-Walters DK, Ademokun AA. B cell repertoire and ageing. Curr 
Opin Immunol. Curr Opin Immunol. 2010 Aug;22(4):514-20. 
• Efferth T.Adenosine triphosphate-binding cassette transporter genes 
in ageing and age-related diseases. Ageing Res 
Rev. 2003 Jan;2(1):11-24.  
• Effross RB. Telomere/Telomerase dynamics within the human 
immune system: effect of chronic infection and stress. Exp Gerontol 
2011. 46:135-40. 
• Effros RB, Boucher N, Porter V, Zhu X, Spaulding C, Walford RL, 
Kronenberg M, Cohen D, Schachter F: Decline in CD28+ T cells in 
centenarians and in long-term T cell cultures: a possible cause for both 
in vivo and in vitro immunosenescence. Exp Gerontol 1994, 29:601-
9. 
• Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, 
Lavagetto G, Casti A, Franceschi C, Passeri M and Sansoni P. 
228 
 
Shortage of circulating naive CD8+ T cells provide new insights of 
immunodeficiency in aging. Blood. 95:2860-2868 (2000)  
• Fassbender K, Masters C, Beyreuther K Alzheimer's disease: an 
inflammatory disease?Neurobiol Aging. 21(3):433-6 (2000) 
• Fecteau JF, Côté G, Néron S. A new memory CD27-IgG+ B cell 
population in peripheral blood expressing VH genes with low 
frequency of somatic mutation. J Immunol. 177:3728-3736 (2006) 
• Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, 
Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez 
T, Chiappelli F, Bernard G.Ineffective phagocytosis of amyloid-beta 
by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 
7(3):221-32 (2005) 
• Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. 
Imaging of onset and progression of Alzheimer's disease with voxel-
compression mapping of serial magnetic resonance images. Lancet. 
2001 Jul 21;358(9277):201-5. 
• Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, 
Candore G, Caruso C; IMUSCE. The extreme longevity: the state of 
the art in Italy. Exp Gerontol. 2008 Feb;43(2):45-52. 
• Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, 
Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani 
GC, Salvioli S. Inflammaging and anti-inflammaging: a systemic 
perspective on aging and longevity emerged from studies in humans. 
Mech Ageing Dev. 2007 Jan;128(1):92-105. 
• Franceschi C, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, 
Capri M, Salvioli S, Valensin S, De Benedictis G, Di Iorio A, Caruso 
229 
 
C, Paolisso G, Monti D. Genes involved in immune 
response/inflammation, IGF1/insulin pathway and response to 
oxidative stress play a major role in the genetics of human longevity: 
the lesson of centenarians. Mech Ageing Dev. 126:351-361 (2005) 
• Franceschi C, Bonafè M. Centenarians as a model for healthy aging. 
Biochem Soc Trans. 31:457-461 (2003) 
• Franceschi C, Valensin S, Bonafè M, Paolisso G, Yashin AI, Monti 
D, De Benedictis G. The network and the remodeling theories of 
aging: historical background and new perspectives. Exp Gerontol. 
35(6-7):879-96. Review (2000)  b 
• Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani 
E, De Benedictis G. Inflamm-aging. An evolutionary perspective on 
immunosenescence. Ann N Y Acad Sci. Jun;908:244-54.  Review 
2000a 
• Franceschi C, Monti D, Barbieri D, Grassilli E, Troiano L, Salvioli S, 
Negro P, Capri M, Guido M, Azzi R et al. Immunosenescence in 
humans: deterioration or remodelling? Int Rev Immunol. 12(1):57-74 
(1995) 
• Frasca D, Diaz A, Romero M, Phillips M, Mendez NV, Landin AM, 
Blomberg BB. Unique biomarkers for B-cell function predict the 
serum response to pandemic H1N1 influenza vaccine. Int 
Immunol. 2012 Mar;24(3):175-82. 
• Frasca D, Blomberg BB. Aging affects human B cell responses. J Clin 
Immunol. 31(3):430-435 (2011) 
• Frasca D, Diaz A, Romero M, Landin AM, Phillips M, Lechner SC, 
Ryan JG, Blomberg BB. Intrinsic defects in B cell response to 
230 
 
seasonal influenza vaccination in elderly humans. Vaccine. 2010 Nov 
29;28(51):8077-84. 
• Frasca D, Landi AM, Lechner SC, Ryan JG, Schwartz R, Riley RL, 
Blomberg BB. Ageing down-regulates the transcription factor E2A, 
activation-induced cytidine deaminase, and Ig class switch in human 
B cells. J Immunol. 180:5283-5290 (2008) 
• Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-
cell functions including immunoglobulin class switch are 
downregulated in aged mice and humans. Sem Immunol. 17:378-384 
(2005) 
• Fülöp T, Larbi A, Pawelec G. Human T Cell Aging and the Impact of 
Persistent Viral Infections. Front Immunol. 2013 Sep 13;4:271. 
Review. 
• Gangemi S, Basile G, Monti D, Merendino RA, Di Pasquale G, 
Bisignano U, Nicita-Mauro V, Franceschi C. Age-related 
modifications in circulating IL-15 levels in humans. Mediators 
Inflamm. 2005 Aug 31;2005(4):245-7. 
• George AJ, Ritter MA. Thymic involution with ageing: obsolescence 
or good housekeeping? Immunol Today (1996) 17:267–72.  
• Gerli R, Monti D, Bistoni O, Mazzone AM, Peri G, Cossarizza A, Di 
Gioacchino M, Cesarotti ME, Doni A, Mantovani A, Franceschi C, 
Paganelli R.Chemokines, sTNF-Rs and sCD30 serum levels in 
healthy aged people and centenarians. Mech Ageing Dev. 2000 Dec 
20;121(1-3):37-46. 
• Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, 
Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK. B-cell diversity 
231 
 
decreases in old age and is correlated with poor health status. Ageing 
cell. 8:18-25 (2009) 
• Ginaldi L., Loreto M. F.,. Corsi M. P, Modesti M., and De Martinis 
M., “Immunosenescence and infectious diseases,”Microbes and 
Infection, vol. 3, no. 10, pp. 851–857, 2001. 
• Globerson A, Effros RB. Ageing of lymphocytes and lymphocytes in 
the aged. Immunol Today. 2000 Oct;21(10):515-21.  
• Goldberger A.L., Peng C.K., Lipsitz L.A. What is physiologic 
complexity and how does it change with aging and disease? Neurobiol 
Aging. 23, 23-6. (2002)  
• Goldeck D, Larbi A, Pellicanó M, Alam I, Zerr I, Schmidt C, Fulop 
T, Pawelec G. Enhanced Chemokine Receptor Expression on 
Leukocytes of Patients with Alzheimer's Disease. 2013. PLoS One, 8 
(6). 
• Gomez CR, Karavitis J, Palmer JL, Faunce DE, Ramirez L, Nomellini 
V, Kovacs EJ. Interleukin-6 contributes to age-related alteration of 
cytokine production by macrophages.Mediators 
Inflamm. 2010;2010:475139 
• Goto M. Inflammaging (inflammation + aging): A driving force for 
human aging based on an evolutionarily antagonistic pleiotropy 
theory? BioScience Trends. 2(6):218-230 (2008) 
• Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of 
and risk for development of neuronal degeneration in Alzheimer's 
disease. J Leukoc Biol. 72(2):233-8. (2002) Review. 
• Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J 
Clin Virol. 35:489-492 (2006) 
232 
 
• Grimm MO, Rothhaar TL, Hartmann T. The role of APP proteolytic 
processing in lipid metabolism. Exp Brain Res. DOI: 10.1007/s00221-
011-2975-6 (2011) 
• Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-
bound heat shock protein 70 (Hsp70) mediates perforin-independent 
apoptosis by specific binding and uptake of granzyme B. J Biol Chem. 
2003 Oct 17;278(42):41173-81. 
• Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec 
G, Solana R. Immunosenescence and vaccine failure in the elderly. 
Aging Clin Exp Res. 2009  
• Jun;21(3):201-9. 
• Guerrettaz LM, Johnson SA, Cambier JC. Acquired hematopoietic 
stem cell defects determine B-cell repertoire changes associated with 
aging. Proc Natl Acad Sci USA. 105:11898-11902 (2008) 
• Gui J, Zhu X, Dohkan J, Cheng L, Barnes PF, Su D-M. The aged 
thymus shows normal recruitment of lymphohematopoietic 
progenitors but has defects in thymic epithelial cells. Int Immunol 
(2007) 19:1201–11.  
• Gupta S, Su H, Bi R, Agrawal S, Gollapudi S. Life and death of 
lymphocytes: a role of immunosenescence. Immun Ageing. 23:2-12 
(2005) 
• Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer 
T, Syrovets T, Laumonnier Y, Fabricius D, Simmet T, Jahrsdörfer B. 
Human B cells secrete granzyme B when recognizing viral antigens 
in the context of the acute phase cytokine IL-21. J Immunol. 2009 Aug 
1;183(3):1838-45.  
233 
 
• Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, 
Klein MR, van Lier RA. Phenotipic and functional separation of 
memory and effector human CD8+ T cells. J Exp Med. 186:1407-
1418 (1997) 
• Harris DP, Ortiz F, Adler FM, Yu K, Maines ML, Barba D, Viggiani 
SI, Wolf SM, Fitten LJ, Chodosh J, Vickrey BG. Challenges to 
screening and evaluation of memory impairment among Hispanic 
elders in a primary care safety net facility. Int J Geriatr Psychiatry. 
2011 Mar;26(3):268-76. 
• Heron MP, Smith BL. Deaths: leading causes for 2003. Natl Vital Stat 
Rep. 55:1-92 (2007). 
• Inamine A, Takahashi Y, Baba N, Miyake K, Tokuhisa T, Takemori 
T, Abe R. Two waves of memory B-cell generation in the primary 
immune response. Int Immunol. 2005 May;17(5):581-9. 
• Kaech SM, Wherry EJ, Ahmed R: Effector and memory T-cell 
differentiation: implications for vaccine development. Nat Rev 
Immunol, 2:251-262 (2002) 
• Kaminski D.A., Wei C., Qian Y., Rosenberg A.F., Sanz I., 2012. 
Advances in human B cell phenotypic profiling. Front. Immunol. 3, 
302-316. 
• Klein, U., Rajewsky, K., Küppers, R. Human immunoglobulin 
(Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface 
antigen carry somatically mutated variable region genes: CD27 as a 
general marker for somatically mutated (memory) B cells. J. Exp. 
Med. 188, 1679-89 (1998) 
234 
 
• Kogut I, Scholz JL, Cancro MP, Cambier JC. B cell maintenance and 
function in aging. Semin Immunol. 2012 Oct;24(5):342-9. 
• Kohler S, Wagner U, Pierer M, Kimmig S, Oppmann B, Möwes B, 
Jülke K, Romagnani C, Thiel A. Post thymic in vivo proliferation of 
näive CD4+ T cells constrains the TCR repertoire in healthy human 
adults. Eur J Immunol 35: 1987 (2005)  
• Kolibab K, Smithson SL, Rabquer B, Khuder S, Westerink MA. 
Immune response to pneumococcal polysaccharides 4 and 14 in 
elderly and young adults: analysis of the variable heavy chain 
repertoire. Infect Immun. 2005 Nov;73(11):7465-76. 
• Krabbe K., Pedersen M., Bruunsgaard H.: Inflammatory mediators in 
the elderly. Exp Gerontol 39, 687-699 (2004) 
• Krawinkel MB: Interaction of nutrition and infections globally:an 
overview. Ann Nutr Metab 2012, 61(Suppl 1):39-45. 
• Kunkel, E.J., Butcher, E.C., 2003. Plasma-cell homing. Nat. Rev. 
Immunol. 3, 822-829. 
• Kurschus FC, Bruno R, Fellows E, Falk CS, Jenne DE. Membrane 
receptors are not required to deliver granzyme B during killer cell 
attack. Blood. 2005 Mar 1;105(5):2049-58.  
• Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian 
E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not 
CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis. 
17(1):91-103 (2009) 
• Lee JS, Lee WW, Kim SH et al.: Age-associated alteration in naive 
and memory Th17 cell response in humans. Clin Immunol 2011, 
140:84-91. 
235 
 
• Leuner K, Muller WE and Reichert AS (2012). From mitochondrial 
dysfunction to amyloid beta formation: novel insights into the 
pathogenesis of Alzheimer's disease. Mol Neurobiol, 46: 186-193 
• Li L, Hsu HC, Grizzle WE, Stockard CR, Ho KJ, Lott P, et al. Cellular 
mechanism of thymic involution. Scand J Immunol (2003) 57:410–
42. 
• Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, 
Chen YH. Amyloid beta interaction with receptor for advanced 
glycation end products up-regulates brain endothelial CCR5 
expression and promotes T cells crossing the blood-brain barrier. J 
Immunol. 2009 May 1;182(9):5778-88. 
• Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann 
S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, Soares MV, 
Akbar AN. Cytomegalovirus infection induces the accumulation of 
short-lived, multifunctional CD4+CD45RA+CD27+ T cells: the 
potential involvement of interleukin-7 in this process. Immunology. 
2011 Mar;132(3):326-39.  
• Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, 
Franceschi C, Caruso C. Innate immunity and inflammation in ageing: 
a key for understanding age-related diseases. Immun Ageing. 
18;2:8(2005) 
• Listì F, Candore G, Modica MA, Russo MA, Di Lorenzo G, Esposito-
Pellitteri M, Colonna-Romano G, Aquino A, Bulati M, Lio D, 
Franceschi C, Caruso C. A study of serum immunoglobulin levels in 
elderly persons that provides new insights into B cell 
immonosenescence. Ann N Y Acad Sci. 1089:487-495 (2006)  
236 
 
• Looney RJ, Falsey A, Campbell D, Torres A, Kolassa J, Brower C, 
McCann R, Menegus M, McCormick K, Frampton M, Hall W, 
Abraham GN. Role of cytomegalovirus in the T cell changes seen in 
elderly individuals. Clin Immunol. 1999 Feb;90(2):213-9. 
• Lund FE. Cytokine-producing B lymphocytes-key regulators of 
immunity. Curr Opin Immunol. 20:332-338 (2008) 
• Lynch HE, Goldberg GL, Chidgey A, Van den Brink MR, Boyd R, 
Sempowski GD. Thymic involution and immune 
reconstitution. Trends Immunol (2009)30:366–73.  
• Ma D, Wei Y, Liu F. Regulatory mechanisms of thymus and T cell 
development. Dev Comp Immunol (2013) 39:91–102.  
• Macallan DC, Wallace DL, Zhang Y, Ghattas H, Asquith B, de Lara 
C, Worth A, Panayiotakopoulos G, Griffin GE, Tough DF, Beverley 
PC. B-cell kinetics in humans: rapid turnover of peripheral blood 
memory cells. Blood. 2005 May 1;105(9):3633-40.  
• Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, 
Zhu L, Chen YH Peripheral T cells overexpress MIP-1alpha to 
enhance its transendothelial migration in Alzheimer's disease. 
Neurobiol Aging. 28(4):485-96. (2007) 
• Martin F, Chan AC. B cell immunobiology in disease: evolving 
concepts from the clinic. Annu Rev Immunol. 2006;24:467-96. 
• Martin Prince RB, Cleusa Ferri (2011) World Alzheimer Report 2011. 
Vol. 2013, Alzheimer’s Disease International, London 
• Miller JP, Cancro MP. B cells and aging: balancing the homeostatic 
equation. Exp Gerontol. 2007 May;42(5):396-9. Epub 2007 Feb 4. 
237 
 
• Mitchell WA, Lang PO, Aspinall R. Tracing thymic output in older 
individuals. Clin ExpImmunol (2010) 161:497–503. 
• Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, 
Budson AE, Sperling R, Selkoe DJ, Weiner HL Increased T cell 
reactivity to amyloid beta protein in older humans and patients with 
Alzheimers disease.  J Clin Invest 112, 415-22 (2003) 
• Moore SE, Fulford AJ, Darboe MK, Jobarteh ML, Jarjou LM,Prentice 
AM: A randomized trial to investigate the effects of pre-natal and 
infant nutritional supplementation on infant immune development in 
rural Gambia: the ENID trial: Early Nutrition and Immune 
Development. BMC Pregnancy Childbirth 2012, 12:107. 
• Nasi M, Troiano L, Lugli E, Pinti M, Ferraresi R, Monterastelli E, et 
al. Thymic output and functionality of the IL-7/IL-7 receptor systemin 
centenarians: implications for the neo lympho- genesis at the limit of 
human life. AgingCell (2006) 5:167–75.  
• Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, Witkowsky 
J, Fulbright J, Weyand CM, Goronzy JJ. The influence of age on T 
cell generation and TCR diversity. J Immunol. (2005) 174:7446-7452 
• Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral 
infections of upper respiratory tract in elderly people living in the 
community: comparative, prospective, population based study of 
disease burden. BMJ. 315:1060-1064 (1997) 
• Nociari MM, Telford W, Russo C. Postthymic development of CD28-
CD8+ T cell subset: age-associated expansion and shift from memory 
to naive phenotype. J Immunol. 162(6):3327-3335 (1999) 
238 
 
• Nussbaum RL, Ellis CE.Alzheimer's disease and Parkinson's disease. 
N Engl J Med. 348(14):1356-64 (2003) 
• Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S, 
Müller CA, Pircher H, Pawelec G. Age-associated accumulation of 
CMV-specific CD8+ T cells expressing the inhibitory killer cell 
lectin-like receptor G1 (KLRG1).  Exp Gerontol. 38(8):911-20 (2003) 
• Oviedo-Orta E, Li CK, Rappuoli R.Perspectives on vaccine 
development for the elderly. Curr Opin 
Immunol. 2013 Aug;25(4):529-34 
• Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, 
Looney RJ, Sanz I, and Anolik H. Novel human Transitional B cell 
Populations Revealed by B cell Depletion Theraphy. J Immunol. 
182:5982-5993 (2009) 
• Palmer DB.The effect of age on thymic function. Front. Immunol., 
2013 Oct 7;4:316. 
• Pan-Hammarström Q, Zhao Y, Hammarström L. Class switch 
recombination: a comparison between mouse and human. Adv 
Immunol. 2007;93:1-61. 
• Pavlidis N, Stanta G, Audisio RA. Cancer prevalence and mortality in 
centenarians: a systematic review. Crit Rev Oncol Hematol. 2012 
Jul;83(1):145-52 
• Pawelec G. Immunosenescence: Role of cytomegalovirus. Exp 
Gerontol. 2013 Nov 28. doi :10.1016/j.exger.2013.11.010. 
• Pawelec G and Larbi A. Immunity and ageing in man: Annual Review 
2006/2007. Exp Gerontol. 43:34-38 (2008) 
239 
 
• Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, 
Wikby A. Human immunosenescence: is it infectious? Immunol Rev. 
205:257-268 (2005) 
• Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J 
et al. T cell and ageing. Front Biosci. 7:d1056-d1183 (2002) 
• Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal 
muscle as a secretory organ. Nat Rev Endocrinol. 2012 Apr 
3;8(8):457-65.  
• Pellicanò M, Bulati M, Buffa S, Barbagallo M, Di Prima A, Misiano 
G, Picone P, Di Carlo M, Nuzzo D, Candore G, Vasto S, Lio D, 
Caruso C, Colonna-Romano G. Systemic immune responses in 
Alzheimer's disease: in vitro mononuclear cell activation and cytokine 
production. J Alzheimers Dis. 21(1):181-192 (2010) 
• Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, 
Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian 
E, Pawelec G. Immune profiling of Alzheimer patients. J 
Neuroimmunol. in press (2011) 
• Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms 
J. Synapse formation and function is modulated by the amyloid 
precursor protein.J Neurosci. 26(27):7212-21(2006) 
• Rattan SI. Increased molecular damage and heterogeneity as the basis 
of aging. Biol Chem. 2008 Mar;389(3):267-72.  
• Reale M, Iarlori C, Feliciani C, Gambi D.Peripheral chemokine 
receptors, their ligands, cytokines and Alzheimer's disease. J 
Alzheimers Dis. 14(2):147-59 (2008) 
240 
 
• Reiley WW, Wittmer ST, Ryan LM, Eaton SM, Haynes L, Winslow 
GM, et al. Maintenance of peripheral T cell responses 
during Mycobacterium tuberculosisinfection. J 
Immunol (2012) 189:4451–8.  
• Richartz-Salzburger E, Batra A, Stransky E, Laske C, Köhler N, 
Bartels M, Buchkremer G, Schott K. Altered lymphocyte distribution 
in Alzheimer's disease. J Psychiatr Res. 41(1-2):174-8 (2007)  
• Rieger A, Bar-Or A. B-cell-derived interleukin-10 in autoimmune 
disease: regulating the regulators. Nat Rev 
Immunol. 2008 Jun;8(6):486-7. 
• Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 
2011 Feb 21;192(4):547-56. 
• Rogers J, Luber-Narod J, Styren SD, Civin WH Expression of 
immune system associated antigens by cells of the human central 
nervous system: Relationship to the pathology of Alzheimer’s disease. 
Neurobiol Aging 9, 339-349(1998) 
• Roman BE, Beli E, Duriancik DM, Gardner EM: Short-term 
supplementation with active hexose correlated compound improves 
the antibody response to influenza B vaccine. Nutr Res 2013, 33:12-
17. 
• Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, 
Weissman IL. Cell intrinsic alterations underlie hematopoietic stem 
cell aging. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9194-9. 
Epub 2005 Jun 20. 
• Rossi MI, Yokota T, Medina KL, Garrett KP, Comp PC, Schipul Jr 
AH, Kincade PW. B lymphopoiesis is active throughout human life, 
241 
 
but there are developmental age-related chances. Blood. 101(2):576-
584 (2003)   
• Roush W. Live long and prosper? Science 273(5271):42-6 (1996) 
• Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, 
Garagnani P, Giuliani C, Fontanesi E, Ostan R, Bucci L, Sevini F, 
Yani SL, Barbieri A, Lomartire L, Borelli V, Vianello D, Bellavista 
E, Martucci M, Cevenini E, Pini E, Scurti M, Biondi F, Santoro A, 
Capri M, Franceschi C. Immune system, cell senescence, aging and 
longevity--inflamm-aging reappraised. Curr Pharm Des. 
2013;19(9):1675-9.  
• Salvioli S, Olivieri F, Marchegiani F, Cardelli M, Santoro A, 
Bellavista E, Mishto M, Invidia L, Capri M, Valensin S, Sevini F, 
Cevenini E, Celani L, Lescai F, Gonos E, Caruso C, Paolisso G, De 
Benedictis G, Monti D, Franceschi C. Genes, ageing and longevity in 
humans: problems, advantages and perspectives. Free Radic Res. 
2006 Dec;40(12):1303-23. 
• Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli 
M,Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè 
M. IL-6 triggers malignant features in mammospheres from human 
ductal breast carcinoma and normal mammary gland. J Clin Invest. 
2007 Dec;117(12):3988-4002. PubMed PMID: 18060036; 
• Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune 
diseases. Front Biosci. 12:2546-2567 (2007) 
• Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional 
heterogeneity of human memory B cells. Semin Immunol. 20(1):67-
82 (2008) 
242 
 
• Sauce D, Appay V. Altered thymic activity in early life: how does it 
affect the immune system in young adults? Curr Opin 
Immunol (2011) 23:543–8.  
• Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. 
Accumulation of memory T cells from childhood to old age: central 
and effector memory cells in CD4(+) versus effector memory and 
terminally differentiated memory cells in CD8(+) compartment. Mech 
Ageing Dev. 2006 Mar;127(3):274-81.  
• Saurwein-Teissl M, Blasko I, Zisterer K, Neuman B, Lang B, 
Grubeck-Loebenstein B. An imbalance between pro- and anti-
inflammatory cytokines, a characteristic feature of old age. Cytokine. 
2000 Jul;12(7):1160-1. 
• Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. 
Chronic cytomegalovirus infection and inflammation are associated 
with prevalent frailty in community-dwelling older women. J Am 
Geriatr Soc. 53:747-754 (2005) 
• Scholz JL, Diaz A, Riley RL, Cancro MP, Frasca D. A comparative 
review of aging and B cell function in mice and humans. Curr Opin 
Immunol. 2013 Aug;25(4):504-10.  
• Schutyser, E., Struyf, S., Van Damme, J., 2003. The CC chemokine 
CCL20 and its receptor CCR6. Cytokine Growth Factor. Rev. 14(5), 
409-426. 
• Selkoe DJ.Alzheimer's disease results from the cerebral accumulation 
and cytotoxicity of amyloid beta-protein.J Alzheimers Dis. 3(1):75-
80 (2001) 
243 
 
• Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. 
Regulation of aged humoral immune defense against pneumococcal 
bacteria by IgM memory B cell. J Immunol. 175:3262-3267 (2005)  
• Shi Y., Wei C., Lee F., Anolik J.: Functional analysis of human 
memory B-cell subpopulations: IgD+CD27+ B cells are crucial in 
secondary immune response by producing high affinity IgM. Clinical 
Immunol 108, 128-137 (2003) 
• Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, 
Lokshin AE. Dynamic alteration of soluble serum biomarkers in 
healthy aging. Cytokine. 39(2):123-9 (2007)  
• Simone R, Zicca A, Saverino D: The frequency of regulatory 
CD3+CD8+CD28SCD25+ T lymphocytes in human peripheral blood 
increases with age. J Leuk Biol 2008, 84:1454-1461. 
• Singh T, Newman AB. Inflammatory markers in population studies of 
aging. Ageing Res Rev. 2011 
• Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito 
L, Longhi R, Ferrante P Lymphocyte subset patterns and cytokine 
production in Alzheimer's disease patients. Neurobiol Aging 28, 
1163-1169 (2007) 
• Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, 
Tavolari S, Huang T, Chan MW, Marini FC, Rosol TJ, Bonafé M, 
Hall BM. Fibroblasts isolated from common sites of breast cancer 
metastasis enhance cancer cell growth rates and invasiveness in an 
interleukin-6-dependent manner. Cancer Res. 2008 Nov 
1;68(21):9087-95. beyer 
244 
 
• Sultana R, Baglioni M, Cecchetti R, Cai J, Klein JB, Bastiani 
P, Ruggiero C, Mecocci P, Butterfield DA. Lymphocyte 
mitochondria: toward identification of peripheral biomarkers in the 
progression of Alzheimer disease. Free Radic Biol Med. 2013 
Dec;65:595-606.  
• Taub DD, Longo DL. Insights into thymic aging and 
regeneration. Immunol Rev(2005) 205:72–93.  
• Terry DF, Wyszynski DF, Nolan VG, et al. Serum heat shock protein 
70 level as a biomarker of exceptional longevity. Mech Ageing Dev 
2006; 127:862 8. 
• Terry DF, Wilcox MA, McCormix MA, Pennington JY, Schoenhofen 
EA, Andersen SL et al. Cardiovascular advantages among the 
offspring of centenarians. J Am Geriatr Soc. 52:2074-2076 (2004b) 
• Terry DF, Wilcox MA, McCormix MA, Perls TT. Cardiovascular 
disease delay in centenarian offspring. J Gerontol A Biol Sci Med Sci. 
59:385-389 (2004a)  
• Terry DF, Wilcox M, McCormick MA, Lawler E, Perls 
TT.Cardiovascular advantages among the offspring of centenarians.J 
Gerontol A Biol Sci Med Sci. 2003 May;58(5):M425-31. 
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, 
Anderson LJ, Fukuda K. Mortality associated with influenza and 
respiratory syncytial virus in the United States. JAMA. 2003 Jan 
8;289(2):179-86. 
• Trans. 2003 Apr;31(2):457-61. Review. PubMed PMID: 12653662. 
• Troen B.R. The biology of aging Mt Sinai J Med. 70(1):3-22 (2003) 
245 
 
• Trzonkowski P., My´sliwska J., Godlewska B.et al., “Immune 
consequences of the spontaneous pro-inflammatory status in 
depressed elderly patients,” Brain, Behavior, and Immunity, vol. 18, 
no. 2, pp. 135–148, 2004. 
• Vasto S, Candore G, Listì F, Balistreri CR, Colonna-Romano G, 
Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C. 
Inflammation, genes and zinc in Alzheimer’s disease. Brain Res Rev. 
58:96-105 (2008) 
• Vasto S., Candore G., Balistreri CR, Caruso M., Colonna-Romano G., 
Grimaldi MP: Inflammatory networks  in ageing, age-related diseases 
and longevity. Mech Aging Dev 128, 83-91 (2007) 
• Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G, Vella A. 
Expression of CD27 and CD23 on peripheral blood b lymphocytes in 
humans of different ages. Blood Transfus. 7:29-34 (2009)  
• Vescovini R, Biasini C, Telera AR, Basaglia M, Stella A, Magalini F, 
Bucci L, Monti D, Lazzarotto T, Dal Monte P, Pedrazzoni M, Medici 
MC, Chezzi C, Franceschi C, Fagnoni FF, Sansoni P. Intense 
antiextracellular adaptive immune response to human ytomegalovirus 
in very old subjects with impaired health and cognitive and functional 
status. J Immunol. 2010 Mar 15;184(6):3242-9.  
• Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, 
McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP. 
Cytomegalovirus infection and the risk of mortality and frailty in older 
women: a prospective observational cohort study. Am J Epidemiol. 
171:1144-1152 (2010) 
246 
 
• Warren LA, Rossi DJ. Stem cells and aging in the hematopoietic 
system. Mech Ageing Dev. 130(1-2):46-53 (2009) 
• Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, 
Lee EH, Milner EC, Sanz I. A new population of cells lacking 
expression of CD27 represents a notable component of the B cell 
memory compartment in systemic lupus erythematosus. J Immunol. 
178:6624-6633 (2007) 
• Wei C, Jung J, Sanz I. OMIP-003: phenotypic analysis of human 
memory B cells. Cytometry A. 2011 Nov;79(11):894-6. 
• Weiner HL, Frenkel D. Immunology and immunotherapy of 
Alzheimer's disease. NatRev Immunol. 2006 May;6(5):404-16. 
Review. Erratum in: Nat Rev Immunol. 2006 Jun;6(6):490. 
• Welsh-Bacic, D., Lindenmeyer, M., Cohen, C.D., Draganovici, D., 
Mandelbaum, J., Edenhofer, I., Ziegler, U., Regele, H., Wüthrich, 
R.P., Segerer, S., 2011. Expression of the chemokine receptor CCR6 
in human renal inflammation. Nephrol. Dial. Transplant. 26(4), 1211-
1220.  
• Weng NP, Akbar AN, Goronzy J: CD28(S) T cells: their role in the 
age-associated decline of immune function. Trends Immunol 2009, 
30:306-312. 
• Weng NP. Telomere and adaptive immunity. Mech Ageing Dev. 
129(1-2):60-6 (2008) 
• Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia 
R, von Andrian UH, Ahmed R. Lineage relationship and protective 
immunity of memory CD8 T cell subsets. Nat Immunol 4:225-234 
(2003) 
247 
 
• Wick G, Jansen-Durr P, Berger P, Blasko I, Grubeck-Loebenstein B. 
Diseases of aging. Vaccine. 18:1567-1583 (2000) 
• Wikby A, Johansson B, Ferguson F, Olsson J. Age-related changes in 
immune parameters in a very old population of Swedish people: a 
longitudinal study. Exp Gerontol. 1994 Sep-Oct;29(5):531-41. 
• Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson 
F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations 
and an association with Cytomegalovirus seropositivity in the elderly: 
the Swedish NONA immune study. Exp Gerontol. 2002 Jan-
Mar;37(2-3):445-53.  
• William J, Euler C, Christensen S, Shlomchik MJ. Evolution of 
autoantibody responses via somatic hypermutation outside of 
germinal centers. Science. 297:2066-2070 (2002) 
• Wirths, S., Lanzavecchia, A., 2005. ABCB1 transporter discriminates 
human resting naive B cells from cycling transitional and memory B 
cells. Eur. J. Immunol. 35 (12), 3433–3441. 
 
 
248 
 
  
249 
 
 
 
 
 
 
Curriculum Vitae 
 
  
250 
 
 
 
 
 
CURRICULUM VITAE 
Adriana Martorana was born on 8th June 1982 in Palermo, Italy.  
In 2000 she got a socio-psycho-pedagogy Diploma.  
In 2009 she graduated in Biotechnology for industrial and scientific 
research at the University of Palermo.  
In 2009 she qualified also as a professional biologist.  
In January 2011, she started her doctorate under the supervision of 
Prof. G. Colonna Romano purchasing advanced specialized studies 
in Immunology with particular attention on mechanisms of aging. 
 
 
 
